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C1q is a complement protein present in the serum and plays an important 
role in modulating the host immune system. The genetic deficiency of C1q, which 
impairs the production of functional C1q, has profound impact on the immune 
system, as it almost certainly cause the autoimmune disease, systemic lupus 
erythematosus (SLE). Although the genetic C1q deficiency is relatively rare, 
acquired C1q deficiency is more frequently observed in SLE patients, which 
would contribute to SLE pathogenesis.   
C1q is assembled from three subunits, each being coded by an independent 
gene. The three genes are located as a cluster (C1qA-C1qC-C1qB) and are 
specifically expressed in macrophages and dendritic cells. We observed that the 
three C1q genes were expressed in a synchronized manner at both basal and 
IFNγ-induced levels in human monocyte-derived DCs and macrophages.  
To understand the underlying mechanism, the three gene promoters were 
cloned. In isolation, the C1qA and C1qC gene promoters were suppressed, rather 
than enhanced, by IFNγ. This departs from the expected IFNγ enhancement in 
C1q gene expression. When the C1qB gene promoter was cloned at the 3’ 
direction of the C1qA and C1qC gene promoters across the reporter gene, it 
restored their responses to IFNγ. This was attributed to a 53-bp element in the 




The IFNγ-induced C1qB gene promoter activity was abrogated when PU.1, 
IRF8 and STAT1 expression was knocked down using shRNA. PU.1 and IRF8, 
but not STAT1, were shown to bind to the 53-bp element. However, shRNA 
knockdown of STAT1 inhibits IFNγ-induced IRF8 expression and subsequently 
inhibits the IFNγ induction of the C1qB gene promoter.  
The C1q gene cluster is conserved across different animal species and 
studies of these C1q gene promoters also revealed responses to IFNγ, but the 
modes of response vary. Evolutionary changes were revealed between the 
regulation patterns of C1q expression in the mammalian species and those in the 
zebrafish, but the genomic organization of the three C1q genes as a gene cluster is 
still well conserved to coordinate the expression of the three genes. 
To understand the C1q gene promoters in vivo, a C1q transgenic mouse 
model was generated by expressing GFP under the C1qA gene promoter. This 
would help in elucidating the regulation patterns of C1q expression in vivo and 
thus provides greater insights into the pathogenesis of SLE than the study of C1q-
knockout mice, especially into the acquired C1q deficiency in SLE patients. 
Collectively, our results reveal a novel transcriptional mechanism by which 
the expression of the three C1q genes is synchronized, offer an excellent model 
for dissecting SLE pathogenesis due to acquired C1q deficiency and provide a 
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Chapter 1 - Introduction 
1.1 The immune system 
1.1.1 The innate and adaptive immunity 
The immune system provides defense against various microbial pathogen 
infections as well as endogenous abnormalities such as malignancy and clearance 
of damaged tissues. The vertebrate immune system is divided into innate and 
adaptive immunity, which are two different but intricately linked subsystems 
(Dunkelberger and Song, 2010). Evolutionarily, the innate immune system is 
more ancient and found in both invertebrates and vertebrates (Hoffmann et al., 
1999), while adaptive immunity is only reported to arose in jawed vertebrates and 
thereafter (Pancer and Cooper, 2006).  
The innate immunity starts the defense against pathogens rapidly in a 
general manner, immediately after the intrusion (Dempsey et al., 2003). It 
involves the recognition of microbial surfaces by anti-microbial peptides and 
complements, the recognition of pathogen-associated molecular patterns (PAMPs) 
which are conserved and repetitive surface structures on pathogens, by germline-
encoded pattern recognition receptors (PRRs) on phagocytes and secretion of 
cytokines and chemokines by these phagocytes to recruit other immune cells 
(Dempsey et al., 2003; Takeuchi and Akira, 2010). It forms the first line of 
defense against microbial infections, including viruses, bacteria, fungi and 
parasites (Medzhitov and Janeway, 2000).  
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In contrast to the fast but non-specific response of innate immunity, the 
adaptive immunity provides prolonged protection against a specific pathogen with 
immunological memory build-up. During the first encounter, the immunological 
defense against a specific pathogen develops across 4 – 7 days. Once the 
immunological memory is formed, re-encounter with the same pathogen could 
result in a faster and stronger immune response against it (Dunkelberger and Song, 
2010).  
1.1.2 The complement system 
Complement system is one of the key components of innate immune system 
providing critical protection against microbial infections. It is an enzymatic 
cascade, involving over 30 plasma and cell-associated proteins (Walport, 2001). 
Firstly discovered in 1896 by Bordet, the complement system is a heat-liable 
component in the serum and complements anti-bacterial activities of heat-stable 
antibodies (Dunkelberger and Song, 2010; Erlich, 1910).  
The complement system is activated through three different pathways: the 
classical pathway, the lectin pathway and the alternative pathway (Figure 1.1). In 
the classical pathway, C1q recognizes immune complexes formed on microbial 
structures as well as other microbial ligands and apoptotic cells to trigger the 
complement system (Lu et al., 2008; Reid, 1986) . In the lectin pathway, it starts 
with mannose-binding lectin (MBL) recognizing carbohydrate structures with 
specific patterns on the microbial surfaces (Fujita et al., 2004). In the alternative 
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pathway, spontaneous hydrolysis of C3 on the microbial surfaces starts the 
complement cascade, but normally inhibited by other factors (Reid, 1986; 
Thurman and Holers, 2006; Walport, 2001).  
Despite the differences in the initiation stage, the complement activation 
will eventually lead to microbial killing and clearance through the generation of 
potent pro-inflammatory mediators (anaphylatoxins; C3a and C5a) to recruit 
immune cells; opsonization of the microbial surface via various cleaved 
complement proteins (opsonins; C3b and iC3b) to facilitate phagocytosis; and the 
assembly of membrane attack complexes (MAC) to cause target lysis (Fujita et al., 






 Figure 1.1. Schematic illustration of complement activation.  Complement 
system can be activated through classical, lectin and alternative pathways. The 
classical pathway starts with the binding to antibodies bound to the microbial 
surface by C1 complex consisting of one recognition subunit C1q, four serine 
proteases including two C1r and two C1s. C1s first cleaves C4 into C4a and C4b, 
and then cleaves C2 into C2a and C2b. C4b complexes with C2a to form classical 
pathway C3 convertase C4b/C2a. The lectin pathway is initiated by MBL binding 
of carbohydrate motifs on the microbial surfaces. Similar to the C1 complex, 
MBL forms complex with MBL-associated serine protease 1 (MASP1) and 
MASP2. MASP2 functions like C1s to facilitate formation of classical pathway 
C3 convertase. The alternative pathway is initiated by spontaneous hydrolysis of 
C3 on the microbial surfaces which results in the deposition of C3b. C3b recruits 
factor B to form a C3bB complex. Factor D cleaves factor B bound to C3b to 
form the alternative pathway C3 convertase C3b/Bb. Both classical pathway and 
alternative pathway C3 convertases cleave C3 into C3a and C3b. C3b binds 
covalently around the site of complement activation. Some of this C3b binds to 
C4b2a or C3bBb to form C5 convertase which cleaves C5 into C5a and C5b. C5b 
recruits C6, C7, C8 and several C9 to form the MAC. All three pathways result in 
the generation of MAC and opsonins (C3b) on the microbial surface and 
anaphylatoxins (C4a, C3a and C5a) to recruit immune cells. This diagram is 




1.2 The function of C1q 
1.2.1 C1q in complement activation  
C1q is the recognition subunit of C1 complex which initiates the classical 
pathway leading to complement activation (Reid, 1986).  C1q initiates the 
classical pathway through binding to the fragment crytallizable (Fc) region of 
immunoglobulin  (Ig)  G  or  IgM bound to antigens on the surface of a microbial 
pathogen (Duncan and Winter, 1988), and recruits serine proteases C1r and C1s to 
form the C1 complex (one molecule of C1q, two molecules of C1r, and two 
molecules of C1s) (Duncan and Winter, 1988; Reid, 1986). Upon binding to its 
targets, C1q undergoes conformational changes which activate C1r and 
subsequently activate C1s. The activated C1s starts the enzymatic cleavage 
cascade of complement proteins (Loos and Colomb, 1993; Reid, 1986; Tomlinson, 
1993; Walport, 2001).  
Besides the antibody-dependent mechanism, C1q is also able to activate 
complement classical pathway through binding to other ligands found on Gram-
positive and Gram-negative bacteria, viruses, cellular and sub-cellular structures 
from damaged cells, apoptotic cells, proteins, carbohydrates, lipids and 
polyanions (Cooper, 1985), which mainly involved the globular head domain of 




1.2.2 C1q in apoptotic cell clearance 
In addition to microbial pathogens and immune complexes, C1q also 
recognize apoptotic cells and thus facilitates their up-taken via phagocytosis 
(Korb and Ahearn, 1997; Lu et al., 2007; Ogden et al., 2001; Ogden et al., 2005).  
Apoptosis, followed by rapid phagocytic clearance is the primary 
mechanism by which organisms get rid of unwanted cells (Elmore, 2007). It is 
characterized by a number of physical hallmarks, such as the flipping of 
phosphatidylserine (PS) from the inner side of the plasma membrane to the outer 
leaflet, plasma membrane blebbing, nuclear condensation and DNA surface 
exposure. These changes decrease its immunogenicity and enhance its uptake by 
phagocytes (Elmore, 2007; Fadok et al., 2001). Most apoptotic cells are cleared at 
early stage of apoptosis when they are non-inflammatory, but during 
overwhelming apoptosis or impaired phagocytosis, apoptotic cells may remain in 
tissues, become inflammatory and even secondary necrotic cells. This impaired 
clearance of apoptotic cells activates the complement pathways (Trouw et al., 
2008). 
The binding of C1q to apoptotic cells was first observed on the surface 
blebs of human keratinocytes irradiated with UVB in vitro (Korb and Ahearn, 
1997). In later studies, C1q was also shown to bind directly to DNA and PS via its 
globular domain (Paidassi et al., 2008a; Paidassi et al., 2008b). Moreover, 
calreticulin was reported as a receptor for C1q and collectins including MBL 
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(Malhotra et al., 1990). Calreticulin is ubiquitously expressed in the endoplasmic 
reticulum (ER) (Michalak et al., 1999), but moves to the cell surface during 
apoptosis (Ogden et al., 2001). Therefore, it is believed to be the receptor on 
apoptotic cell for C1q binding and was reported to enhance the phagocytosis of 
apoptotic cells through the CD91 receptor on phagocytes (Donnelly et al., 2006; 
Ogden et al., 2001). Moreover, the phagocytic removal of apoptotic cells by 
residing macrophages was impaired in C1q-deficient mice (Taylor et al., 2000). 
Similar defect in phagocytosis was observed with monocyte-derived macrophages 
of C1q-deficient patients cultured in autologous serum and it was corrected by 
addition of normal human C1q (Chen et al., 2000). Furthermore, this defect was 
also observed in macrophages derived from monocytes of patients with systemic 
lupus erythematosus (SLE) in vitro (Herrmann et al., 1998). In this apoptotic cell 
clearance mechanism, phagocytosis is mediated by C1q and its receptors on 
apoptotic cells and phagocytes, without complement activation. 
Another reported mechanism is through C1q recognition of IgM bound to 
apoptotic cells leading to the activation complement classical pathway (Ogden et 
al., 2005; Quartier et al., 2004; Zwart et al., 2004). Only the late apoptotic cells 
were reported to be bound with IgM but not the early ones (Zwart et al., 2004). In 
this mechanism, C1q facilitates apoptotic cell clearance via generation of C3b 
opsonins on these cells (Quartier et al., 2004). C3b can be further cleaved into a 




1.2.3 The modulatory functions of C1q 
In addition to its role as a recognition molecule, C1q is also known to 
regulate the functions and activities of various immune cell types including 
dendritic cells (DCs), macrophages, lymphocytes and many other cell types (Lu et 
al., 2007; Lu et al., 2008; Nayak et al., 2010; van Kooten et al., 2008).  
1.2.3.1 Modulation of macrophages 
Macrophages are known as the scavengers to clear pathogens and unwanted 
materials inside the body. In addition to the role as scavengers, macrophages are 
also professional antigen presenting cells (APCs) and capable to secrete various 
cytokines to mediate immune responses.  
C1q was shown to mediate both the phagocytic functions of macrophages 
and their production of cytokines and other immune mediators (Lu et al., 2008). 
The phagocytic activities of macrophages was shown to be enhanced by direct 
opsonization of Listeria monocytogenes by C1q (Alvarez-Dominguez et al., 1993). 
Moreover, C1q is able to induce complement activation and C3 opsonin 
deposition on Streptococcus pneumonia via the help of lectin receptor SIGN-R1, 
which binds to both C1q and S. pneumonia (Kang et al., 2006). Furthermore, C1q 
was shown to enhance Fc receptor (FcR)-dependent and complement receptor 
(CR)-1-dependent phagocytosis by human monocytes and cultured macrophages 
(Bobak et al., 1988; Bobak et al., 1987). 
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Soluble C1q, endogenously produced by murine macrophages, was found to 
promote macrophage tumor necrosis factor-alpha (TNF-α) receptor synthesis and 
result in the autocrine signaling by TNFα to increase nitric oxide (NO) production 
(Jiang et al., 1996). Furthermore, TNF-α and C3 production by macrophages was 
induced by soluble C1q, leading to enhanced phagocytosis (Bajtay et al., 2000). 
Nevertheless, immobilized C1q was also observed to enhance phagocytosis of 
macrophages via interaction with CD93 on macrophages (Nepomuceno et al., 
1997). 
C1q deficiency led to defects in apoptotic cell removal by macrophages 
form both C1q deficient mice (Taylor et al., 2000) and  C1q-deficient patients 
(Chen et al., 2000), which could be corrected by addition of normal C1q. 
Nevertheless, reduced uptake of apoptotic cells by macrophages in lupus patients 
was found to be correlated with decreased serum level of C1q (Bijl et al., 2006). 
The impaired phagocytic function observed in macrophages caused by C1q 
deficiency suggests an important role of C1q in apoptotic cell clearance by 





1.2.3.2 Modulation of dendritic cells (DCs) 
DCs are major professional APCs that bridge innate and adaptive immunity 
(Banchereau and Steinman, 1998; Vyas et al., 2008). DCs are able to either 
activate adaptive immune response or induce tolerance based on their 
microenvironment and available immune mediators present (Banchereau and 
Steinman, 1998; Morelli and Thomson, 2007).  
C1q was shown to enhance the uptake of apoptotic cells by DCs through 
opsonization and modulate cytokine production by DCs, though conflicting 
results were presented by different groups (Baruah et al., 2006; Fraser et al., 2009; 
Nauta et al., 2004). C1q-opsonized apoptotic cells were shown to increase 
interleukin (IL)-12p70 production by DCs in one study (Baruah et al., 2006), 
while the other study showed unchanged IL-12p70 production, but increased 
TNF-α, IL-6 and IL-10 production (Nauta et al., 2004). The increased production 
of TNF-α and IL-10, but not IL-6 was also observed by another group (Fraser et 
al., 2009). 
Besides C1q-opsonized apoptotic cells, either soluble or immobilized C1q 
alone was also shown to affect DC differentiation and maturation, this renders 
these DCs less immunostimulatory or more tolerogenic, though conflicting results 
exist from different groups  (Castellano et al., 2007; Csomor et al., 2007; Teh et 
al., 2011).  
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Soluble C1q was shown to be able to render the differentiation of 
monocyte-derived DCs into immature DCs with high phagocytic capacity and low 
surface expression of CD80, CD83 and CD86, similar to normal DCs (Castellano 
et al., 2007). But mature DCs induced by lipopolysaccharide (LPS), in the 
presence of soluble C1q, showed impaired production of TNF-α, IL-6 and IL-10 
and limited up-regulation of co-stimulatory molecules CD80, CD83 and CD86. 
The ability to stimulate allogeneic T cells and the production of interferon gamma 
(IFNγ) by these T cells was also impaired in these DCs (Castellano et al., 2007). 
Moreover, C1q was also shown to suppress LPS-stimulated IL-12p40 production 
in murine bone marrow-derived DCs (BMDC) (Yamada et al., 2004).  
DCs cultured with immobilized C1q also showed similar major 
histocompatibility complex (MHC), CD40, CD80, CD86, CD83 and C-C 
chemokine receptor type 7 (CCR7) expressions as normal DCs. However, 
increased phagocytosis of apoptotic cells and elevated IL-10 but reduced IL-12 
and IL-23 production were observed. Furthermore, these DCs showed reduced 
type 1 T helper cells (Th1) and Th17 induction from allogeneic CD4(+) T cells 
(Teh et al., 2011). Similar results were shown in another study that reduced 
cytokine production was observed in DCs differentiated on immobilized C1q 
(Fraser et al., 2009). These suggest that under normal situations, tissue-deposited 
C1q around DCs may induce tolerogenic properties in developing DCs. However, 
conflicting results were also reported  in another experimental design, which 
showed up-regulation of co-stimulatory molecules CD83, CD86, CCR7 and MHC 
II, together with the increased expression of TNF-α, IL-10 and IL-12  (Csomor et 
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al., 2007). Moreover, allogeneic T cell proliferation was promoted and increased 
IFNγ production by these T cells was observed (Csomor et al., 2007). 
1.2.3.3 Modulation of other cell types 
The functions of B cells and T cells were also shown to be regulated by C1q 
(Nayak et al., 2010). Aggregated C1q enhanced Ig production by peripheral B 
cells (Daha et al., 1990) and similar increase of Ig production was also observed 
in activated B cells (Young et al., 1991). In a study using C1q-knockout mice, 
increased positive selection of B1b cells and IgM autoantibodies against self-
antigens exposed on apoptotic cells was observed, while negative selection of 
auto-reactive conventional B cells decreased. This breaks B cell tolerance on self-
antigens (Ferry et al., 2007). In T cells cultured with immobilized C1q, increased 
IL-10 and reduced IL-4 were observed in human (Lu et al., 2007). While in C1q 
knockout mice, defective IFNγ production by antigen-specific T cells was 
observed, which subsequently led to reduced production of IgG2a and IgG3 
(Cutler et al., 1998). 
Neutrophils incubated with soluble C1q showed increased CR3 expression 
and enhanced adherence (Eggleton et al., 1994), while immobilized C1q caused 
increased production of superoxide anion production in neutrophils (Goodman 
and Tenner, 1992). Activation and aggregation of platelets were induced by C1q 
alone through interaction with globular head receptor (gC1qR) (Peerschke et al., 
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1993). This is also observed in the presence of immune complexes during tissue 
damage (Peerschke and Ghebrehiwet, 1997). 
C1q was also shown to regulate the chemotaxis of fibroblasts (Oiki and 
Okada, 1988), adherent neutrophils (Leigh et al., 1998) and immature monocyte-
derived DCs (Vegh et al., 2006) through the interaction with gC1qR on these cells. 
Moreover, C1q also binds to calreticulin and gC1qR to induce chemokinesis of 
eosinophils (Kuna et al., 1996) and mast cells (Ghebrehiwet et al., 1995). 
C1q also interacts with endothelial cells to modulate their adhesion and 
spreading (Feng et al., 2002), production of cytokines and chemokines to attract 
immune cells to site of inflammation (van den Berg et al., 1998) and expression 
of adhesion molecules for leukocytes when C1q bound to immune complexes 
(Lozada et al., 1995).  
Nevertheless, C1q induces apoptosis in prostate cancer cells by activating 
tumor suppressor WOX-1 and destabilizing cell adhesion, and this was also 
observed in breast cancer cells and neuroblastoma cells (Hong et al., 2009). This 
anti-proliferation response by C1q interaction was also observed in human 
peripheral T cells (Chen et al., 1994), murine primary mast cells (Ghebrehiwet et 
al., 1995), microglial cells (Farber et al., 2009) and several cultured cell lines 




1.3 C1q-related diseases  
Given the various functions of C1q in the immune system that involve 
diverse cell types, C1q and its deficiency are associated with a wide range of 
diseases, including infectious, autoimmune, cardiovascular and neurological 
diseases. Although it may not be the primary etiology of all related diseases, it 
plays either a direct or indirect role in the disease manifestations. 
1.3.1 Infectious diseases 
C1q recognizes pathogens directly or indirectly through immune complexes, 
leading to the elimination of pathogens through complement activation and 
opsonization for uptake by phagocytes (Joiner et al., 1984; Lu et al., 2008).  
Antibodies against pathogens are normally required for C1q-activated 
complement pathway. However, antibody-independent activation of complement 
pathway through direct interaction of C1q and pathogens was also observed with 
Gram-negative bacteria Klebsiella pneumonia (Alberti et al., 1993), Gram-
positive bacteria type Ia group B Streptococcus (Eads et al., 1982), animal 
retrovirus Moloney murine leukemia virus (MMLV) (Bartholomew et al., 1978) 
and human immunodeficiency virus (HIV)-1 (Ebenbichler et al., 1991). 
Furthermore, complement-independent elimination via phagocytosis was 
observed with direct opsonization of Listeria monocytogenes by C1q (Alvarez-
Dominguez et al., 1993). Therefore, C1q deficiency increases host susceptibility 
to various types of pathogen infections. C1q-deficient mice showed significant 
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increase of susceptibility to malaria parasite Plasmodium chabaudi infection 
(Taylor et al., 2001), polymicrobial peritonitis (Celik et al., 2001) and  
Salmonella enterica serovar Typhimurium infection (Warren et al., 2002).  
Besides fighting against pathogens through activating complement and 
facilitating phagocytosis, C1q was also shown to be able to reduce the 
stoichiometric threshold for antibody-mediated neutralization of West Nile virus 
(WNV) (Mehlhop et al., 2009). This prevents the antibody-dependent 
enhancement (ADE) of WNV infection which can result in exacerbation of 
infection (Pierson et al., 2007). 
1.3.2 Autoimmune diseases 
Autoimmunity is an abnormal immune response against self-antigens. It 
results from the loss of self-tolerance, which is essential for normal immune 
functions. Although the mechanism behind the loss of self-tolerance is still 
elusive, the induction and development of autoimmune diseases is believed to 
involve interactions between various predisposed genetic elements and epigenetic 
changes caused by environmental factors (Hewagama and Richardson, 2009).  
Insufficient clearance and tissue deposition of apoptotic cells and immune 
complexes are believed to cause autoimmunity by promoting the production of 
autoantibodies, as they are rich source of autoantigens (Casciola-Rosen et al., 
1994; Mevorach et al., 1998; Truedsson et al., 2007). As C1q plays an important 
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role in apoptotic cell clearance as described in section 1.2.2, its deficiency leads to 
impaired clearance and accumulation of apoptotic cells and immune complexes, 
resulting in the exposure of autoantigens to the immune system (Carneiro-
Sampaio, 2008; Casciola-Rosen et al., 1994; Mevorach et al., 1998; Schifferli et 
al., 1986; Truedsson et al., 2007). The formation of autoantibodies due to the 
exposure of self-antigens was observed in patients with autoimmune diseases 
(Manderson et al., 2004; Rahman and Isenberg, 2008).  
Hereditary C1q deficiency, although relatively rare, is strongly associated 
with the development of systemic lupus erythematosus (SLE) (Carneiro-Sampaio 
et al., 2008). About 88% genetic C1q deficiency patients presented SLE or SLE-
like symptoms (Schejbel et al., 2011). SLE is a systemic autoimmune disease 
characterized by autoantibody production, immune complex formation and 
deposition, and extensive tissue injury, which affects multiple organs (Moser et 
al., 2009; Tsokos, 2011). Female predominance in SLE patients was observed 
with a gender distribution of 7:1 (Bowness et al., 1994; Rahman and Isenberg, 
2008). The predominance is lost in SLE patients with hereditary C1q deficiency 
(Pickering et al., 2000).  
In animal models, C1q deficient mice created by Botto and collaborators, 
developed glomerulonephritis characterized by increased apoptotic cells and 
autoantibodies detected in these mice, resembling the phenotypes of SLE patients 
(Botto et al., 1998). Furthermore, in some SLE patients without genetic C1q 
deficiency, reduced C1q mRNA expression and impaired up-regulation C1q 
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production in response to stimulation were observed in cultured monocytes from 
their peripheral blood (Moosig et al., 2006). This suggests that in addition to 
genetic defects in coding regions, defects in epigenetic regulation of C1q may 
contribute to the disease onset and development of SLE. Nevertheless, the facts 
that C1q inhibits IC-induced IFNα production in plasmacytoid DCs (pDCs) (Lood 
et al., 2009), and induces the tolerogenic properties of developing DCs (Teh et al., 
2011), together suggest that C1q plays a protective role in SLE pathogenesis and 
its deficiency is a strong risk factor for the disease pathogenesis.  
Besides the primary C1q deficiency in patients with genetic C1q deficiency, 
acquired C1q deficiency was also observed in SLE patients (Edelbauer et al., 
2011; Wu et al., 2011), especially when the patients develop lupus nephritis 
(Sinico et al., 2009; Trendelenburg and Schifferli, 2000; Tsirogianni et al., 2009). 
This could be caused by C1q consumption by immune complexes and anti-C1q 
autoantibodies (Gordon et al., 2000; Greisman et al., 1987). High tier of anti-C1q 
autoantibodies was found to lead to hypocomplementemia and lupus nephritis 
which worsen the disease state (Horvath et al., 2001; Sinico et al., 2009; 
Trendelenburg, 2005; Tsirogianni et al., 2009). Moreover, the administration of 
anti-C1q autoantibodies in mice resulted in glomerular deposition of C1q-
containing immune complexes and renal damage (Trouw et al., 2004). This 
suggests a pathogenic role of C1q in SLE propagation. The double-edged-sword 
properties of C1q is also reflected in its ability to activate complement pathway, 
resulting in the generation of anaphylatoxins to recruit inflammatory cells causing 
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inflammation and tissue injury in both human SLE patients and mice models 
(Cook and Botto, 2006; Turnberg et al., 2006). 
This paradoxical role of C1q in the pathogenesis of SLE could be explained 
by dividing its role based on the disease states of SLE. During the onset of SLE, 
C1q provides a protective function by facilitating the clearance of apoptotic cells 
and immune complexes, as well as maintaining tolerance via its interaction with 
DCs. In normal individuals, the process of this clearance is rapid, without the 
activation of complement and inflammation (Zwart et al., 2004). However, in 
SLE patients, impaired clearance occurs due to C1q deficiency or other genetic 
defects together with environmental factors. Thus the accumulation of apoptotic 
cells and immune complexes causes inflammation and loss of tolerance to self-
antigens. In this stage, the presence of C1q in the deposited immune complexes 
leads to the formation of anti-C1q autoantibodies, and thus C1q becomes 
pathogenic in the disease propagation.  
1.3.3 Other C1q-related diseases 
In addition to its protective role in infectious diseases and early onset of the 
autoimmune diseases, C1q contributes to the pathogenesis of cardiovascular 
diseases with inappropriate complement activation. Vascular endothelial cells 
express gC1qR which is able to binds to C1q and cause complement activation 
during atherosclerosis, worsening the inflammation of the endothelium (Yin et al., 
2007). Similar inappropriate activation of complement was also observed during 
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vascular injury which is due to platelet activation after binding to C1q (Peerschke 
et al., 2009). Moreover, C1q binds to modified low density lipoproteins, that 
accumulate in atherosclerotic lesions, and activate complement system (Biro et al., 
2007). Other than atherosclerosis, C1q also contributes to the myocardial damage 
through complement activation. It binds to C-reactive protein, whose level is 
elevated during myocardial infarction.  (Kostner, 2004; McGrath et al., 2006; 
Nijmeijer et al., 2001). 
Besides cardiovascular diseases, C1q also plays a paradoxical role in the 
central nervous system (CNS). On the protective side, C1q helps in synapse 
pruning during brain development (Stevens et al., 2007). Its absence in mice 
development results in increased epilepsy due to impaired elimination of 
excessive synapses (Chu et al., 2010). Moreover, immobilized C1q enhances 
clearance of apoptotic neurons and neuron blebs and suppresses inflammatory 
cytokine production by microglial cells, which are phagocytes in CNS to remove 
debris during development and injury (Fraser et al., 2010). Nevertheless, in the 
substantia nigra in Parkinson disease patients, C1q is involved in the clearance of 
extracellular neuronmelanin and degenerative neuron debris by microglia 
(Depboylu et al., 2011). 
On the other hand, soluble C1q activates microglia to produce 
proinflammatory cytokines (Farber et al., 2009) and it activates complement 
system at ischemic lesions of cerebral ischemic patients, worsening the disease 
conditions (Pedersen et al., 2009). Elevated level of C1q was also detected in the 
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cerebrospinal fluid in the rat model of global cerebral ischemia (Schafer et al., 
2000). Moreover, in the brain of patients with Alzheimer's disease, which is 
characterized by extracellular deposition of senile plaques, intracellular 
neurofibrillary tangle and neuron loss (Selkoe, 1991), up-regulation of C1q and 
other complement proteins were observed (Yasojima et al., 1999). The binding of 
C1q to β-amyloid in the senile plaques (Rogers et al., 1992; Tacnet-Delorme et al., 
2001) and tau in the neurofibrillary tangle (Shen et al., 2001) was found to be 
responsible for the activation of complement system which resulted in 
inflammation and neuron damage. Nevertheless, C1q was shown to contribute in 
early prion pathogenesis (Klein et al., 2001) and its absence delays the onset of 
scrapie prion diseases (Mabbott et al., 2001).  C1q was later shown to bind 
directly to scrapie prion protein and activate complement system (Mitchell et al., 
2007). It contributes to scrapie pathogenesis through promoting the uptake of 
scrapie by conventional DCs (cDCs) in initial prion capture and subsequent 







1.4 C1q production and regulation 
1.4.1 C1q production 
Liver hepatocytes have been shown to be the major biosynthesis site of 
most components of the complement system (Colten, 1976). Despite the hepatic 
production of most complement proteins, C1q is produced by macrophages and 
DCs which are professional APCs required for adaptive immunity and tolerance 
to self-antigens (Lu et al., 2008; van Kooten et al., 2008). This special extra 
hepatic production of C1q correlates with its various physiological functions 
outside the complement system. 
The peritoneal macrophages are the first group of cells identified as a major 
source of serum C1q (Kaul and Loos, 1993; Muller et al., 1978; Rabs et al., 1986). 
Cultured monocyte-derived macrophages were also shown to express C1q 
identical to serum C1q (Kaul and Loos, 1995; Tenner and Volkin, 1986). C1q was 
later found to be produced by microglial cells (Dietzschold et al., 1995) and 
kupffer cells (Armbrust et al., 1997), which are macrophages in CNS and liver 
respectively, as well as stromal cells, macrophages in bone marrow (Tripodo et al., 
2007). In addition to macrophages, DCs are also reported as the main production 
site of C1q. Follicular DCs and interdigitating DCs in the rat spleen were the first 
group of DCs shown to produce C1q (Schwaeble et al., 1995). Subsequently, both 
human and mouse DCs were also shown to produce C1q (Cao et al., 2003; 
Castellano et al., 2010; Castellano et al., 2004; Lu et al., 2008; Tripodo et al., 
2007). There is an agreement on C1q production by immature DCs which are 
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found in peripheral tissues, though there are conflicts on C1q synthesis by mature 
DCs between different studies (Cao et al., 2003; Castellano et al., 2004; 
Schwaeble et al., 1995). Although monocyte-derived macrophages and DCs 
constitutively express C1q, the undifferentiated circulating monocyte precursors 
lack C1q expression and the expression is detected immediately after the 
differentiation takes place (Lu et al., 1996; Lu et al., 2008). 
Besides macrophages and DCs, several other cell types were also reported 
with C1q production in early studies as well as recent ones, including intestine 
epithelial cells (Colten et al., 1968; Morris et al., 1978), fibroblasts (Reid and 
Solomon, 1977), chondrocytes (Bradley et al., 1996) and decidual endothelial 
cells (Bulla et al., 2008) . However, with more specific reagents for different C1 
subcomponents, epithelial cells and fibroblasts were found to produce only C1s 
and C1r, with C1q being produced by mononuclear phagocytes (Lu et al., 2008). 
The hematopoietic origin of C1q-producing cells was also affirmed by the 
restoration of C1q production in irradiated C1q-knockout mice with bone marrow 






1.4.2 Regulation of C1q expression 
Factors of microbial and host origins can modulate C1q expression, 
although C1q production in DCs and macrophages is constitutive (Lu et al., 2008; 
van Kooten et al., 2008). As reviewed in 2008 (Lu et al., 2008), Toll-like receptor 
(TLR) ligands such as LPS and zymosan, immune complexes, inflammatory 
cytokines anti-inflammatory drugs and hormones were shown to regulate C1q 
expression and secretion, though conflicting results were observed with respect to 
cell types and stimuli (Armbrust et al., 1997; Baruah et al., 2006; Castellano et al., 
2010; Castellano et al., 2004; Faust and Loos, 2002; Kaul and Loos, 2001; 
Trinder et al., 1995; Walker, 1998; Zhou et al., 1991). Among all the factors, 
IFNγ was shown to be the most potent positive regulator of C1q expression, with 
the least conflicting data reported by different groups (Lu et al., 2008).  
Given the elusive regulation pattern of C1q production by factors from 
various origins and the specific expression by professional APCs, together with its 
various roles in modulating immune cells, the control of C1q expression plays an 
important role in modulating immune system and maintaining self-tolerance. This 
provides the possibility that transient changes in C1q production by macrophages 
and DCs due to infection, inflammation or medical treatments may be a protective 
mechanism against the development of autoimmune diseases like SLE. The 
defects in signal transduction upon stimulation in some SLE patients resulting in 




1.5 Interferon γ (IFNγ) and its role in systemic lupus 
erythematosus (SLE) 
IFNγ is the only member of the type II interferon (IFN) family and hallmark 
of Th1 response. It is an important macrophage activator, critical for innate and 
adaptive immunity against viral and intracellular bacterial infections and for 
tumor control. Its importance stems in part from its function in the defense against 
microbial infections directly, and most importantly from its immunostimulatory 
and immunomodulatory functions in innate and adaptive immunity (Saha et al., 
2010; Schoenborn and Wilson, 2007). Given its importance in modulating 
immunity, aberrant IFNγ expression is associated with a number of 
autoinflammatory and autoimmune diseases (Young and Bream, 2007).  
1.5.1 The role of IFNγ in SLE 
The pathogenic role of IFNγ has been demonstrated in both human and 
murine lupus (Theofilopoulos et al., 2001). Elevated levels of IFNγ were shown 
to be associated with disease activity of SLE patients (Akahoshi et al., 1999). 
Activation of the IFNγ signaling pathway was also observed in peripheral blood 
mononuclear cells of SLE patients (Karonitsch et al., 2009).  
Distinct gene expression patterns between SLE patients and healthy controls 
were identified using global gene expression profiling of peripheral blood 
mononuclear cells from these two groups. Dysregulation in the expression of IFN-
inducible genes was shown in half of the patients studied. Furthermore, this IFN-
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inducible gene expression pattern serves as a marker for more severe disease 
involving the kidneys, hematopoietic cells, and the CNS. These results provide 
insights into the genetic pathways underlying SLE, and identify a subgroup of 
patients who may benefit from therapies targeting the IFN pathway (Baechler et 
al., 2003; Hayashi, 2010; Lourenco and La Cava, 2009). It was also reported that 
monocytes in some SLE patients were not able to up-regulate C1q production in 
response to IFNγ stimulation (Moosig et al., 2006).  
Given that IFNγ is the most potent inducer of C1q production (Lu et al., 
2008) and its elevated level was associated with SLE (Akahoshi et al., 1999; 
Karonitsch et al., 2009), defects in IFNγ signaling transduction may contribute to 
the pathogenesis and development of SLE. To elucidate the influence of C1q 
dysregulation on SLE pathogenesis, a model is proposed for SLE pathogenesis 
due to the dysregulation of C1q expression in response to IFNγ (Figure 1.2).  
When viral infection occurs, infected cells were induced to undergo 
apoptosis and immune complexes are formed as the result of antibody 
neutralization with the viral particles. The existing C1q binds to the apoptotic 
cells and immune complexes to facilitate their clearance by tissue macrophages. T 
cells are also activated due to viral infection and secret various types of cytokines 
to mediate immune responses against viral infection. As part of the anti-viral 
cytokines, IFNγ is secreted by T cells and activate DCs and macrophages.  
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In normal individuals, C1q production by DCs and macrophages is up-
regulated in response to IFNγ. The newly synthesized C1q compensates the C1q 
consumption due to apoptotic cells and immune complexes. This helps in fast 
removal of apoptotic cells and immune complexes and prevents the onset of 
complement activation, excessive inflammation and finally autoantibody 
formation due to cross-presentation of self-antigens by DCs.  
However, in SLE patients with defects in C1q up-regulation, IFNγ is not 
able to induce C1q production. This leads to the excessive consumption of C1q 
and accumulation of apoptotic cells and immune complexes due to impaired 
clearance which is normally augmented by C1q. This eventually causes 
complement activation, excessive inflammation and finally autoantibody 




Figure 1.2. Proposed model for SLE pathogenesis due to the dysregulation of 
C1q expression in response to IFNγ.  When viral infection occurs, infected cells 
were induced to undergo apoptosis and immune complexes are formed as the 
result of antibody neutralization with the viral particles. The existing C1q binds to 
the apoptotic cells and immune complexes to facilitate their clearance by tissue 
macrophages. T cells are also activated due to viral infection and secret various 
types of cytokines to mediate immune responses against viral infection. As part of 
the anti-viral cytokines, IFNγ is secreted by T cells and activate DCs and 
macrophages. In normal individuals, C1q production by DCs and macrophages is 
up-regulated in response to IFNγ. The newly synthesized C1q compensates the 
C1q consumption due to apoptotic cells and immune complexes. This helps in the 
fast removal of apoptotic cells and immune complexes, and prevents the onset of 
complement activation, excessive inflammation and finally autoantibody 
formation due to cross-presentation of self-antigens by DCs. However, in SLE 
patients with defects in C1q up-regulation, IFNγ is not able to induce C1q 
production. This leads to the excessive consumption of C1q and accumulation of 
apoptotic cells and immune complexes due to impaired clearance which is 
normally augmented by C1q. This eventually causes complement activation, 
excessive inflammation and finally autoantibody formation due to cross-
presentation of self-antigens by DCs.  
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1.5.2 IFNγ regulatory network and transcription factors (TFs) involved  
As IFNγ is able to regulate various functions of different cell types, its 
signaling network involves various signaling molecules, kinases, transcription 
factors (TFs) and tissue-specific TFs (Hu and Ivashkiv, 2009). Though there are 
various reported pathways involved in IFNγ signaling, it mainly starts via Janus 
activated kinase (JAK)-signal transducer and activator of transcription (STAT) 
pathway (Hu and Ivashkiv, 2009; Stark, 2007). The binding of IFNγ to its 
receptor activates the receptor-associated JAK1 and JAK2 and phosphorylation of 
a receptor tyrosine residue (Y440) that serves as a docking site for STAT1 (Stark, 
2007). STAT1 is then activated by phosphorylation and translocated to the 
nucleus, where it binds to a regulatory element, gamma-activating sequence (GAS) 
to modulate the transcription of various IFNγ-responsive genes by recruiting 
several transcription co-modulators (Hu and Ivashkiv, 2009; Stark, 2007).   
In addition to JAK-STAT pathway, other pathways were also reported to 
participate in IFNγ-mediated gene transcription (Saha et al., 2010). IFNγ is able 
to activate phosphatidylinsositol-3-kinase (PI3K) pathway, which activates 
protein kinase C (PKC), leading to the activation of mitogen activated protein 
kinase (MAPK) pathway. The activation of MAPK pathway activates STAT1 
(Choudhury, 2004). Moreover, the activation of various forms of PKCs and 
MAPKs by IFNγ was also reported by several other studies (Deb et al., 2003; 
Kovarik et al., 1999; Srivastava et al., 2004; Valledor et al., 2008).  
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Besides the first wave of transcription modulated by direct STAT1 binding 
to IFNγ-responsive gene promoters, STAT1 is also able to induce the expression 
of several TFs in the first wave, and start the second wave of transcription 
modulation (Hu and Ivashkiv, 2009; Schroder et al., 2004). These second wave 
TFs include several members of the interferon regulatory factor (IRF) family. 
They either form complex with STAT proteins to mediate gene transcription, or 
form complexes with other TFs to regulate gene transcription through binding to 
various cis elements. These elements include GAS, interferon-stimulated response 
element (ISRE) and composite elements consisting of IRF motifs and binding 
sites for other TFs in cell-specific manners (Kanno et al., 2005).  
IRF9 forms complex with STAT1 to activate gene transcription via binding 
to ISRE (Bluyssen et al., 1995). Furthermore, IRF1 and IRF2 activate or repress 
target gene transcription also via binding to ISRE (Harada et al., 1994; Kumatori 
et al., 2002). Moreover, PU.1 (as known as SPI1), a member of the Ets family, 
was shown to complex with IRF8 and IRF4 to regulate transcription via binding 
to various composite elements (Kanno et al., 2005), include modified GAS 
element (Contursi et al., 2000; Decker et al., 1997), Ets/IRF composite element 
(EICE) (Marecki et al., 2001; Schroder et al., 2007), Ets/IRF response element 
(EIRE) (Meraro et al., 2002) and IRF-Ets composite site (IECS) (Tamura et al., 
2005). Though these cis elements are named differently, there are only subtle 
differences between these elements (Kanno et al., 2005; Marecki and Fenton, 
2000). The discovery of novel chimeric sequences of ISRE and GAS (Kaneko et 
al., 2006) suggests other novel elements exist and remain undiscovered.  
30 
 
1.6 C1q structure and genomic organization 
1.6.1 C1q structure 
The human C1q is a 460 kDa glycoprotein consisting of 18 polypeptides 
with 6 A, 6 B and 6 C chains (Reid, 1989; Sellar et al., 1991). The three subunit 
chains are structurally similar, that each chain has a N-terminal collagenous 
domain and a C-terminal globular head domain (Kishore and Reid, 1999).  
The N-terminal collagenous domains of A and B chains are connected via 
disulphide bond to form A-B heterodimer. Similarly, 2 C chains also form C-C 
homodimer via disulphide bond at N-terminal domains. One A-B heterodimer and 
one C chain from the C-C homodimer forms one A-B-C heterotrimer, a triple 
helix structure. This subsequently brings two A-B-C heterotrimers together to 
form ABC-CBA triple helix structure unit. Further interactions at the collagenous 
domains allow three ABC-CBA structures to form one functional C1q molecule 
(Figure 1.3) (Lu et al., 2008; Reid and Porter, 1976).  
Under the electron microscope, the configuration of a functional C1q 
molecule is viewed as a "bundle-of-tulips" (Brodsky-Doyle et al., 1976). 
Disruptions at Gly-Xaa-Yaa motifs could dissociate one C1q molecule into 6 
heteromeric ABC structures followed by their globular heads (Reid and Porter, 
1976). These globular heads exist as a compact and almost spherical 
heterotrimeric structure through non-polar interactions (Gaboriaud et al., 2003). 
This implies a modular organization of the globular heads from three different 
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subunit chains and the differential recognition properties of C1q (Gaboriaud et al., 
2003; Kishore et al., 2003; Kojouharova et al., 2003). 
 
Figure 1.3. Formation of the functional C1q molecule.  C1q is assembled from 
C1qA, C1qB and C1qC chains. Each chain consists of an N-terminal collagenous 
domain and a C-terminal globular head domain. The A and B chains, as well as 
the 2 C chains dimerize through disulphide bonds at the N-termini to form A-B 
heterodimer and C-C homodimer, respectively. Further interactions between A-B 
dimer and C-C dimer lead to the formation of a ABC-CBA triple helix structure 
unit. More interactions at the collagenous domains bring three such structures 
together to form one functional C1q molecule. This figure is adapted and 
modified from Lu et al., 2008. 
1.6.2 C1q genomic organization 
The three C1q subunit chains are products from three distinct genes in the 
genome, namely C1qA, C1qB and C1qC.  At the genomic level, the human C1qA, 
C1qB, and C1qC genes are found to be clustered on a 25 kb fragment on a human 
genomic contig (accession No. NT_004610) in the reference sequence (RefSeq) 
database from the National Center for Biotechnology Information (NCBI) website. 
This stretch of sequence falls into the region of 1p34.1-1p36.3 of the short arm on 
human chromosome 1 (Sellar et al., 1992). The genes are arranged in a 5’ to 3’ 
orientation, in the order of C1qA-C1qC-C1qB, with an approximately 4 kb 
intergenic region between C1qA and C1qC and a 5 kb region between C1qC and 
32 
 
C1qB (Figure. 1.4A) (Sellar et al., 1991). The three genes have similar 
exon/intron organization. Each gene contains three exons and two introns with the 
translation starting codon (ATG) being located in the second exon (Figure 1.3A) 
(Kishore and Reid, 2000; Sellar et al., 1991).  
Conserved genomic organization was observed from mouse C1q genes on 
mouse chromosome 4 (Petry et al., 1996) and zebrafish C1q genes on zebrafish 
chromosome 21 (Hu et al., 2010). A further search through the RefSeq database 
from the NCBI website revealed a highly conserved arrangement of C1q genes 
within a short stretch region in the genome of a number of species, though they 
locate on different chromosomes and on positive or negative strand of the 
genomic DNA sequence (Figure 1.4B). These species include human 
(chromosome 1, NC_000001.10, positive strand), chimpanzee (chromosome 1, 
NC_006468.3, positive strand), mouse (chromosome 4, NC_000070.5, negative 
strand), rat (chromosome 5, NC_005104.2, negative strand), dog (chromosome 2, 
NC_006584.2, negative strand), cattle (chromosome 2, NC_007300.4, negative 
strand), chicken (chromosome 21, NC_006108.2, negative strand) and zebrafish 
(chromosome 21, NC_007132.5, negative strand). The conservation of the C1q 
gene organization suggests that the transcriptional regulation of the C1q genes is 






Figure 1.4. Genomic organization of C1q subunit genes is conserved across 
different species.  The human C1q subunit genes are arranged in the order of 
C1qA-C1qC-C1qB and the untranslated regions and translated regions are 
represented by blue and pink boxes, respectively (A). The genomic organization 
of C1q subunit genes across different species is conserved in the order of C1qA-
C1qC-C1qB and C1qA, C1qB and C1qC are represented by red, blue and purple 





1.7 The regulation of genes as clusters 
In eukaryotes, instead of being randomly distributed in the genome, highly 
expressed genes, especially housekeeping genes, tend to gather as clusters within 
specific chromosome regions to reach coordinated expression (Caron et al., 2001; 
Lercher et al., 2002). A gene cluster is thus defined as a group of genes that are 
functionally related or their gene products need to be co-expressed to form a 
complex stoichiometrically (Davila Lopez et al., 2010; Niehrs and Pollet, 1999).  
Recent genome studies revealed that gene clustering is common in 
eukaryotic genomes (Boutanaev et al., 2002), and well conserved during 
evolution (Hurst et al., 2004). Several gene cluster loci on the chromosomes were 
characterized and evolutionary conserved among mammals and zebrafish (Aggad 
et al., 2010; Dumoutier et al., 2000; Igawa et al., 2006; Lutfalla et al., 2003), 
including those in the innate immune response system . Well-studied 
representatives of these gene clusters include β-globin gene cluster during 
erythropoiesis (Li et al., 2002) and Hox genes during body development (Spitz et 
al., 2005).  
The discovery of locus control region in the β-globin locus has shown that 
the long-range interactions of various cis regulatory elements and dynamic 
chromatin alteration are important in developmental and cell lineage-specific 
regulation of gene expression, in addition to gene-proximal elements (Li et al., 
2002). This suggests that the coordinated regulation of these gene clusters is 
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facilitated by interactions between gene proximal and shared long-range 
regulatory elements. 
The precise coordination is believed to be achieved through spatial 
organization of chromatin and RNA polymerases within discrete sites scattered in 
the nucleus, known as transcription factories (Szentirmay and Sawadogo, 2000). 
Within these factories, active RNA polymerases are concentrated and work 
together on the transcription of a specific group of genes (Jackson et al., 1998; 
Pombo et al., 1999; Pombo et al., 2000). This concept was verified by the tissue-
specific expression of mouse α-globin gene cluster, which was shown to be 
regulated through moving in of the gene promoters and regulatory elements to a 
pre-existing transcription unit in the nucleus (Zhou et al., 2006). Furthermore, the 
expressions of α-globin gene cluster and an unrelated gene NME4 located 300kb 
away from α-globin gene cluster were found to be associated due to shared 
chromosome environment within each factory over long distance (Lower et al., 
2009).  
Genes within the same loci were also reported to be linked to certain 
diseases (Igawa et al., 2006; Kotenko, 2002; Vilcek, 2003). An example of 
disease-related gene clusters is the nicotinic acetylcholine receptor (nAChR) 
subunit β4/α3/α5 gene cluster, which was shown to be related to nicotine 
addiction and lung cancer (Improgo et al., 2010).  It was found to be coordinately 
expressed under the control of proximal promoters and shared long-range 
regulatory elements via the use of transgenic mice with P-1 derived artificial 
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chromosome (PAC) encoding endogenous rat cluster of nAChR genes (Xu et al., 
2006). Moreover, genome-wide chromatin immunoprecipitation (ChIP) analysis 
reveals the intersection of lineage-determining TFs, stimulus-activated TFs and 
cis-elements of responsive genes from clusters determines the tissue-specific 
response to inflammation (Natoli et al., 2011).  
High similarity levels in proteins between humans and chimpanzees have 
suggested that the molecular evolution of cis-regulatory regions play an important 
role in the evolution of the phenotype (King and Wilson, 1975). From genome-
wide studies, signatures of positive selection in promoter regions were shown to 
be widespread all over the genome (Haygood et al., 2007; Planas and Serrat, 
2010). Moreover, mutations or polymorphisms in both cis- and trans-elements 
play important roles in regulatory evolution of gene expression (Landry et al., 
2007). Analysis on yeast genes has further proved that both cis- and trans-
mutation contributed to the divergence of expression (Tirosh et al., 2009). 
Nevertheless, studies on the evolution of genes related to immune responses, 
dietary changes and behavior and cognition has shown the evolutionary 






1.8 Objectives of this study 
Given the importance of C1q in the regulation of immune system (Lu et al., 
2008; Nayak et al., 2010; van Kooten et al., 2008) and the development of various 
diseases (Fraser et al., 2010; Lu et al., 2008; Mehlhop et al., 2009; Schejbel et al., 
2011), understanding of the mechanisms underlying the transcriptional control of 
C1q expression could contribute to the understanding of its tissue-specific 
expression and the molecular basis underlying the pathogenesis of different 
diseases, in particular, the pathogenesis of SLE without genetic C1q deficiency.  
On the gene cluster aspect, C1q genes fulfill the requirement of a gene 
cluster (Davila Lopez et al., 2010; Niehrs and Pollet, 1999), as C1q genes are 
closely located on the chromosome (Sellar et al., 1991; Sellar et al., 1992), and 
their products interact physically to form a functional C1q molecule (Kishore and 
Reid, 2000; Reid, 1989; Reid and Porter, 1976). Thus it is interesting to find out 
how the three C1q genes are coordinately expressed and use it as a model to study 
gene cluster. Furthermore, C1q gene cluster evolutionary study may also provide 
more valuable information to other gene cluster studies. 
This study aims to characterize the C1q gene promoters, and elucidate the 
transcriptional control of C1q gene expression through the use of promoter 
luciferase assay and progressive deletions on the promoters to characterize the 
response element. It also aims to identify the TFs responsible for the induction of 
promoter activity through small hairpin RNA (shRNA) silencing system, DNA 
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affinity binding assay and ChIP assay. Moreover, it aims to find out the 
mechanism how the three genes are coordinately regulated. Furthermore, C1q 
promoters of other species will be investigated to understand the evolution of C1q 
gene cluster. In this study, IFNγ will be used as the stimulus, as it is the most 













Chapter 2  - Materials and methods 
2.1 Materials 
2.1.1Antibodies and reagents 
2.1.1.1 Antibodies 
The details of the antibodies used in this study are presented in Table 2.1. 
Table 2.1. List of antibodies used in the study. 
Target Host Conjugation Clone (Isotype) Usage Source 
Primary antibodies 
β-actin mouse - AC-15 WB S-A 
IRF1 rabbit - C20 WB, ChIP SCB 
IRF8 goat - C-19/C-19x WB, ChIP SCB 
PU.1 rabbit - H-135 or H-135x WB, ChIP SCB 
STAT1 rabbit - #9172 WB, ChIP CST 
CD14 mouse PE UCHM1 (IgG2a) FC Ancell 
isotype mouse PE RPC5 (IgG2a) FC Ancell 
Secondary antibodies 
Rabbit IgG goat AP - WB B-R 
Goat IgG rabbit AP - WB B-R 
Mouse IgG goat AP - WB B-R 
 
Usage 
WB - western blotting  ChIP - chromatin immunoprecipitation 
FC - flow cytometry 
 
Source 
Ancell: Ancell, Bayport, MN, USA 
BR:  Bio-Rad, Hercules, CA, USA  
CTS:  Cell Signaling Technology, Danvers, MA, USA 
S-A:  Sigma-Aldrich, St Louis, MO, USA  




2.1.1.2 General chemicals and solutions 
All chemical salts were obtained from (Sigma-Aldrich, St Louis, MO, USA) 
or Merck (Darmstadt, Germany), and all buffer stocks were obtained from 1st 
base (Singapore), unless otherwise listed in Table 2.2. 
Table 2.2. List of chemicals and solutions. 
Chemical/solution Source 
30% (w/v) Acrylamide/Bis solution, 37.5:1 
Bio-Rad 
(Hercules, CA, USA) 
Ammonium persulfate (APS) 
Dithiothreitol (DTT) 





(Santa Clara, CA, USA) 
 
2.1.1.3 Common reagents 
Gel for SDS-polyacrylamide gel electrophoresis (PAGE)  
Components of the SDS-PAGE gels used in this study are listed in Table 
2.3. 





4% 10% 12.5% 
Water 3.02 4.02 3.22 
0.5 M Tris-HCl pH 6.8 1.25 - - 
1.5 M Tris-HCl pH 8.8 - 2.5 2.5 
30% (w/v) Acrylamide/Bis solution, 37.5:1 0.65 3.33 4.13 
10% (w/v) SDS 0.05 0.1 0.1 
10% (w/v) APS 0.025 0.05 0.05 
TEMED 0.005 0.01 0.01 




Protease inhibitor cocktail 
The protease inhibitor cocktail was purchased from Sigma-Aldrich. It contains 
AEBSF, aprotinin, bestatin hydrochloride, E-64, leupeptin hemisulfate salt and 
pepstatin A. For the cell lysate of 10
9
 cells, 1 ml of the cocktail was added. 
Protein A agarose resins and streptavidin agarose resins 
Protein A agarose resins were obtained from Pierce Thermo Scientific (Rockford, 
IL, USA)  
Proteinase K 
Proteinase K (20 mg/ml) was obtained from New England Biolabs (Ipswich, MA, 
USA). 
Restriction endonucleases (REs) 
All REs used were obtained from Promega (Madison, WI, USA). 
RNase A 
DNase- and protease-free RNase (10 mg/ml) was obtained from Fermentas 
(Canada). 
Sonicated salmon sperm DNA 
The salmon sperm DNA was purchased from Sigma-Aldrich. The DNA was 
dissolved in nuclease-free water at a concentration of 5 mg/ml, and sonicated with 
Bioruptor (Diagenode, Liege, Belgium).  
T4 DNA ligase 
T4 DNA ligase for standard ligation was obtained from Promega. 
Western blot membrane 










1 x phosphate buffered saline (PBS) pH 7.4 (Diluted from commercial 10 x stock) 
KH2PO4      1.76 mM 
Na2HPO4      10.4 mM 
NaCl       137 mM 
KCl       2.7 mM 
Flow wash buffer 
PBS       1 x 
Heat inactivated (HI)-fetal bovine serum (FBS) 2.5% (v/v) 
Sodium azide      0.05% (w/v) 
1 x TAE pH 8.0 (Diluted from commercial 10 x stock) 
Tris-acetate      40 mM 
Ethylenediaminetetraacetic acid (EDTA)  1 mM 
Digestion buffer for genomic DNA extraction 
Tris-HCl pH 8.0     100 mM 
EDTA       5 mM 
NaCl       200 mM 
SDS       0.2 % (w/v) 
TE buffer 
Tris-HCl pH 8.0     10 mM 
EDTA       1 mM 
Proteinase K buffer 
Tris-HCl pH 8.0     10 mM 
EDTA       5 mM 
SDS       0.5 % (w/v) 
Radioimmune precipitation assay (RIPA) buffer 
Tris-HCl pH 7.0     50 mM 
EDTA       1 mM 
NaCl       150 mM 
Na-deoxycholate     0.25% (w/v) 
Nonidet P-40      1% (v/v) 






5 x reducing Laemmli SDS sample buffer 
Tris-HCl pH 6.8     250 mM 
Glycerol      50% (v/v) 
SDS       10% (w/v) 
Bromophenol Blue     1% (w/v) 
DTT       0.5 M 
10 x SDS-PAGE electrophoresis buffer 
Tris base      250 mM 
Glycine      2.5M 
SDS       1% (w/v) 
Adjust the pH to 8.3  
For 1 x SDS-PAGE electrophoresis buffer, one unit of the 10 x buffer was added 
to 9 units of deionized water. 
10 x western blot transfer buffer 
Tris base      250 mM 
Glycine      1.92 M 
For 1 x Western blot buffer, one unit of the 10 x buffer was added to 7 units of 
deionized water and two units of 100% methanol. 
Tris buffered saline (TBS) 
Tris-HCl pH 7.4     50 mM 
NaCl       150 mM 
PBS-T/TBS-T buffer 
PBS/TBS      1X 
Tween-20      0.05% (v/v) 
Western blot blocking buffer and antibody diluent 
TBS-T       1X 
Non-fat milk      5% (w/v) 
Western blot stripping buffer 
Tris-HCl pH 6.8     62.5 mM 
SDS       2% (v/v) 
β-metacaptoethanol     0.1 M 
Buffers for DNA affinity binding assay 
Oligonucleotide annealing buffer 
Tris-HCl pH 8.0     10 mM 
EDTA       1 mM 




Tris-HCl pH 8.0     10 mM 
EDTA       1 mM 
NaCl       100 mM 
TGEDN buffer 
Tris-HCl pH 8.0     20 mM 
Glycerol      10% (v/v) 
EDTA       1 mM 
DTT       1 mM 
NaCl       100 mM 
Triton X-100      0.1% (v/v) 
Buffers for ChIP assay 
Lysis buffer 1 
Tris-HCl pH 8.0     50 mM 
EDTA       2 mM 
Triton X-100      1% (v/v) 
Glycerol      10% (v/v) 
Protease inhibitor cocktail was added freshly prior to use. 
Lysis buffer 2 
Tris-HCl pH 8.0     50 mM 
EDTA       5 mM 
SDS       1% (v/v) 
Protease inhibitor cocktail was added freshly prior to use. 
Dilution buffer 
Tris-HCl pH 8.0     50 mM 
EDTA       5 mM 
NaCl       200 mM 
Triton X-100      1% (v/v) 
Wash buffer  
Tris-HCl pH 8.0     20 mM 
EDTA       2 mM 
NaCl       150 mM 
Triton X-100      1% (v/v) 





Final Wash buffer  
Tris-HCl pH 8.0     20 mM 
EDTA       2 mM 
NaCl       500 mM 
Triton X-100      1% (v/v) 
SDS       0.1% (v/v) 
Elution buffer 
Tris-HCl pH 8.0     50 mM 
EDTA       5 mM 
DTT       10 mM 
SDS       1% (v/v) 
2.1.3 Cell culture media 
Opti-MEM, high glucose DMEM with L-Glutamine, RPMI-1640 with L-
Glutamine, Leibovitz's L-15 medium, 100 x non-essential amino acids and 
gentamicin (50 mg/ml) were purchased from Gibco (Invitrogen, Carlsbad, CA, 
USA). Bovine calf serum (BCS) and FBS was obtained from Hyclone Thermo-
Fisher Scientific (Waltham, MA, USA). 200 mM L-glutamine and 100 x 
penicillin/streptomycin (10,000 U/ml or 10 mg/ml) were obtained from PAA 
Laboratories (Pasching, Austria), Dimethyl sulfoxide (DMSO), chloroquine and 
10 x trypsin-EDTA was purchased from Sigma-Aldrich. Human granulocyte 
macrophage colony-stimulating factor (GM-CSF), human macrophage colony-
stimulating factor (M-CSF), human IL-4, human IFNγ (hIFNγ) and mouse IFNγ 
(mIFNγ) were purchased from R & D Systems (Minneapolis, MN, USA). 
Monocyte adhesion media 
RPMI-1640 with L-Glutamine 
BCS      5% (v/v) 




DC/Macrophage culture media 
RPMI-1640 with L-Glutamine 
BCS      10% (v/v) 
L-glutamine     2 mM 
Penicillin/streptomycin   100 U/ml 
Sodium pyruvate    1 mM 
β-metacaptoethanol    0.0012% (v/v) 
Primary cell stimulation media 
RPMI-1640 with L-Glutamine 
HI-BCS     10% (v/v) 
Penicillin/streptomycin   100 U/ml 
Complete DMEM 
DMEM (high glucose) with L-Glutamine 
BCS      10% (v/v) 
L-glutamine     2 mM 
Penicillin/streptomycin   100 U/ml 
For culturing human HEK293 cells and murine macrophage RAW264.7 cells. 
Complete RPMI 
RPMI-1640 with L-Glutamine 
HI-BCS     10% (v/v) 
L-glutamine     2 mM 
Penicillin/streptomycin   100 U/ml 
For culturing transfected RAW264.7 cells. 
Complete L-15 medium 
Leibovitz's L-15 medium  
FBS      15% (v/v) 
Penicillin/streptomycin   100 U/ml 
Gentamicin     10 μg/ml 







2.1.4 Cell lines 
HEK293 cells 
HEK293 cell is a human embryonic kidney cell line (Graham et al., 1977) 
obtained from American type culture collection (ATCC; Manassas, VA, USA). 
Cells were maintained in complete DMEM at 37 ºC in the presence of 5% CO2. 
Cells were dislodged via trypsinization and sub-cultured at a ratio of 1:4 (v/v) 
every 3 days.  
PAC-2 cells 
PAC-2 cell is a zebrafish embryonic fibroblast cell line obtained from 
Professor Nicholas S. Foulkes (Karlsruhe Institute of Technology, Universität 
Heidelberg, Germany) as gift (Vallone et al., 2007). Cells were maintained in 
complete L15 medium at 28 ºC in normal atmosphere. Cells were dislodged via 
trypsinization and sub-cultured at a ratio of 1:4 (v/v) every 3 days.  
RAW264.7 cells 
RAW264.7 cell is a mouse macrophage cell line (Raschke et al., 1978) 
obtained from ATCC. Cells were maintained in T-75 flasks with complete 
DMEM at 37 ºC in the presence of 5% CO2. Cells were dislodged via scraping 
and sub-cultured at a ratio of 1:3 (v/v) every 2 days. 
Cell line stocks 
For long term storage, cells were frozen in liquid nitrogen. The cells were 
allowed to grow in active growth phase and pelleted at 100 g for 5 min. Cells 





cells/ml. The cell suspension was subsequently aliquoted to cryogenic vial (Nalge 
Nunc International A/S, Roskilde, Denmark) at 1 ml/vial, frozen at -80 ºC 
overnight and transferred to liquid nitrogen for long term storage.  
2.1.5 Plasmid and bacterial artificial chromosome (BAC) 
pGL3-basic plasmid 
The pGL3-basic plasmid (Promega) is a 4,818 bp luciferase reporter vector 
that contains the firefly luciferase gene lacking eukaryotic promoter and enhancer 
sequences. The multiple cloning sites (MCS) upstream of the luciferase gene 
allow the insertion of putative regulatory sequences. It was used for the 
quantitative analysis of cis elements of promoters.  
pRL-null plasmid 
The pRL-null plasmid (Promega) is a 3,320 bp luciferase reporter vector 
that contains the Renilla luciferase gene lacking eukaryotic promoter and 
enhancer sequences. The MCS upstream of the luciferase gene allows the 
insertion of putative regulatory sequences. It was used to construct a control 
plasmid, pRL-β-actin. This pRL-β-actin and commercially purchased pRL-CMV 
(cytomegalovirus) were used as internal control plasmid for luciferase assay. 
pSUPER-basic 
The pSUPER-basic plasmid (OligoEngine, Seattle, WA, USA) is a 3,176 bp 
vector that contains the polymerase III H1-RNA gene promoter. It was use to 
knockdown gene expression through synthesizing small interfering RNA 




The pcDNA3.1/Myc-His A plasmid (Invitrogen) is a 5,493 bp vector 
derived from pcDNA3.1 (+) plasmid. It contains a CMV promoter upstream of 
MCS and is designed for high-level and stable expression of recombinant proteins 
in mammalian cells. 
Bacterial artificial chromosome (BAC) 
The BAC clones (mouse: RP24-114O15; cattle: CH240-54M10, chicken: 
CH261-29N4, and zebrafish: CH211-238N12) encompassing all C1q subunit 
genes were purchased as DH10β Escherichia coli strains from BACPAC resource 
center (Oakland, CA, USA). These BAC clones contain all three C1q subunit 
genes and were used to clone the promoter luciferase constructs for each species, 
respectively. 
2.1.6 Bacteria 
2.1.6.1 Reagents and media for Bacterial culture 
Antibiotics 
Ampicillin and kanamycin were purchased from Merck (Darmstadt, 
Germany) and AppliChem (Darmstadt, Germany), respectively. Ampicillin and 
kanamycin were dissolved in water to reach the stock concentration of 100 mg/ml 
and 30 mg/ml respectively. Their working concentration is 1000 x dilution from 




Luria-Bertani (LB) broth 
LB broth was prepared from Difco LB broth (Miller) powder (BD 
Biosciences, Franklin Lakes, NJ, USA) by suspending 25 g of the powder in 1 L 
of distilled water. The LB broth was subsequently autoclaved at 121 ºC for 15 min. 
LB agar plate 
LB agar plates were prepared from LB broth with 1.5% (w/v) Difco agar 
granulated powder (BD Biosciences). The mixture was autoclaved at 121 ºC for 
15 min and poured onto petri dishes at 20 ml per petri dish to solidify. For 
selection, the autoclaved LB agar liquid was allowed to cool down to around 60 
ºC before the addition of antibiotics, and then poured onto petri dishes. 
S.O.C medium 
S.O.C medium was obtained from Invitrogen and used in the transformation 
of chemically competent bacteria. 
2.1.6.2 Chemically competent bacteria 
The E. coli DH5α strain was purchased from Invitrogen. A single colony 
was inoculated in 10 ml of LB broth at 37 ºC overnight with shaking at 200 rpm. 
The overnight culture was diluted 100 times with fresh LB broth and cultured at 
37 ºC with shaking at 200 rpm. The optical density (OD)600 reading of the culture 
was monitored via Ultrospec 2100 pro (GE healthcare, Piscataway, NJ, USA). 
When the OD reading reached 0.4, the culture was quickly cooled down on ice 
and pelleted at 1800 x g for 10 min at 4 ºC. Each cell pellet was resuspended in 10 
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ml of ice-cold CaCl2 and pelleted. Each cell pellet was resuspended in 10 ml of 
ice-cold CaCl2 again and incubated on ice for 30 min before pelleted. Each cell 
pellet was finally resuspended in 2 ml of 0.22 μm-filtered, ice-cold CaCl2 with 14% 
(v/v) glycerol. These chemically competent bacteria were then aliquoted into pre-
chilled tubes with 50 μl per tube and snap-frozen on dry ice. They are stored at -
80 ºC before use. 
2.1.6.3 Bacterial glycerol stock 
For long term storage of bacteria, 500 μl of fresh bacterial culture was 












2.2 Molecular biology techniques 
2.2.1 Nucleic acid isolation and purification 
2.2.1.1 Genomic DNA 
Genomic DNA isolation form mouse tail 
Genomic DNA was isolated from mouse tail following a published protocol 
with some modifications (Wang and Storm, 2006). Approximately 2 mm of 
mouse tail was digested with 300 μl digestion buffer and 120 μg of proteinase K 
at 56 ºC for four hours. The genomic DNA was precipitated with two volume of 
cold 100% (v/v) ethanol. The DNA was pelleted at 16,000 x g for 15 min at 4 ºC, 
and washed twice with 70% (v/v) ethanol. The DNA was air-dried and dissolved 
in appropriate amount of TE buffer. 
Genomic DNA isolation from blood 
Genomic DNA was extracted from peripheral blood leukocytes using the 
QIAamp DNA Blood Mini Kit (Qiagen) following manufacturer’s protocol. The 
DNA was eluted by 200 μl of nuclease-free water and stored at -20 ºC until use. 
2.2.1.2 Total RNA 
Total RNA was extracted using the Nucleospin RNA II (Clontech, 
Mountain View, CA) kit following manufacturer’s protocol. The RNA was eluted 




2.2.1.3 Plasmid DNA 
Small scale DNA plasmid isolation (Mini-prep) 
A single, well-isolated colony from a fresh LB agar plate (containing 
antibiotics) was inoculated in 5 ml of LB medium (containing antibiotics) at 37 ºC 
overnight with shaking. The overnight culture was pelleted and the supernatant 
was discarded. Wizard® Plus SV Minipreps DNA Purification System (Promega) 
was used to isolate plasmids following the procedure described in the 
manufacturer’s instruction. Normally 50 μl of nuclease-free water was used for 
elution and the purified plasmid DNA was stored at -20 ºC.  
Large scale DNA plasmid isolation (Maxi-prep) 
A single, well-isolated colony from a fresh LB agar plate (containing 
antibiotics) was inoculated in 2 ml of LB medium (containing antibiotics) at 37 ºC 
for 8 hours with shaking. Subsequently, 200 μl of the culture was added into 200 
ml of LB medium (containing antibiotics) at 37 ºC overnight with shaking. The 
overnight culture was pelleted and the supernatant was discarded. DNA Plasmid 
Maxi kit (Qiagen) was used to isolate plasmids following the procedure described 
in the manufacturer’s instruction. Normally 200 μl of nuclease-free water was 
used to dissolve the DNA pellet and the purified plasmid was stored at -20 ºC. 
2.2.1.4 Polymerase chain reaction (PCR) products and restriction 
endonuclease (RE) digestion products 
The PCR and RE digestion products were purified using Illustra GFX PCR 
and gel band purification kit (GE healthcare) according to product instruction. In 
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the case of separating different products based on size, the reaction mix was 
loaded to agarose gel and the desired DNA band was excised and weighed in a 1.5 
ml tube. The DNA was eluted with appropriated amount of nuclease-free buffer. 
The purified DNA was kept at -20 ºC for long term storage. 
2.2.1.5 Nucleic acid quantification 
The DNA and RNA concentration was determined using the Nanodrop 
spectrophotometer (Thermo Scientific, Waltham, MA) and the A260/280 ratio 
was typically around 1.8 and 2.1 for DNA and RNA, respectively. 
2.2.2 DNA agarose gel electrophoresis 
Typically the analysis and separation of PCR products and plasmids were 
achieved by standard agarose gel electrophoresis using a horizontal submarine 
electrophoresis unit powered by EPS 3500 electrophoresis power pack (GE 
healthcare). DNA samples were mixed with 6 x DNA loading dye (Fermentas) 
and loaded into the gel, together with 100 bp or 1 kb GeneRuler DNA ladder 
(Fermentas). The gel was visualized under the transilluminator (Vilber Luormat, 
France). 
2.2.3 Reverse transcription 
First strand complementary DNA (cDNA) was generated by reverse 
transcription (RT)-PCR from RNA using iScript
TM
 cDNA synthesis kit (Bio-Rad) 
according to the manufacturer's instructions. The synthesized cDNA was diluted 
to 100 μl with nuclease-free water and stored at -20 ºC for long term storage. 
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2.2.4 Polymerase chain reaction (PCR) 
PCR reactions were performed using either pfu DNA polymerase (Promega) 
for RLM-RACE (section 2.2.6) and cloning PCR (section 2.2.10.1); or GoTaq 
DNA polymerase (Promega) for ChIP assay (section 2.4.6) and normal PCR for 
general screening purpose; or pfuTurbo DNA polymerase (Stratagene, La Jolla, 
CA, USA) for SDM (section 2.2.10.5). The details on PCR reaction mix and 
cycling parameters are described in respective sections.  
For normal PCR, each reaction mix consisted of 2.5 μl cDNA, 1 μl forward 
and reverse primer mix (10 μM each),  0.5 μl dNTP (Promega), 5 μl 5 x GoTaq 
Flexi buffer, 0.125 μl GoTaq DNA polymerase and 15.875 μl nuclease-free water. 
The cycling parameters for normal PCR  were 95 ºC for 2 min, 35 cycles of 
denaturation (95 ºC for 30 sec) and annealing (55 ºC for 30 sec) and extension (72 
ºC for 1 min / kb), final extension for 7 min at 72 ºC and hold at 10 ºC. 
The primers for PCR were designed via the help of the PerlPrimer open 
source software (Marshall, 2004).  For the designing for qPCR primers and PCR 
primers for general screening purpose, primers spanning two consecutive exons 
would be selected whenever possible so as to eliminate the possibility of 
amplifying the target gene on unspliced genomic DNA. 
2.2.5 Quantitative real-time PCR (qPCR) 
The qPCR was performed in triplicates for each sample in a total reaction 
volume of 20 μl in a 96-well reaction plate (Applied Biosystems Life 
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Technologies). Each reaction mix consisted of 2 μl cDNA, 10 μl 2 x GoTaq qPCR 
Master Mix  (Promega), 1 μl forward and reverse primer mix (10 μM each) and 7 
μl nuclease-free water. The reaction plate was then ran on the ABI Systems 7500 
Real-Time PCR machine (Applied Biosystems Life Technologies) using the 
Comparative Ct quantitation method. The conditions for the run were 50 ºC for 2 
min, 95 ºC for 10 min and 40 cycles of denaturation (95 ºC for 15 sec) and 
annealing and extension (60 ºC for 1 min).  
The dissociation curve analysis was performed at the end of each run to 
ensure the specificity of the primers used. Relative expressions of respective 
genes were calculated based on the ΔΔCt method by using β-actin as the 
endogenous control. The primers used are listed in Table 2.4. 
Table 2.4. Forward (-F) and reverse (-R) primer pairs for qPCR. 





































2.2.6 RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE) 
The transcription start site (TSS) for each C1q gene was determined using 
the 5’RLM-RACE kit (Invitrogen) with RNA isolated from cultured human 
macrophages (1-5 µg). After dephosphorylation with calf intestine phosphatase, 
RNA was decapped at the 5’ end with tobacco acid pyrophosphatase and ligated 
to the 44-bp GeneRacer RNA oligo at the 5’ end. The ligated RNA was used to 
synthesize cDNA with C1q RT gene-specific primers (RT-GSPs) (Table 2.5) as 
described in section 2.2.3. The GeneRacer 5' primers embedded in the GeneRacer 
RNA oligo and respective C1q gene-specific reverse primers (GSRPs) (Table 2.6) 
were used to amplify the 5’ end sequences by PCR. The PCR reaction mix was 
prepared as described in Table 2.7 and the cycling parameters were listed in Table 
2.8. 
Table 2.5. RT-GSPs used in cDNA synthesis. 
Primers Sequence (5’ – 3’) 
C1qA RT-GSP  GCCTCAGAGCCCTGGTAAAT 
C1qB RT-GSP  CTGGCGTGGTAGGTGAAGT 
C1qC RT-GSP GCCACAGAAGGTGACCACTTT 
 
Table 2.6. GSPs and provided forward primers used in PCR of 5’ end 
Primers Sequence (5’ – 3’) 
GeneRacer 5' primer CGACTGGAGCACGAGGACACTGA 
GeneRacer 5' nested primer GGACACTGACATGGACTGAAGGAGTA 
C1qA GSRP GGTAGCCCACCTTGCCGGGGTTT 
C1qB GSRP GGCGATTTTCTGGGTGGCCTTGTAGT 
C1qC GSRP GCCGGGTTCTCCCTTCTGCCCTTT 
C1qA nested GSRP CTTCCCGTCTGGTGCTCGGCACAA 
C1qB nested GSRP GATTAGGCCCAGGAGCAGGAGCAACA 





Table 2.7. PCR reaction mix for RLM-RACE. 
Reagent Volume (µl) 
Nuclease free water 39  
pfu DNA polymerase buffer (10 x) 5 
dNTP (10 mM)  1 
Forward primer (10 µM) 1 
Reverse primer (10 µM) 1 
cDNA 2.5 
pfu DNA polymerase (5 U/µl) 0.5 
Total volume 50 
 
Table 2.8. PCR cycling parameters for RLM-RACE. 
Segment Cycle(s) Temperature (ºC) Time 


















5 1 72 10 min 
6 1 10 ∞ 
The PCR products were purified as described in section 2.2.1.4. The 
purified PCR products were ligated into the TOPO TA vectors as described in 
section 2.2.7 and sequenced as described in section 2.2.8.  
2.2.7 TOPO TA cloning  
The purified PCR products were ligated into TOPO TA vectors using the 
TOPO® Cloning Reaction kit (Invitrogen). The TA cloning reaction was set up as 
in Table 2.9. The reaction was incubated for 10 min at room temperature and then 
placed on ice. The cloned TA-PCR product vectors were transformed, prepared 




Table 2.9. TOPO® Cloning Reaction. 
Reagent Volume used 
Fresh purified PCR product 4 µl 
Salt solution 1 µl 
pCR®2.1-TOPO® TA vector 1 µl 
Final volume 6 µl 
 
2.2.8 Sequencing reaction 
The sequencing PCR was performed via the Big Dye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems). The reaction mix was set up as described 
in Table 2.10. The sequencing cycle parameters were listed in Table 2.11. The 
sequencing primers were listed in Table 2.12. 
Table 2.10. Sequencing reaction mix. 
Reagent Volume (μl) 
Nuclease-free water 5 
5x sequencing buffer 2 
Big dye (Applied Biosystems) 1 
Plasmid template (0.1-0.2 μg/μl) 1 
Sequencing Primer (10 mM) 1 
Total volume 10 
 
Table 2.11. Cycling parameters for sequencing PCR. 








2 1 10 ∞ 
Table 2.12. Primers used for sequencing. 
Primer Vectors Sequence (5’ – 3’) 
T3 pCR®2.1-TOPO® forward AATTAACCCTCACTAAAGGG 
T7 pCR®2.1-TOPO® reverse TAATACGACTCACTATAGGG 
RV3 pGL3 promoter region forward CTAGCAAAATAGGCTGTCCC 
RV4 pGL3 reporter gene reverse GACGATAGTCATGCCCCGCG 
GL2 pGL3 promoter region reverse CTTTATGTTTTTGGCGTCTTCCA 
T7 pcDNA3.1/myc-His A forward TAATACGACTCACTATAGGG 
BGH pcDNA3.1/myc-His A reverse TAGAAGGCACAGTCGAGGC 
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After the sequencing PCR reaction, PCR products were purified by adding 
31.5 µl absolute ethanol, 7 µl nuclease-free water and 1.5 µl 3 M NaOAc (pH 4.6). 
The mixture was incubated at -20 ºC for 30 min and spun at top speed for 30 min. 
The DNA pellet was washed once with 500 µl of 70 % (v/v) ethanol and was 
dried at room temperature. The DNA sample was sent to AIT Biotech (Singapore) 
for sequencing. 
2.2.9 Transformation 
All constructs were transformed into E. coli DH5α homemade competent 
cells prepared as described in section 2.1.6.2, except plasmids generated from 
TOPO TA cloning and site-directed mutagenesis (SDM), which were transformed 
into one shot TOP10 competent cells (Invitrogen) and XL-1-Blue supercompetent 
cells (Stratagene), respectively.  
Tubes of competent cells were thawed on ice. Appropriate amount of 
normal ligation reaction, TOPO TA cloning reaction or SDM reaction was added 
to the 50 μl of competent cells and incubated on ice for 30 min. The mixture was 
subjected to heat shock at 42 ºC for 90 sec, 30 sec or 45 sec for normal ligation 
reaction, TOPO TA cloning reaction or SDM reaction, respectively. After 
incubation on ice for another 2 min, 200 μl of S.O.C medium (Invitrogen) was 
added to competent cells. The cells were allowed to recover for 1 hour at 37 ºC 
with shaking (220 rpm). Around 200 μl of the bacteria were then plated onto LB 
agar plates containing respective antibiotics, and incubated overnight (16-24 
hours) at 37 ºC.  
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2.2.10 Molecular cloning 
2.2.10.1 Cloning PCR 
Cloning PCR was performed with high fidelity pfu DNA polymerase 
(Promega) and primers containing 5' specific RE sites. The three human C1q gene 
promoter regions were amplified by cloning PCR using primers in Table 2.13. 
The Reaction mix was prepared as described in Table 2.14 and the cycling 
parameters were listed in Table 2.15. The C1q gene promoter regions of other 
species were amplified via PCR similarly using the primers listed in Table 2.16. 
Table 2.13. Primers for PCR amplification of human C1q promoters. 
Primers Sequence (5’ – 3’) RE site 
C1qA-2497-F GCGGTACCAGGCAGCACTCAGCTCACATTAC KpnI 
C1qA-1800-F GCGGTACCCTGGAATGGGAAGCTCCTT KpnI 
C1qA-1067-F GCGGTACCCACCTGCTCCATGAAGCA KpnI 
C1qA-627-F GCGGTACCTCCCAAAATGCTGGGATT KpnI 
C1qA-231-F GCGGTACCCTGTGCTTCGCTGGTTCT KpnI 
C1qA+79-R GCCTCGAGTTGTCAACTCCAACTGGATGCT XhoI 
C1qB-2303-F CCGCTAGCAGGTGAGGGGGTGTAGGTTTCTT NheI 
C1qB-1724-F CCGCTAGCGCCTGTAATCCCAGCACTT NheI 
C1qB-1068-F CCGCTAGCAGGTCTGCATCTGCCACCT NheI 
C1qB-684-F CCGCTAGCAGAGGGAGGGGTATCAATA NheI 
C1qB-273-F CCGCTAGCTGAGGAACACCCCTGCCCAGT NheI 
C1qB-141-F CCGCTAGCCACCCGTCTCATTTACAGT NheI 
C1qB-133-F CCGCTAGCTCATTTACAGTAAATCCAGT NheI 
C1qB-125-F CCGCTAGCAGTAAATCCAGTGGGTTGCA NheI 
C1qB-119-F CCGCTAGCATCCAGTGGGTTGCAGAA NheI 
C1qB-37-F CCGCTAGCCTGCTGGTCCATGGGA NheI 
C1qB+104-R CCAAGCTTGTGTCCTGTGAGGCCACT HindIII 
C1qB-28-R CCAAGCTTCAGCAGGCTGGCCCCTTT HindIII 
C1qB-45-R CCAAGCTTCCCGTCCCCTCACTGT HindIII 
C1qB-72-R CCAAGCTTCTGCTGCCCTCAGGCAGTTT HindIII 
C1qB-81-R CCAAGCTTCAGGCAGTTTCAGGTCCTA HindIII 
C1qB-90-R CCAAGCTTCAGGTCCTATTTCTGCAA HindIII 
C1qC-2396-F CCGCTAGCCTTCACACCCACAGACACACTCA NheI 
C1qC-1612-F CCGCTAGCGAAATGGGGTGTGCAGTGA NheI 
C1qC-997-F CCGCTAGCGCCTGACAGCCCCTTCAT NheI 
C1qC-615-F CCGCTAGCTGCCGCCAAAGCGGGTCCAT NheI 
C1qC-258-F CCGCTAGCGTTTATACACACACACACA NheI 
C1qC+81-R CCAAGCTTGCAGGTGGGCGGTTTCT HindIII 
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Table 2.14. Reaction mix for cloning PCR. 
Reagent Volume (µl) 
Nuclease free water 39  
pfu DNA polymerase buffer (10 x) 5 
dNTP (10 mM)  1 
Forward primer (10 µM) 1 
Reverse primer (10 µM) 1 
Genomic DNA / BAC DNA 2.5 
pfu DNA polymerase (5 U/µl) 0.5 
Total volume 50 
 
Table 2.15. Cycling parameters for Cloning PCR. 
Segment Cycle(s) Temperature (ºC) Time 








3 1 72 10 min 
4 1 10 ∞ 
 
Table 2.16. Primers for PCR amplification of C1q promoters of other species. 
Primers Sequence (5’ – 3’) RE site 
Chimpanzee 
C1qA-2407-F GGCGCTAGCAGGCAGCACTCAGCTCACATTACCA NheI 
C1qA+193-R CCGAGATCTCCTGTTGTCAACTCCAACTGGATGCT BglII 
C1qB-2336-F CCGCTCGAGGTCACAGTGTCATATCAGAAACCTGT XhoI 
C1qB+311-R CGCAAGCTTGTCCTGTGAGGCCGCTGGGCTGA HindIII 
C1qC-1665-F CCGCTCGAGCGGCAGTAGAGGCCAAGCTAGAGAA XhoI 
C1qC+131-R GGCAAGCTTCAGGAAGGTGGCGGAAGGTGGAGGA HindIII 
Mouse 
C1qA-1766-F CGGACGCGTTCTCTAAAGCTGAGCCACCCACCA MluI 
C1qA+127-R GCGCTCGAGGCCTCCGTGGTCCGATCAAACT XhoI 
C1qB-2854-F GCGGCTAGCGTCACATGAGGCTTATGGAGTTCA NheI 
C1qB+158-R CGCAGATCTCTGTGTATGGAATCCTGGTGTTCT BglII 
C1qC-1338-F GGCACGCGTCAGTAAGTGGAGAGTGTGGAACCT MluI 







C1qA-2436-F CCGACGCGTCTGTAAAGATAGCTGTTAGCTGGTAG MluI 
C1qA+23-R GCGAGATCTTCAATGCACTGGATACTCTGGCCCTT BglII 
C1qB-2534-F CCGCTCGAGGTAGGCCTGGGATTCAAACTTGCA XhoI 
C1qB+27-R GGCAAGCTTCTGAGGCCGCTGGGCTGGGCAGAGT HindIII 
C1qC-2445-F CCGCTCGAGACCTGCAGGGAGCACCCCTAAA XhoI 
C1qC+58-R GGCAAGCTTCCGGTCTGGTCACGGAGAAGTCCTT HindIII 
Dog 
C1qA-2378-F CCGACGCGTCTCCCTCTCTTCATGTAGAGGTGCAT MluI 
C1qA+41-R GCGAGATCTGGCCGTCAATTCAATGGACCGCTTCT BglII 
C1qB-2427-F CCGCTCGAGTCCCTTTCGGACCACAAAATCTTTGT XhoI 
C1qB+94-R GGCAAGCTTGCTCTCAGCTCAAAGCGGAAGTTCCA HindIII 
C1qC-1301-F CCGCTCGAGCCAAGTACAGTCACGTCCTTGCT XhoI 
C1qC+109-R GGCAAGCTTGGTCTGGTCACAGAGGTGTCCTGGAA HindIII 
Chicken 
C1qA-1817-F CCGCTCGAGATCATGGATTTCTCCCAGCTAAACA XhoI 
C1qA+43-R GGCAAGCTTCTGTCGGAGCTGGCTGCTCTGTTT HindIII 
C1qB-1316-F CCGCTCGAGCATTTTTATTTCCATGACTTGCCTTT XhoI 
C1qB+78-R GGCAAGCTTCTTGTTGCACGGAATGGGAAATAGAA HindIII 
C1qC-669-F CCGCTCGAGTTCCTATCCACATGCTATAGCAAACA XhoI 
C1qC+68-R GGCAAGCTTAGCACTGCCTGCTGGCTCCAAACAAC HindIII 
Zebrafish 
C1qA-2472-F GGCGCTAGCTGTAGCCACTTAATTAGGCCTACT NheI 
C1qA+16-R CCGAGATCTGGGCAGTAAAATTGAGGAAAGA BglII 
C1qB-2426-F CCGCTCGAGCAGAAACTGTTACAAATTCACCACTA XhoI 
C1qB+58-R GGCAAGCTTTTCAAGAAGGCTGTTGGAAAACAGA HindIII 
C1qC-1623-F CCGCTCGAGATATGAACGTGCCAGTACACAAAGA XhoI 
C1qC+39-R CGCAAGCTTAGAAGCAGAGCCACTCAATCCTTCA HindIII 
The cloning PCR of human PU.1 (hPU.1), human IRF8 (hIRF8), zebrafish 
PU.1 (zPU.1) and zebrafish IRF8 (zIRF8) was also performed under the same 




Table 2.17. Primers for PCR amplification of coding sequences of TFs. 
Primers Sequence (5’ – 3’) RE site 
hPU.1-F CCGAATTCTGGATGTTACAGGCGT EcoRI 
hPU.1-R GGCTCGAGTCAGTGGGGCGGGTG XhoI 
hIRF8-F CCGAATTCAGGATGTGTGACCGGAAT EcoRI 
hIRF8-R GGCTCGAGTTAGACGGTGATCTGTT XhoI 
zPU.1-F CCAAGCTTCCCAATGCTGCATCCGTACA HindIII 
zPU.1-R GCGGATCCTTACATGTAATGCTTTCTGTCT BamHI 
zIRF8-F CCAAGCTTCAAGATGAACTCGGGCGGTCGCAGA HindIII 
zIRF8-R CGCTCGAGTCAGACTGGTATCTGTAAGTTGT XhoI 
 
2.2.10.2 Restriction endonuclease (RE) digestion 
The cloning PCR products with specific RE cutting site at both ends were 
subjected to RE digestion before they were ligated into respective vectors. REs 
were selected based on their ability to work in compatible buffer and no cleavage 
sites within the cloned sequence. The respective REs for each cloning PCR 
product were listed together with their primers in the primer tables (Table 2.13, 
2.16 and 2.17). The digestion reaction was assembled according to manufacturer's 
instructions.  
After RE digestion at 37 ºC for 4 hours, the digested DNA were separated 
by gel electrophoresis as described in section 2.2.2 and purified as described in 
section 2.2.1.4. The purified products post RE digestion were ligated to respective 
linearized plasmids as described in section 2.2.10.3. 
2.2.10.3 DNA ligation 
The ligation reaction was set up in a 10 μl reaction with 1 μl of 10 x ligation 
buffer, 1 μl of T4 DNA ligase (Promega) and appropriate amount of insert and 
65 
 
linearized empty plasmid with 3:1 molar ratio of insert to plasmid. The ligation 
reaction was kept at room temperature for four hours and transformed as 
described in section 2.2.9. The successful plasmids were purified as described in 
section 2.2.1.3 and the DNA sequence was verified by sequencing as described in 
section 2.2.8. 
2.2.11 Site-directed mutagenesis (SDM) 
QuickChange® Site-Directed Mutagenesis Kit (Stratagene) was used to 
introduce point mutations in the critical sequence of the putative IFNγ-responsive 
element located in the B273 basic promoter sequence of C1qB promoter. The 
mutagenesis reaction was conducted according to the manufacturer’s instruction 
with primers listed in Table 2.18. The primers were designed following the 
criteria stated in the manufacturer’s instruction. The product was transformed as 
described in section 2.2.9. Successful plasmids were purified as described in 
section 2.2.1.3 and the DNA sequence was verified by sequencing as described in 
section 2.2.8. 
Table 2.18. Primers used in SDM for mutations introduced to B273 plasmid. 




































2.2.12 Construction of shRNA plasmid 
To target TFs for gene suppression, the pSUPER RNAi system 
(OligoEngine, Seattle, WA) was used to generate specific shRNA plasmids. The 
sequences used to target mouse TFs were selected based on published sources and 
listed in Table 2.19. As negative control, a scramble sequence that does not target 
any known human or mouse gene was also included.  
Two complementary oligonucleotides containing respective target sequence 
were synthesized and annealed into double-stranded DNA fragments. Basically, 1 
μl of each complementary oligonucleotide (3 μg/μl) was added to 48 μl of 
oligonucleotide annealing buffer. The mix was boiled at 100 ºC for 5 min and left 
to cool down naturally to room temperature.  
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Table 2.19. Target sequences used in generation of shRNA plasmids 
shRNA target Target sequence  Reference 
Scramble TGTAGATGGGTACGCGCTC  (Lee et al., 2006) 
mIRF1 GAAGATAGCCGAAGACCTT  (Yu et al., 2009) 
mIRF8-1 ACCACCACCTGCCTTGAAG  (Lee et al., 2006) 
mIRF8-2 ACTCATTCTGGTGCAGGTA  (Lee et al., 2006) 
mPU.1-1 GCCATAGCGATCACTACTG  (Joo et al., 2008) 
mPU.1-2 AGGGCAACCGCAAGAAGAT  (Atar and Levi, 2005) 
mSTAT1 TTGCAAGAGCTGAACTATA  




These double-stranded DNA fragments contained BamHI and HindIII 
sticky end at 5' and 3' respectively. At the same time, the pSUPER.basic plasmid 
was linearized with BglII and HindIII as described in section 2.2.10.2. The 
annealed double-stranded DNA fragments were then ligated into the linearized 
pSUPER.basic plasmid as described in section 2.2.10.3. BglII and BamHI 
produced compatible cohesive ends, so that the BglII site was destroyed by the 
ligation. Therefore, the ligation reaction was subsequently treated with 10 units of 
BglII at 37 ºC for 30 min to destroy empty pSUPER.basic plasmid to reduce the 








2.3 Cell biology techniques 
2.3.1 Isolation of monocytes from human buffy coats 
Enriched peripheral blood leukocytes were obtained in the form of buffy 
coat preparations derived from the whole blood of healthy donors (Blood 
Donation Centre, Singapore). Briefly, the whole blood was diluted two-fold in 
PBS, and aliquoted at 30 ml / tube layering over 12 ml of Ficoll-Paque gradient 
(Amersham Bioscience Corp., Piscataway, NJ). It was then centrifuged at 400 x g 
for 30 min (acceleration – 1, deceleration – 0). The buffy coat containing 
peripheral blood mononuclear cells (PBMCs) were collected at the gradient 
interface. The cell suspension was topped up with PBS to 50 ml per tube and 
centrifuged at 200 x g for 15 min. The cell pellet was once again resuspended and 
washed with PBS at the same condition. Another two washes were performed at 
100 x g for 10 min. The extensive washings were done to remove the platelets. 
The cells were then resuspended in 80 ml of monocyte adhesion medium and 
cultured for two hours at 37 ºC with 5% CO2.The non-adherent cells, which were 
mainly lymphocytes, were removed with four washes using the monocyte 
adhesion media. The adherent cells, which were mainly monocytes, were 
harvested by gentle scraping.  
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2.3.2 In vitro generation of DCs and macrophages 
2.3.2.1 DC culture 
DC were differentiated from monocytes by culturing the cells in 6-well 
culture plates at a density of 0.5 x 10
6
 cells/ml in DC/Macrophage culture media 
supplemented with 20 ng/ml human GM-CSF and 40 ng/ml human IL-4. Half of 
the media was replaced with fresh media containing cytokines every other day. 
The cells were used at Day 6. When stimulation was required, the medium was 
replaced on Day 6 with primary cell stimulation medium containing 100 ng/ml 
hIFNγ. The cells were harvested 24 hours after stimulation. 
2.3.2.2 Macrophage culture 
Macrophages were differentiated from monocytes by culturing the cells in 
6-well culture plate at a density of 0.5 x 10
6
 cells/ml in DC/Macrophage culture 
media supplemented with 20 ng/ml M-CSF. Half of the media was replaced with 
fresh media containing cytokines every other day. The cells were used at Day 6. 
When stimulation was required, the medium was replaced on Day 6 with primary 
cell stimulation medium containing 100 ng/ml of hIFNγ. The cells were harvested 
24 hours after stimulation. 
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2.3.3 Transient transfection 
2.3.3.1 Liposome-based transfection 
2.3.3.1.1 Transfection of HEK293 cells 
Transfection of HEK293 cells was performed using the liposome-based 
GenePORTER 2 Transfection Reagent (Genlantis, San Diego, CA, USA) 
according to manufacturer’s recommendations. HEK293 cells were seeded in 48-
well plate format at 0.8 – 1.0 x 105 cells/500 µl/well and cultured overnight at 37 
ºC with 5% CO2 to reach 60-70% confluence. Prior to transfection, half of the 
medium was removed from each well, and the cells was transfected with 0.5 µg of 
the plasmid DNA mix per well. The plasmid DNA mix was composed of 0.18 μg 
of pGL3 plasmid containing respective C1q promoter, 0.02 μg of pRL-CMV 
control plasmid (Promega), 0.15 μg of each TF-expressing pcDNA plasmid and 
topped up with empty pcDNA vector when required. For over-expression-only 
experiments, 0.5 µg of TF-expressing pcDNA plasmid was used. 
Briefly, the 0.5 μg of plasmid was diluted in 12.5 μl of DNA diluent B and 
incubated at room temperature for 5 min. At the same time, 1.75 μl of 
GenePORTER 2 reagent was mixed with 10.75 μl of serum-free Opti-MEM 
(Invitrogen). This mixture was subsequently added to the diluted DNA and 
incubated for 15 min at room temperature, before the DNA-GenePORTER 2 
reagent mixture was added to the cells, drop-wisely. The transfected cells were 
incubated at 37 ºC with 5% CO2 overnight, before the addition of hIFNγ at 100 
ng/ml in 250 μl of complete DMEM. The cells were harvested for luciferase assay 
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24 hours after the addition of hIFNγ. 
2.3.3.1.2 Transfection of PAC-2 cells 
Transfection of PAC-2 cells was performed using the liposome-based 
FuGENE HD transfection reagent (Promega) according to manufacturer’s 
recommendations. PAC-2 cells were seeded in 96 well-plate format at 1 x 10
4
 
cells/100 µl/well for luciferase assay, and in 24 well-plate format at 5 x 10
4
 
cells/500 µl/well for harvesting the medium supernatant containing zebrafish 
IFNγ1 (zIFNγ1) and zIFNγ2. The seeded cells were cultured at 28 ºC in normal 
atmosphere overnight to reach 50% to 80% confluence. For cells seeded on 96-
well plate, 0.2 µg of the plasmid DNA mix was used for each well. The plasmid 
DNA mix was composed of 0.1 μg of pGL3 plasmid containing respective C1q 
promoter, 0.02 μg of pRL-CMV normalizing plasmid (Promega), 0.04 μg of each 
TF-expressing pcDNA plasmid and topped up with empty pcDNA vector when 
required. For cells seeded on 24-well plate, each well of cells were transfected 
with 0.8 μg of zIFNγ1-expressing plasmid, zIFNγ2-expressing plasmid, or empty 
pcDNA vector as negative control.  
Briefly, the plasmid DNA mix was diluted in serum-free Opti-MEM at 10 
μl per 0.2 μg of plasmid DNA. The FuGENE HD reagent was then added to the 
mixture at 0.5 μl per 0.2 μg of plasmid DNA and incubated at room temperature 
for 15 min. The DNA-FuGENE HD reagent mixture was then applied to each 
well drop-wisely. For the cells seeded on 24-well plate, the medium supernatant 
was harvested two days after transfection and used for the IFNγ stimulation to the 
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transfected cells seeded in 96-well plate. For the cells seeded on 96-well plate, 5 
μl of the harvested medium containing zIFNγ1 or zIFNγ2 was applied to each 
well on the 96-well plate respectively 24 hours after transfection. These 
stimulated cells were harvested 48 hours after transfection for luciferase assay. 
2.3.3.2 Electroporation 
Transfection of RAW264.7 cells was performed using Electroporation (Bio-
Rad). RAW264.7 cells were seeded in T75 cell culture flasks and cultured 
overnight at 37 ºC with 5% CO2. Cells were scrapped and harvested by centrifuge 
at 600 x g for 5 min and resuspended in serum-free RPMI 1640 to a final density 
of 2.5 X 10
7
 cells/ml. The DNA mix was prepared using 10 µg of pGL3 plasmid 
containing respective C1q promoter, 1 µg of pRL-β-actin promoter normalizing 
plasmid and topped up to 40 µl with nuclease-free water. In the case of co-
transfection with shRNA plasmids, 10 μg of respective shRNA plasmid was 
mixed with 1 μg of pGL3 plasmid containing B273 promoter and 1 μg of pRL-β-
actin promoter normalizing plasmid and topped up to 40 µl with nuclease-free 
water. 
The 40 µl DNA mix and 400 µl of cell suspension were added into 4mm 
electroporation cuvette (Bio-Rad) and electrically pulsed at 300V with 975 µF 
and infinite resistance. The cells were allowed to stand for 5 min and resuspended 
in 8.5 ml complete RPMI 1640 containing 10 µM Chloroquine. These cells were 
aliquoted to a 48-well plate at 0.5 ml/well and incubated at 37 ºC with 5% CO2 for 
at least 16 hours. The medium was replaced with complete RPMI 1640 containing 
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1.2 % DMSO at 1 ml/well and cultured for another 4 hours. The cells were then 
treated with mIFNγ at 10 ng/ml or PBS as negative control for another 24 hours 
before harvesting for luciferase assay. In the case of co-transfection with shRNA 
plasmids, cell lysate was subjected to western blotting to evaluate the shRNA 
knockdown of respective TF. 
2.3.4 Luciferase Assay 
The promoter activity was measured using the Dual-luciferase reporter 
assay system (Promega). The cells were washed with 1 x PBS and the passive 
lysis buffer was added to the cells at 65 µl/well for cells seeded in 48-well plate, 
and  20 µl/well for cells seeded in 96-well plate. The cells were lysed by culturing 
at room temperature for 45 min with shaking. Basically, 2 µl of the lysate was 
used to mix with the firefly luciferase substrate (25 µl) to read the firefly 
luciferase activity using the TD-20/20 luminometer (Turner Designs, Sunnyvale, 
CA, USA). After the first reading was taken, 25 µl of the Stop & Glow reagent 
containing the Renilla luciferase substrate was then added to measure the control 
Renilla luciferase activity.  
The Renilla luciferase reading was used to normalize the firefly luciferase 
reading to correct variations in transfection efficiencies and cell numbers between 
samples. All luciferase assay experiments were done in triplicates. Data were 
presented in the form of relative luciferase activity unit (RLU) which is defined as 
RLU = firefly luciferase reading / Renilla luciferase reading * 1000. Data were 
expressed as mean values ± standard deviation (SD).  
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2.3.5 Flow cytometry 
The cells for surface molecule analysis were harvested, washed twice with 
cold PBS and resuspended in cold 1% BSA in PBS. Respective PE-conjugated 
antibodies were then added to the cells and incubated on ice for 30 min. 
Subsequently, the cells were washed three times with flow wash buffer, fixed with 
cold 1% paraformaldehyde (PFA) in PBS and stored in 4 ºC before analysis. Flow 
cytometry analysis was carried out on the Dako CyAn flow cytometer using the 
Summit 4.3 software (Dako, Glostrup, Denmark). 
2.4 Protein chemistry techniques 
2.4.1 Preparation of cell lysate 
2.4.1.1 Total cell lysate 
To evaluate the shRNA knockdown of respective TF, shRNA-transfected 
cells were harvested for total cell lysate. Basically, cells were scraped and pelleted 
at 400 x g for 5 min. The cells were washed with 1 x PBS and lysed on ice for 30 
min with RIPA buffer supplemented with protease inhibitor cocktail (Sigma). The 
lysate was centrifuged at 16,000 x g for 30 min at 4 ºC to get rid of the cell debris. 
The cleared lysate was stored at -80 ºC.  
2.4.1.2 Nuclear extraction 
The RAW264.7 cell nuclear protein was extracted for DNA affinity binding 
assay using NE-PER Nuclear Extraction Reagents (Pierce) according to the 
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manufacturer’s instruction. The nuclear fraction was transferred to a pre-chilled 
tube and stored at -80 ºC.  
2.4.1.3 Protein quantification 
The Bradford protein assay kit (Bio-Rad) was used to determine the protein 
concentration of cell lysate. Eight serial dilutions of bovine serum albumin (BSA) 
standard were first prepared with the initial concentration of 1 mg/ml. The 
Bradford dye reagent was diluted 1:4 (v/v) with deionized water and 200 μl of the 
diluted dye reagent was added into the wells of a 96-well plate with each well 
containing10 μl of the BSA standards or samples (diluted five times) pre-added. 
The absorbance was read at 595 nm using Victor3V microplate reader 
(PerkinElmer, Waltham, MA, USA). Both the BSA standards and samples were 
prepared as triplicates, and the average absorbance was used in the calculation. 
The standard curve was constructed by plotting the BSA concentrations against 
the absorbance at 595 nm and samples concentrations were determined from the 
curve. 
2.4.2 SDS-PAGE 
Proteins were separated based on size by SDS-PAGE. Basically, each 
protein sample containing 10 - 30 μg of protein was mixed with 5 x reducing 
Laemmli buffer and boiled at 100 ºC for 10 min. The samples were centrifuged at 
16,000 x g for 10 min and loaded into the wells of 10% or 12.5% SDS-PAGE gel. 
The proteins were resolved by running the gel in 1 x SDS running buffer at 100 - 
120 V until the dye front reached the bottom of the gel. 
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2.4.3 Western blotting 
After resolved by SDS-PAGE, the proteins were electro-blotted onto a 
PVDF membrane in chilled 1 x western blot transfer buffer at 100 V for 90 min at 
4 ºC. The membrane was then blocked with blocking buffer for one hour with 
shaking. Primary antibody with appropriate dilution was then added to the 
membrane and incubated at 4 ºC overnight with shaking. The membrane was 
washed three times with TBS-T buffer, followed by the addition of secondary 
antibody with appropriate dilution. The membrane was incubated for one hour at 
room temperature with shaking and washed three times with TBS-T buffer. 
Proteins were visualized using the Immuno-Star AP chemiluminescent substrate 
(Bio-Rad).  
To detect another protein after chemiluminescent detection, the membrane 
was washed with TBS-T buffer, followed by incubation with 10 ml of western 
blot stripping buffer in a sealed bag at  50 ºC for 20 min. After stripping, the 
membrane was washed with TBS-T buffer for three times with 10 min each time. 
The membrane was then blocked and reprobed with another antibody according to 
the method mentioned previously.  
2.4.4 DNA affinity binding assay 
The two complementary single-stranded biotinylated oligonucleotides 
(listed in Table 2.20) were diluted in oligonucleotide annealing buffer to a final 
concentration of 1 pmol/μl and mixed at a 1:1 molar ratio. The oligonucleotide 
mix was incubated in boiling water for 5 min and cooled down naturally to room 
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temperature. The RAW264.7 cell nuclear fraction was extracted as described in 
section 2.4.1.2. 
Table 2.20. Oligos used for DNA affinity binding assay. 
B133-81 Forward oligo Sequence (5’ – 3’) 
CTCATTTACAGTAAATCCAGTGGGTTGCAGAAATAGGACCTGAAACTGCCTGA 
B133-81 Reverse oligo Sequence (5’ – 3’) 
TCAGGCAGTTTCAGGTCCTATTTCTGCAACCCACTGGATTTACTGTAAATGAG 
The immobilized streptavidin agarose resins were washed and resuspended 
with 100 μl TEN buffer and conjugated with 30 μl of biotinylated 
oligonucleotides to 50 μl of resins by incubating overnight at 4 ºC with rotating. 
The conjugated resins were washed once with 100 μl of TEN Buffer, twice with 
100 μl of TGEDN Buffer and resuspended in 500 μl of TGEDN Buffer. To each 
tube of conjugated resins, 150 μg to 200 μg of nuclear extract and 25 μg of 
sonicated salmon sperm DNA were added. The affinity binding was carried out at 
4 ºC with rotating for four hours and the resins were washed with 0.5 X TGEDN 
buffer for five times. The protein was eluted in 50 μl of elution buffer by 
incubating at 50 ºC for 20 min. The eluted samples were run on 10% SDS PAGE 
with 10 μg of nuclear extract loaded as input and transferred to PVDF membrane. 
The blot was blocked and incubated with respective primary antibody for each TF 
as described in section 2.4.3. 
2.4.5 Chromatin immunoprecipitation (ChIP) assay 
The ChIP assay was done following a published protocol with some 
modifications (Saccani et al., 2002). Primary monocyte-derived macrophages 
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(section 2.3.2.2) were cross-linked by formaldehyde and the cross-linking reaction 
was quenched with 1M glycine. The cells were rinsed three times with PBS and 
harvested by scraping and pelleting at 400 x g for 5 min. The cell pellet was 
resuspended in 1 ml of lysis buffer 1 (L1) and left on ice for 5 min and pelleted 
again. The pellet (nuclei) was then resuspended in 1 ml of lysis buffer 2 (L2) and 
aliquoted into five 1.5 ml tubes. The sonication was conducted with the 
Diagenode Bioruptor at high setting for 15 rounds with floating ice, each round 
composing 30 sec on and 30 sec off. The lysate was centrifuged at 16,000 x g for 
30 sec at 4 ºC and the supernatant was collected. 
For each immuno-precipitation (IP), 50 μg of sonicated lysate was diluted 
1:10 with dilution buffer (DB). A1:10 dilution of L2 by DB was used in further 
incubation and washing steps. The protein-A sepharose resins (20 μl) were pre-
incubated with 5 μg of respective antibody (listed in Table 2.1). The reaction was 
topped-up to 500 μl by L2: DB (1:10) buffer and rotated at 4 ºC for three hours. 
At the same time, the diluted lysate sample was pre-cleared by rotating at 4 ºC for 
three hours with 20 μl of resins, non-immune IgG (Bio-Rad) and 50 μg/ml 
sonicated salmon sperm DNA. A small aliquot of the pre-cleared sample was kept 
as input sample. The antibody-conjugated resins were washed three times and 
resuspend in 200 μl of L2: DB (1:10) buffer with 50 μg/ml sonicated salmon 
sperm DNA and 10 μg/sample of BSA. The pre-cleared sample was then added 
and incubated overnight with rotation at 4 ºC. For control, un-conjugated resins 
and anti-His antibody-conjugated resins were used. 
After the overnight incubation, the resins were pelleted and washed with 
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wash buffer (WB) for five times and final wash buffer (FWB) for three times. The 
resins were then resuspended in 100 μl of elution buffer (EB). For input control, 
70 μl of EB was added to 30 μl of input sample. The DNA was eluted by 
incubating at 65 ºC for four hours with shaking. The elute DNA was purified as 
described in section 2.2.1.4, and detected by PCR using the primers listed in Table 
2.21. The PCR reaction mix and cycling parameters were described in Table 2.22 
and Table 2.23. 
Table 2.21. Primers for ChIP analysis. 
Primers Sequence (5’ – 3’) Genomic location 
C1qA-ChIP-F CGCCCAATGTCCCAGTCTT -122 bp to +79 bp of 
C1qA promoter C1qA-ChIP-R GTTGTCAACTCCAACTGGAT 
C1qB-ChIP-F TGAGTTGGCAGAACCAAA -167 bp to -31 bp of 
C1qB promoter C1qB-ChIP-R CAGGCTGGCCCCTTT 
C1qC-ChIP-F AAAGTGTCAAGTCAGGGAAA -110 bp to +81 bp of 
C1qC promoter C1qC-ChIP-R TGCAGGTGGGCGGTTTCT 
 
Table 2.22. Reaction mix for ChIP PCR. 
Reagent Volume (µl) 
Nuclease free water 31.75  
GoTaq DNA polymerase buffer (5 x) 10 
dNTP (10 mM)  1 
Forward primer (10 µM) 1 
Reverse primer (10 µM) 1 
ChIP DNA sample 5 
GoTaq DNA polymerase (5 U/µl) 0.25 
Total volume 50 
 
Table 2.23. Cycling parameters for ChIP PCR. 
Segment Cycle(s) Temperature (ºC) Time 








3 1 72 10 min 
4 1 10 ∞ 
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2.5 In silico analyses 
2.5.1 TF mapping 
MatInspector was used to identify potential TF binding sites on the 
promoter region and accessed at http://www.genomatix.de/ (Cartharius et al., 
2005). It is online software based on a library of matrix descriptions for TF 
binding sites to locate matches in the input DNA sequence. The library selected 
was TF binding sties (weight matrices), and the matrix group included general 
core promoter elements and vertebrates. Only relevant matches with matrix 
similarity scores above 0.8 were noted. 
2.5.2 Statistics 
Most experiments were performed three times and the figures presented are 
representative of these experiments unless stated otherwise. Data were expressed 
as mean values of experimental triplicates ± standard error. Student’s t test (two-
sided, unpaired) was used to determine statistical significance unless stated 
otherwise. For significance level in the graphs, * represents p < 0.05, ** 







Chapter 3 - Results 
3.1 Coordinated transcription of endogenous human C1q genes 
3.1.1 Introduction 
The fact that C1q is assembled in 1:1:1 ratio from its C1qA, C1qB and 
C1qC subunits (Reid and Porter, 1976) suggests synchronized transcription of the 
three subunit genes. Furthermore, the largely restricted expression in DCs and 
macrophages also suggests that this synchronized transcription of the three 
subunit genes is also cell-specific. Various types of microbial stimuli, cytokines, 
hormones and drugs were shown to regulate C1q expression and secretion, though 
conflicting results were observed (Armbrust et al., 1997; Baruah et al., 2006; 
Castellano et al., 2010; Castellano et al., 2004; Faust and Loos, 2002; Kaul and 
Loos, 2001; Trinder et al., 1995; Walker, 1998; Zhou et al., 1991). However, 
these studies were conducted with a wide range of cell types including different 
sets of primary DCs and macrophages, and cell lines of human, mouse or rat 
origins. They also differed in the techniques of detection and combination of 
stimuli. Despite the inconsistency in the C1q expression regulation by most of the 
stimuli, IFNγ was shown to be the most potent positive regulator of C1q with 
little conflicting data (Lu et al., 2008). 
In this study, we utilized the human primary DCs and macrophages. These 
cells were derived from monocytes isolated from buffy coat of healthy blood 
donors. The expression profile of endogenous C1qA, C1qB and C1qC mRNA 
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was examined to test the hypothesis that C1q genes are coordinately expressed in 
these cells and respond similarly to IFNγ stimulation as they would do as a single 
clustered entity. 
3.1.2 Generation of monocyte-derived DCs and macrophages  
In this part of study, experiments were conducted using human primary DCs 
and macrophages. These cells were derived from monocytes isolated from buffy 
coat of healthy blood donors. Monocytes were isolated by Ficoll-Paque gradient 
centrifugation followed by plastic adhesion according to a published protocol 
(Teh et al., 2011). This method typically yielded 10 - 40 million of monocytes per 
buffy coat. The purity of the monocytes was judged by flow cytometry analysis of 
the monocyte surface marker CD14, and the purity regularly rages from 90% to 
95% (Figure 3.1). 
Human DCs and macrophages were then differentiated from isolated 
monocytes by culturing for 6 days in the presence of human IL-4 and GM-CSF 
for DC, or M-CSF for macrophages.  Half of the medium was changed every 
other day with fresh medium containing cytokines. Cells were harvested and total 






Figure 3.1. Surface expression of CD14 on isolated human monocytes.  
Peripheral  blood mononuclear cells (PBMCs) were isolated from buffy coat 
using the Ficoll-Paque gradient centrifugation method. Platelets were removed by 
washing repeatedly. The cells were then resuspended in medium and allowed to 
adhere onto the plastic surface of culture flasks for two hours. The non-adherent 
cells were removed by washing three to four times in media and the remaining 
adherent cells were harvested by gentle scraping. These cells were then stained 
with PE-conjugated mouse anti-CD14 antibody against to determine the purity of 
the isolated cells. The flow cytometry analysis was gated on live cells as judged 
by forward and side scatter. Solid histogram represents signal obtained using a 
PE-conjugated IgG2a isotype antibody control and the open histogram represents 









3.1.3 Endogenous C1q mRNA levels in cultured DCs and macrophages 
Upon acquiring the monocyte-derived DCs and macrophages after 6 days of 
differentiation, the endogenous C1q mRNA expression levels were examined. 
The monocyte-derived DCs and macrophages were cultured with human IFNγ 
(hIFNγ; 100 ng/ml) or PBS respectively for 24 hours. Cells were harvested to 
isolate total RNA and reverse transcription was performed to obtain cDNA. The 
cDNA was then used to perform the quantitative real-time PCR assay to detect the 
mRNA levels of the C1q subunit genes. In this assay, cDNA was amplified by 
PCR, and the SYBR Green dye binds the amplified double-stranded DNA. As 
increasing copies of DNA were generated, more and more SYBR Green would be 
bound. Increased fluorescence was detected by the real-time PCR machine.  
Normal PCR was also performed and the products were visualized by agarose gel 
electrophoresis. 
As shown in Figure 3.2A, the cultured human monocyte-derived DCs 
constitutively expressed the mRNA of all the three C1q subunit genes at basal 
levels and the mRNA expression levels were coordinately up-regulated by IFNγ 
(Figure 3.2A). Similar basal and IFNγ-stimulated mRNA expression profiles were 
also observed in the cultured human monocyte-derived macrophages (Figure 
3.2B). The magnitudes of up-regulation were the highest with the C1qB mRNA 





Figure 3.2. IFNγ up-regulates endogenous C1qA, C1qB and C1qC mRNA 
levels in human monocyte-derived DCs and macrophages. DCs and 
macrophages were cultured with human IFNγ (hIFNγ; 100 ng/ml) or PBS 
respectively for 24 hours. Cells were harvested to isolate total RNA and reverse 
transcription was performed to obtain cDNA. The mRNA expression levels of 
C1q subunits were quantified using real-time PCR and normalized to GAPDH 
expression as the endogenous control. The electrophoresis data resulted from 
conventional PCR. The IFNγ-stimulated mRNA expression levels for DCs (A) 
and macrophages (B) represent the fold increase over their respective mRNA 
expression levels under PBS control. Data were presented as mean ± SD of 




The C1qA basal mRNA levels were the highest among the three subunits in 
macrophages; however, the IFNγ induction was least effective to the C1qA 
mRNA levels (Figure 3.2). On the other hand, the mRNA levels of C1qB and 
C1qC were highly induced by IFNγ, while the basal mRNA levels of C1qC is 
consistently low in both DCs and macrophages.  
Overall, the three C1q genes showed largely coordinated basal and IFNγ-
stimulated transcription in both human DCs and macrophages. This indicates the 
synchronized transcription regulation pattern of the C1q subunit genes. 
Mechanistically, this could be achieved by similar transcription control 
mechanisms for all the three gene promoters involving similar set of cis- and 
trans- elements.  
The fact that the three C1q genes are closely located in a highly conserved 
chromosomal cluster (Figure 1.4B) implies that the synchronization could also be 
achieved through a core regulation element that influences all the three C1q 
subunit genes (Hu et al., 2010; Sellar et al., 1991). Moreover, coordinated 
transcriptional control of genes within the same gene cluster was reported to be 
observed in eukaryotic genomes (Davila Lopez et al., 2010; Makino et al., 2009; 





3.2 Characterization of human C1q gene promoters 
3.2.1 Introduction 
The mRNA expression profile of the three C1q subunit genes (C1qA, C1qB 
and C1qC) revealed synchronization in both basal and IFNγ-induced transcription 
for all three genes. This suggests the apparently independent C1q subunit genes 
are regulated under the same mechanism in a coordinated manner. However, it 
was unclear whether this coordination was caused by the regulation under the 
similar set of cis- and trans- elements, or caused by a core regulation element that 
influence all three C1q subunit genes. Generally, genes in clusters regulated by 
shared regulatory sites were reported from time to time (Makino et al., 2009; 
Makino and McLysaght, 2008; Niehrs and Pollet, 1999; Xu et al., 2006). 
To examine the first hypothesis, i.e. the three C1q subunit gene promoters 
function independently and the synchronization is achieved by having the relevant 
cis-acting elements replicated in all three promoters, the transcription start site 
(TSS) of each gene was identified and putative promoter activities were assessed 
via dual-luciferase assay. In this assay, the putative promoter sites were inserted 
upstream to the reporter gene, so that the expression of the reporter gene is 
controlled by the putative promoter (Alam and Cook, 1990). Both basal and IFNγ-
induced promoter activities were characterized for the three C1q gene promoters. 





3.2.2 Identification of transcription start site (TSS) for C1q subunit genes 
The first step to locate the 3' end of the promoter region of a specific gene is 
to identify its TSS, which is the 5’ end of the full-length mRNA. In most cases, 
promoter 3’ end overlaps with the TSS or just proximal to the TSS (Suzuki et al., 
2004). The identification of TSS helps to prevent from cloning the wrong 
promoter region, i.e. introns, as unknown untranslated exons may exist in front of 
the known mRNA TSS documented in the database.  
To determine the TSS of the C1q genes, total RNA isolated from human 
monocyte-derived macrophages was used for RNA ligase-mediated rapid 
amplification of 5 c´DNA ends (5’ RLM-RACE). The 5' cDNA fragment of the 
full-length C1q mRNAs were cloned into TOPO TA vectors for sequencing. A 
total of 82 cDNA clones were generated from the 5’ ligated RNA transcripts (20 
for C1qA, 40 for C1qB and 22 for C1qC). They were sequenced to reveal the 5’ 
end sequences of the full-length mRNAs of the three C1q genes. These sequences 
were then compared to the 5’ end sequences given by the GenBank database 
(accession No. NM_015991.2 for C1qA, NM_000491.3 for C1qB and 
NM_172369.3 for C1qC) (Figure 3.3).  
Base on the 5' end sequences revealed the RLM-RACE experiments, only 
10 bp extension was newly found at the 5’ end of the C1qA mRNA sequence, 
while no extra 5' end sequences were revealed for both the C1qB and C1qC genes. 
These results exclude the possibility of unknown exons for all the three C1q genes 






Figure 3.3. Identification of TSS and definition of putative C1qA, C1qB and 
C1qC gene promoter regions. Total RNA isolated from human monocyte-
derived macrophages was used for RLM-RACE. The 5' cDNA fragment of the 
full-length C1q mRNAs were cloned into TOPO TA vectors for sequencing. A 
total of 82 cDNA clones were generated from the 5’ ligated RNA transcripts (20 
for C1qA, 40 for C1qB and 22 for C1qC). The TSS given by RLM-RACE (TSS2) 
was mapped to the TSS given by the GenBank database (TSS1). The new TSS for 
each gene was reassigned as +1 and the putative promoter regions were defined as 
the 2.5 Kb region spanning the TSS regions (-2497 bp to +79 bp for the C1qA 




For the C1qA gene, the TSS given by RLM-RACE (TSS2) was 10 bp more 
to the 5' end of the TSS given by the GenBank database (TSS1), so TSS2 was 
chosen as the TSS for the C1qA gene (Figure 3.3). For the C1qB gene, TSS1 and 
TSS2 were at the same location, so TSS2 was used as the TSS for the C1qB gene 
(Figure 3.3). For the C1qC gene, despite that TSS1 was more to the 5' end than 
TSS2, TSS2 was consistent in most of the clones gotten from the RLM-RACE 
experiments. Thus TSS2 was selected as the TSS for the C1qC gene (Figure 3.3).  
The new TSS for each C1q gene was reassigned as +1. The genomic 
sequence of the C1q genes was identified by blasting against the human genome 
database with these human C1q mRNA sequences. The genomic contig identified 
(accession No. NT_004610) was compared with the three mRNA sequences and 
the putative promoter region of around 2.5 Kb spanning respective TSS for each 
gene was selected (-2497 bp to +79 bp for the C1qA gene, -2303 bp to +104 bp 
for the C1qB gene and -2396 bp to +81 bp for the C1qC gene) (Figure 3.3). 
3.2.3 Activity levels of the C1q subunit gene promoters 
Each putative promoter region was cloned into a firefly luciferase reporter 
plasmid (pGL3-basic luciferase vector) upstream of the firefly luciferase gene. 
Progressive deletions of respective promoter region were performed to establish 
the minimal promoter region required. The pRL-β-actin luciferase reporter 
plasmid, which contained the β-actin promoter upstream of the Renilla luciferase 




A myeloid cell line would be used as the expression system for this 
promoter activity assay, as C1q expression was largely restricted to DCs and 
macrophages (Lu et al., 2008). However, the human myeloid cell lines were hard 
to transfect and thus the RAW264.7 cells, a mouse macrophage cell line (Raschke 
et al., 1978) was used in this study. The plasmids containing respective promoters 
and the pRL-β-actin control plasmid were co-transfected into RAW264.7 cells via 
electroporation, and cultured for 48 hours before they were harvested for dual-
luciferase assay. The effects of IFNγ on the promoter activity were tested by 
treating the cells with IFNγ for 24 hours before they were harvested for luciferase 
assay. PBS was used as negative control. The activity of respective promoter was 
determined through measuring the firefly luciferase activity and the Renilla 
luciferase activity in each sample via dual-luciferase assay . The relative 
luciferase activity was calculated as the ratio of firefly luciferase reading to 
Renilla luciferase reading.  
The putative C1qA gene promoter, including the TSS flanked by a 2794-bp 
5' region and a 79-bp 3' region of the first intron, was inserted into the pGL3 
vector to generate the construct pGL3-C1qA. Deletions from the 5’ end of the 
putative C1qA gene promoter region generated the following constructs: pGL3-
A1800, pGL3-A1067, pGL3-A627, and pGL3-A231.  
The C1qA gene promoter exhibited relatively high basal activity and the 
promoter activity was increased when the promoter was shortened by progressive 
5’ deletions (Figure 3.4). A three-fold increase in the promoter activity was 
observed in the A627 promoter as compared with the full C1qA gene promoter. 
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Despite the high basal activity of the C1qA gene promoter, the promoter activity 
under IFNγ treatment were inhibited from 30% to 50% as compared to their 
respective basal activity and the inhibitory effects were reduced when the 
promoter was shortened (Figure 3.4).  
 
Figure 3.4. The putative C1qA gene promoter exhibits relatively high basal 
activities but the activities are inhibited by IFNγ.  The putative C1qA gene 
promoter included the TSS flanked by a 2794-bp 5' region and a 79-bp 3' region 
of the first intron. This putative promoter region was progressively deleted from 
the 5' end. Both the original C1qA gene promoter and the 5' deleted promoters 
were cloned into pGL3-basic vector. These plasmids were co-transfected with 
pRL-β-actin control plasmids into RAW264.7 cells and harvested after 24-hour 
IFNγ or PBS treatment. Dual-luciferase assay was conducted using the harvested 
cell lysate. Relative luciferase activity was calculated as the ratio of firefly 
luciferase reading to Renilla luciferase reading. Data were presented as mean ± 
standard deviation (SD) of triplicates. Statistical analysis was performed using 
Student’s two-sided t test. Differences were considered statistically significant at 
p < 0.05. ‘*’, ‘**’ and ‘***’represent p< 0.05, p< 0.01 and p< 0.001, respectively. 
All data are representative of at least three independent experiments. 
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The activity of the C1qA gene promoter under IFNγ treatment was 
inconsistent with the effects of IFNγ on the endogenous C1qA mRNA levels in 
human monocyte-derived DCs and macrophages (Figure 3.2 and 3.4). This 
suggests that the isolated C1qA gene promoter behaves differently from the 
endogenous C1qA gene promoter in the chromosomal context.  
The putative C1qB gene promoter, including the TSS flanked by a 2303-bp 
5' region and a 104-bp 3' region of the first intron, was inserted into the pGL3 
vector to generate the construct pGL3-C1qB. Deletions from the 5’ end of the 
putative C1qB gene promoter region generated the following constructs: pGL3-
B1724, pGL3-B1068, pGL3-B684, pGL3-B273 and pGL3-B37.  
The C1qB gene promoter showed slightly lower basal activity as compared 
to the C1qA gene promoter (Figure 3.4 and 3.5). There were no significant 
changes in the promoter basal activity, when the C1qB gene promoter was 
shortened by progressive 5' deletions (Figure 3.5). Although there was a slight 
reduction with the deletion to -273 bp, the difference was not statistically 
significant. Similar to its endogenous counterpart, the C1qB gene promoter 
activity increased by four to five folds upon induction by IFNγ as compared to the 
respective basal promoter activity. Progressive deletions from the 5’ end of the 
promoter did not render its response to IFNγ induction, until the 236-bp fragment 
from -273 bp to -37 bp of the promoter was removed (Figure 3.5). The deletion to 
-37 bp completely eliminated the IFNγ-induced promoter activity. 
94 
 
The induction effects of IFNγ on the C1qB gene promoter activity were 
consistent with that on the endogenous C1qB mRNA levels in human monocyte-
derived DCs and macrophages (Figure 3.2 and 3.5). This suggests that the isolated 
C1qB gene promoter behaves similarly as the endogenous C1qB gene promoter in 
the chromosomal context and the IFNγ-response element resides between -273 bp 
and -37 bp on the C1qB gene promoter. 
 
Figure 3.5. The putative C1qB gene promoter exhibits relatively high basal 
activities and the activities are highly induced by IFNγ.  The putative C1qB 
gene promoter included the TSS flanked by a 2303-bp 5' region and a 104-bp 3' 
region of the first intron. This putative promoter was progressively deleted from 
the 5' end. Both the original C1qB gene promoter and the 5' deleted promoters 
were cloned into pGL3-basic vector. These plasmids were co-transfected with 
pRL-β-actin control plasmids into RAW264.7 cells and harvested after 24-hour 
IFNγ or PBS treatment. Dual-luciferase assay was conducted using the harvested 
cell lysate. Relative luciferase activity was calculated as the ratio of firefly 
luciferase reading to Renilla luciferase reading. Data were presented as mean ± 
SD of triplicates. Statistical analysis was performed using Student’s two-sided t 
test. Differences were considered statistically significant at p < 0.05. ‘*’, ‘**’, 
‘***’ and ‘n.s’ represent p< 0.05, p< 0.01, p< 0.001 and non-significance, 
respectively. All data are representative of at least three independent experiments. 
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The putative C1qC gene promoter, including the TSS flanked by a 2396-bp 
5' region and a 81-bp 3' region of the first intron, was inserted into the pGL3 
vector to generate the construct pGL3-C1qC. Deletions from the 5’ end of the 
putative C1qC promoter region generated the following constructs: pGL3-C1618, 
pGL3-C998, pGL3-C615, and pGL3-C258.  
The putative C1qC promoter exhibited relatively low basal activity and the 
promoter activity increased dramatically when the fragment from -2396 bp to -
1618 bp of the promoter was removed (Figure 3.6). However, further deletion at 
the 5’ end did not further increase the basal promoter activity. Although the 
promoter activity increased after the first 5’ deletion, the promoter activity is still 
much lower than that of the C1qA gene and C1qB gene (Figure 3.4, 3.5 and 3.6). 
Similar to the C1qA gene promoter, the activity of the C1qC gene promoter was 
also inhibited by IFNγ with even stronger inhibitory effects (Figure 3.4 and 3.6).  
The activity of the C1qC gene promoter under IFNγ treatment was again 
inconsistent with the effects of IFNγ on the endogenous C1qC mRNA levels in 
human monocyte-derived DCs and macrophages (Figure 3.2 and 3.5). This 
suggests that the isolated C1qC gene promoter behaves differently from the 
endogenous C1qC promoter in the chromosomal context and it may not be able to 





Figure 3.6. The putative C1qC gene promoter exhibits relatively low basal 
activities and the activities are highly induced by IFNγ.  The putative C1qC 
gene promoter included the TSS flanked by a 2397-bp 5' region and a 81-bp 3' 
region of the first intron. This putative promoter was progressively deleted from 
the 5' end. Both the original C1qC promoter and the 5' deleted promoters were 
cloned into pGL3-basic vector. These plasmids were co-transfected with pRL-β-
actin control plasmids into RAW264.7 cells and harvested after 24-hour IFNγ or 
PBS treatment. Dual-luciferase assay was conducted using the harvested cell 
lysate. Relative luciferase activity was calculated as the ratio of firefly luciferase 
reading to Renilla luciferase reading. Data were presented as mean ± SD of 
triplicates. Statistical analysis was performed using Student’s two-sided t test. 
Differences were considered statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ 
and ‘n.s’ represent p< 0.05, p< 0.01, p< 0.001 and non-significance, respectively. 






3.2.4 Regulation of the C1qA and C1qC gene promoters by the C1qB gene 
promoter from the distal 3' region 
Although the activity of the isolated C1qB gene promoter was consistent 
with the endogenous C1qB mRNA levels in primary human monocyte-derived 
DCs and macrophages, the isolated C1qA and C1qC gene promoters behaved 
dramatically different from their endogenous counterparts (Figure 3.2, 3.4, 3.5 
and 3.6). Furthermore, sequence alignment of C1qA, C1qB and C1qC gene 
promoters revealed no similarities among the three promoters (data not shown). 
These data obtained from the isolated C1q gene promoters are not in favor of the 
first hypothesis that the synchronized transcription is achieved by having the same 
set of relevant cis-acting elements in the three independent C1q gene promoters. 
Instead, it shows that the C1qA and C1qC genes are not effectively regulated by 
their 5' regions upstream of their TSSs, and additional endogenous mechanisms 
may exist, in the chromosomal context, for synchronized transcription of the three 
C1q genes (Figure 3.7A). 
At this point, the second hypothesis, i.e. the synchronization is achieved 
through a core cis-acting element within the gene cluster, needs to be tested. The 
B273 promoter was reckoned as the core cis-acting element, as only the C1qB 
gene promoter was inducible by IFNγ stimulation and B273 is the shortest C1qB 
promoter that retained this property (Figure 3.7A). The B273 promoter was 
inserted into the 3’ end of the luciferase gene in the pGL3-C1qA and pGL3-C1qC 
constructs. This is to mimic the endogenous gene cluster environment for the 
C1qA and C1qC gene promoters (Figure 3.7B). There was a transcription stop 
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sequence right after the inserted B273 promoter to prevent the start of 
transcription from the B273 promoter. 
 
 
Figure 3.7. Proposed model for the regulation of the C1qA and C1qC gene 
promoters by the C1qB gene promoter from the 3' end.  The B273 promoter 
was proposed as the core cis-acting element in the second hypothesis that the 
expression of the three C1q subunit genes is synchronized through a core cis-
acting element within this gene cluster (A). The B273 promoter was cloned into 
the 3’ end of the luciferase gene in pGL3-C1qA and pGL3-C1qC constructs to 
mimic the endogenous gene cluster environment for the C1qA gene and the C1qC 




This placed the luciferase gene under the influence of both the 5' putative 
promoter (the C1qA or C1qC gene promoter) and the 3' distal enhancer sequence 
(the B273 promoter). As a control, the B273 promoter was also cloned into the 3’ 
end of the luciferase gene in the pGL3-basic plasmid, which lacked the 5' putative 
promoter (Figure 3.7B).  
The B273 promoter clearly exhibited both basal and IFNγ-stimulated 
activities across the luciferase gene even in the absence of the 5' putative 
promoter (Figure 3.8). When the C1qA gene promoter was present at the 5' end, 
no obvious differences were observed on its basal promoter activity with the 
addition of the 3' B273 promoter. However, its response to IFNγ was rendered to 
slightly positive by the B273 promoter across the luciferase gene (Figure 3.8). 
Likewise, the 3' B273 promoter also rendered the 5' C1qC gene promoter to 
respond to IFNγ positively and the induction effects were more striking than it did 
to the C1qA gene promoter (Figure 3.8). 
This experimental design mimicked the natural chromosomal orientation of 
the three C1q gene promoters. Further comparison of these promoter activity 
results with the endogenous mRNA levels reveals that the trends in the folds of 
induction by IFNγ are consistent in the promoter activities and the endogenous 
mRNA levels (Figure 3.9).  These results suggest that the B273 promoter region 
may indeed act as the core cis-acting element for all the three C1q subunit genes 





Figure 3.8. The C1qB gene promoter regulates the C1qA and C1qC gene 
promoters as a distal regulator from the 3’ end.  The B273 promoter was 
cloned into the 3’ end of the luciferase gene in the pGL3-basic, pGL3-C1qA and 
pGL3-C1qC constructs. These plasmids were co-transfected with pRL-β-actin 
control plasmids into RAW264.7 cells and harvested after 24-hour IFNγ or PBS 
treatment. Dual-luciferase assay was conducted using the harvested cell lysate. 
Relative luciferase activity was calculated as the ratio of firefly luciferase reading 
to Renilla luciferase reading. Data were presented as mean ± SD of triplicates. 
Statistical analysis was performed using Student’s two-sided t test. Differences 
were considered statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ 
represent p< 0.05, p< 0.01, p< 0.001 and non-significance, respectively. All data 









Figure 3.9. The trends in the folds of induction by IFNγ are consistent in the 
promoter activities and the endogenous mRNA levels.  The folds of induction 
in mRNA expression levels represent the fold increase of the IFNγ-stimulated 
mRNA expression levels over their respective basal mRNA expression levels 
under PBS control. The folds of induction in promoter activity levels represent the 
fold increase of the IFNγ-stimulated promoter activity levels over their respective 
basal promoter activity levels under PBS control. These data were deduced using 
the data from Figure 3.2 and 3.8.  
3.2.5 Summary 
Although the endogenous C1q subunit genes were coordinately expressed in 
a synchronized manner (Figure 3.2), the isolated C1q gene promoters displayed 
varying levels of basal activities and behaved differently in response to IFNγ 
stimulation (Figure 3.4, 3.5 and 3.6). The isolated C1qA and C1qB gene 
promoters exhibited relatively high basal promoter activities, while the C1qC 
gene promoter exhibited trivial basal activity as compared to the C1qA and C1qB 
gene promoters (Figure 3.4, 3.5 and 3.6). The isolated C1qB gene promoter is 
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highly inducible by IFNγ, similar to its endogenous counterpart, while the isolated 
C1qA and C1qC gene promoters were inhibited, instead of induced by IFNγ 
(Figure 3.4, 3.5 and 3.6). These results rule out the first hypothesis that the three 
C1q subunit gene promoters function independently and the synchronized 
expression is achieved through the same set of relevant cis-acting elements in all 
the three promoters. 
The second hypothesis that the coordinated expression of the three C1q 
genes is synchronized through a core cis-acting element was tested.  The B273 
promoter was reckoned as the core cis-acting element and thus was inserted into 
the 3’ end of the luciferase gene in the pGL3-C1qA and pGL3-C1qC constructs 
(Figure 3.7). The 3' B273 promoter across the luciferase gene rendered the C1qA 
and C1qC gene promoters to respond positively to IFNγ stimulation. Thus the 
suppression on isolated C1qA and C1qC gene promoters in response to IFNγ 
could be due to the absence of B273 promoter as the distal enhancer and other 
components of this enhancer may act as suppressor when the enhancer is 
incomplete (Pennacchio et al., 2013).  
This suggests that the B273 promoter is the core cis-acting element and 
regulates the C1qA and C1qC gene promoters to synchronize the expression of 
the three C1q subunit genes in response to IFNγ stimulation as a distal enhancer 
in this transcription factory. Thus further characterization of the B273 promoter is 
important to understand the underlying mechanism of this synchronized IFNγ-
induced expression of these three C1q genes. 
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3.3 Identification of the novel IFNγ-responsive element in the 
C1qB gene promoter 
3.3.1 Introduction 
The promoter activity profiles of the three C1q genes revealed that only the 
C1qB gene promoter contains the relevant cis-acting element responsible for the 
IFNγ-induced promoter activity. The B273 promoter behaves as the core cis-
acting element that regulates the C1qA and C1qC gene promoters to synchronize 
the expression of the three C1q genes. Therefore, further characterization of the 
B273 promoter region could provide detailed information on the IFNγ-responsive 
element helps in understanding of the mechanism underlying the synchronized 
response of the three C1q gene promoters to IFNγ stimulation. 
To characterize the B273 promoter region, the transcription factor (TF) 
binding sites residing this region was mapped out via in silico analysis. 
Progressive deletions from both 5' and 3' directions were used to identify the 
precise location of the putative regulatory element. Subsequently, highly 
conserved cis-elements with potential relevance to IFNγ induction were identified 






3.3.2 Predicted putative transcription factor (TF) binding sites 
To identify the cis-acting elements involved in the IFNγ-stimulated 
activities, the B273 promoter region was analyzed using the MatInspector 
software to map out the potential TF binding sites (Cartharius et al., 2005). All 
the predicted TF binding sites with matrix similarity score above 0.8 were 
considered and irrelevant matches were eliminated. A few c-Rel and NF-κB sites 
were identified within the region from -273 bp to +104 bp. A PU.1 binding site 
was identified right after the TSS and a ISRE-GAS chimeric sequence was 
identified around 100 bp upstream of the TSS (Figure 3.10).  
As mentioned in Section 1.5.2, chimeric sequences of GAS and ISRE, and 
other Ets/IRF composite sequences were found in promoters of IFNγ-responsive 
genes (Contursi et al., 2000; Decker et al., 1997; Kaneko et al., 2006; Kanno et 
al., 2005; Marecki et al., 2001; Meraro et al., 2002; Schroder et al., 2007; Tamura 
et al., 2005). Thus this GAS-ISRE chimeric sequence was the most likely 
candidate that is responsible for the IFNγ-responsive promoter activities. 
 
Figure 3.10. Predicted cis-acting elements in the B273 promoter. The 
sequence of the B273 promoter was analyzed via MatInspector program. Only the 
predicted cis-acting elements with matrix similarity score above 0.8 were 
highlighted. The TSS was label with +1 and in larger font. 
105 
 
3.3.3 Identification of the IFNγ-responsive element boundaries in the C1qB 
gene promoter 
To verify the prediction on the IFNγ-responsive elements, more stringent 
progressive deletions from both the 5' and the 3' directions were conducted on the 
B273 promoter region to identify the exact boundaries of the IFNγ-responsive 
element.  
The 5’ deletions of the B273 promoter region in the pGL3-B273 construct 
generated the following constructs: pGL3-B141, pGL3-B133, pGL3-B125 and 
pGL3-B119 constructs. The 5' deletion to -141 bp removed the c-Rel site but still 
retained the ISRE-GAS chimeric site (Figure 3.10). This deletion only slightly 
reduced the IFNγ-induced activity (Figure 3.11). Further deletion of another 8-bp 
fragment to the -133 bp began to reduce the IFNγ-induced promoter activity.  
When another 8-bp fragment from -133 bp to -125 bp were deleted, the IFNγ-
induced B273 promoter activity was totally abrogated (Figure 3.11), though the 
integrity of the ISRE-GAS chimeric site was still maintained (Figure 3.10). This 
suggests that the predicted ISRE-GAS chimeric sequence is not sufficient for the 
IFNγ-induced activity of the C1qB gene promoter, and the 8-bp DNA sequence 





Figure 3.11. Identification of the 5' boundary of the putative IFNγ-responsive 
element in the C1qB gene promoter. Further 5' deletions of the B273 promoter 
region were made at -141, -133, -125 and -119 bp to identify the 5' boundary of 
the putative IFNγ-responsive element in the C1qB gene promoter. These plasmids 
were co-transfected with pRL-β-actin control plasmids into RAW264.7 cells and 
harvested after 24-hour IFNγ or PBS treatment. Dual-luciferase assay was 
conducted using the harvested cell lysate. Relative luciferase activity was 
calculated as the ratio of firefly luciferase reading to Renilla luciferase reading. 
Data were presented as mean ± SD of triplicates. Statistical analysis was 
performed using Student’s two-sided t test. Differences were considered 
statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ represent p< 0.05, p< 
0.01, p< 0.001 and non-significance, respectively. All data are representative of at 
least three independent experiments. 
To further characterize the novel IFNγ-responsive element, further 3’ 
deletions were made on the promoter region of the pGL3-B133 construct to 
generate the following constructs: pGL3-B133/-45, pGL3-B133/-72, pGL3-
B133/-81, and pGL3-B133/-90. The 3’ deletion to -28 bp, which removed the 
TSS of the C1qB gene promoter, dramatically reduced the promoter basal activity, 
but the promoter still retained the ability to be induced by IFNγ (Figure 3.12). 
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Further deletions to -45 bp, -72 bp, and -81 bp showed no impairment of its 
inducibility by IFNγ (Figure 3.12). However, further deletion from -81 bp to -90 
bp at the 3’ end totally abrogated the response of the B133 promoter to IFNγ 
(Figure 3.12). This result suggests that the 5’ boundary of the IFNγ-responsive 
element is between -133 bp and -125 bp, and the 3’ boundary is between -81 bp 
and -90 bp. The 53-bp fragment from -133 bp to -81 bp is sufficient and essential 
to confer most of the IFNγ-induced activity of the C1qB gene promoter. 
 
Figure 3.12. Identification of the 3' boundary of the putative IFNγ-responsive 
element in the C1qB gene promoter. Further 3' deletions of the B133 promoter 
region were made at -28, -45, -72, -81 and -90 bp to identify the 3' boundary of 
the putative IFNγ-responsive element in the C1qB gene promoter. These plasmids 
were co-transfected with pRL-β-actin control plasmids into RAW264.7 cells and 
harvested after 24-hour IFNγ or PBS treatment. Dual-luciferase assay was 
conducted using the harvested cell lysate. Relative luciferase activity was 
calculated as the ratio of firefly luciferase reading to Renilla luciferase reading. 
Data were presented as mean ± SD of triplicates. Statistical analysis was 
performed using Student’s two-sided t test. Differences were considered 
statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ represent p< 0.05, p< 
0.01, p< 0.001 and non-significance, respectively. All data are representative of at 
least three independent experiments. 
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3.3.4 Sequence alignment of the C1qB gene promoter regions across selected 
species 
In order to specify the involvement of different regions of the identified 53-
bp putative IFNγ-responsive element, the identified region of the human C1qB 
gene promoter was aligned with similar regions in the C1qB gene promoters of 
selected species. These species include human (NC_000001.10), chimpanzee 
(NC_006468.3), mouse (NC_000070.5), rat (NC_005104.2), dog (NC_006584.2), 
cattle (NC_007300.4), chicken (NC_006108.2) and zebrafish (NC_007132.5), as 
the C1q gene cluster was shown to be conserved in these species (Figure 1.4B).  
 
Figure 3.13. Sequence alignment of the putative IFNγ-responsive element 
regions of selected species. The sequence of the putative IFNγ-response element 
within the putative human C1qB gene promoter region (NC_000001.10) was 
aligned with corresponding sequences in the C1qB gene promoters of chimpanzee 
(NC_006468.3), mouse (NC_000070.5), rat (NC_005104.2), dog (NC_006584.2), 
cattle (NC_007300.4), chicken (NC_006108.2) and zebrafish (NC_007132.5). 
Alignment was performed via clustalX version 2 (http://www.clustal.org/clustal2) 
(Larkin et al., 2007) and presented using Jalview 
(http://www.jalview.org/webstart/jalview.jar) (Waterhouse et al., 2009). The TF 
binding sites identified and well conserved region were highlighted. 
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The identified 53-bp putative IFNγ-response element was shown to be 
conserved in the C1qB gene promoters of mammalian species, but was not found 
in chicken or zebrafish, as no similarities were found in the C1qB promoters of 
these two species (Figure 3.13). The well conserved region included the GAS-
ISRE chimeric site and a palindrome sequence centered at -124 bp (Figure 3.13). 
Further search on the conserved sequences revealed another two palindrome 
sequences centered at -105 bp and -96 bp. It was already shown by a number of 
studies that the symmetric or imperfect symmetric palindrome sequences were 
perfect TF binding sites (Berry et al., 1989; Chang and Murialdo, 1990; Cho-
Chung, 1998; Orchard et al., 1990; Shibata-Sakurai et al., 1993).  
The imperfect symmetric palindrome sequence around -105 bp (Figure 3.13) 
fits in the GAS sequence, which is possibly an STAT1 dimer binding site, as well 
as an Ets-IRF heterodimer binding site (Kanno et al., 2005). Furthermore, the 
imperfect palindrome sequence around -96 bp including the two GAAA at both 
sides matches the consensus of ISRE which is a well-established IFN response 
element with GAAA-(N2-5)-GAAA (Kalvakolanu and Roy, 2005; Kanno et al., 
2005). The palindrome sequence centered at -124 bp was neither predicted as any 
TF binding sites by software nor reported in any published papers, however, the 
deletion of the 5' half of this palindrome sequence (-133 bp to -125 bp) totally 
abrogated the inducibility of the B273 promoter in response to IFNγ (Figure 3.11). 
These conserved symmetric or imperfect symmetric palindrome sequences in the 
identified 53-bp putative IFNγ-response element are the most likely candidates 
responsible for the IFNγ-induced promoter activity.  
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3.3.5 Mutagenesis studies on putative IFNγ-responsive cis-regulatory element 
The involvement of these conserved regions along the 53-bp fragment to the 
IFNγ-induced promoter activity was further evaluated by site-directed 
mutagenesis (SDM) on the promoter region of the pGL3-B273 construct to 
introduce single-nucleotide mutations (Figure 3.14).  
 
Figure 3.14. Illustration of site-directed mutagenesis on the B273 promoter.  
Site-directed mutagenesis was used to introduce single-nucleotide mutations. The 
mutation was introduced in the way that the type of the nucleotide is still the same, 
i.e. A to G, T to C, G to A and C to T.  
Most of the mutations showed varying levels of impairment in the IFNγ-
stimulated promoter activities. The activity appeared to be completely abolished 
by some single-nucleotide mutations, i.e. A96G, A102G, A120G, A121G, T122C, 
T127C and T128C (Figure 3.15). It suggests that the integrity of the 53-bp 
element is essential for the C1qB gene promoter to respond to IFNγ.  
Interestingly, although A96G mutation completely inactivated this element, 
the mutations at the flanking nucleotides, i.e. C95T and G97A, substantially 
increased the basal activity of this promoter without compromising the IFNγ-
stimulated activity (Figure 3.15). This implies that the palindrome sequence 
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centered at -96 bp is not only responsible for the stimulated activity in response to 
IFNγ, but also important in the control of basal activity of the C1qB gene 
promoter, so that the expression level of C1qB is well controlled to match the 
expression levels of the other two subunit genes. It might also apply influence 
over the basal activities of the C1qA and C1qC promoters in vivo. 
 
Figure 3.15. Effects of single nucleotide mutations on the IFNγ-induced B273 
promoter activity. Single-nucleotide mutations were introduced to the pGL3-
B273 plasmid via site-directed mutagenesis. These plasmids were co-transfected 
with pRL-β-actin control plasmids into RAW264.7 cells and harvested after 24-
hour IFNγ or PBS treatment. Dual-luciferase assay was conducted using the 
harvested cell lysate. Relative luciferase activity was calculated as the ratio of 
firefly luciferase reading to Renilla luciferase reading. Data were presented as 
mean ± SD of triplicates. Statistical analysis was performed using Student’s two-
sided t test. Differences were considered statistically significant at p < 0.05. ‘*’, 
‘**’, ‘***’ and ‘n.s’ represent p< 0.05, p< 0.01, p< 0.001 and non-significance, 






The exact boundaries of the putative IFNγ-response element were identified 
by deletions from both 5' and 3' directions on the B273 promoter (Figure 3.11 and 
3.12). The identified 53-bp fragment was found to be well conserved in mammals 
and the conserved regions along the 53-bp fragment were either symmetric or 
imperfect symmetric palindrome sequences centered at -96 bp, -105 bp and -124 
bp (Figure 3.13). The symmetric or imperfect symmetric palindrome sequences 
were shown by a number of studies as suitable TF binding sites (Berry et al., 1989; 
Chang and Murialdo, 1990; Cho-Chung, 1998; Orchard et al., 1990; Shibata-
Sakurai et al., 1993).  
The palindrome sequences centered at -96 bp and -105 bp were predicted as 
the novel GAS-ISRE element by the MatInspector program and fitted in the 
consensus found in promoters of IFNγ-responsive genes revealed by other studies 
(Contursi et al., 2000; Decker et al., 1997; Kaneko et al., 2006; Kanno et al., 
2005; Marecki et al., 2001; Meraro et al., 2002; Schroder et al., 2007; Tamura et 
al., 2005). While the other sequence centered at -124 bp was not predicted or 
found in literature, however, the deletion of the 5' half of this palindrome 
sequence (-133 bp to -125 bp) totally abrogated the inducibility of the B273 
promoter in response to IFNγ (Figure 3.11). Mutations at these conserved 
nucleotides revealed that the integrity of the identified 53-bp fragment is essential 
for the C1qB gene promoter to respond to IFNγ and important in the control of 




3.4 Identification of transcription factors (TFs) involved in the 
regulation of C1q expression by IFNγ 
3.4.1 Introduction 
The GAS and ISRE elements, which form an essential region of the 53-bp 
fragment (Figure 3.13), are well defined IFNγ-responsive element (Kanno et al., 
2005; Marecki and Fenton, 2000; Marecki et al., 2001). They were reported in 
some IFNγ-responsive genes and appeared as either chimeric sequences of GAS 
and ISRE, or other Ets/IRF composite sequences (Contursi et al., 2000; Decker et 
al., 1997; Kaneko et al., 2006; Kanno et al., 2005; Marecki et al., 2001; Meraro et 
al., 2002; Mirkovitch et al., 1992; Schroder et al., 2007; Tamura et al., 2005).  
Based on the known interactions of these elements to TFs, IRF1, STAT1, 
IRF8 and PU.1 were chosen as the candidates to study the interactions between 
the 53-bp IFNγ-responsive element and its related TFs. These TFs were chosen, 
because IRF1 is highly up-regulated by IFNγ and binds to ISRE (Kanno et al., 
2005; Ramsauer et al., 2007); STAT1 dimer binds to GAS sequence after the 
activation of Jak-STAT signaling pathway and there is a post Jak-Stat activation 
of transcription through the binding of the IRF8-PU.1 complex to GAS elements 
(Decker et al., 1997; Kanno et al., 2005; Shuai and Liu, 2003). But this only 
happens in GAS elements with the Ets/IRF chimeric motif (TTTCNNGGAA), 
and some of these GAS elements only recruit Ets/IRF complexes, but not STAT1 
dimers (Decker et al., 1997; Kanno et al., 2005).  
114 
 
The interactions of these TFs to the 53-bp IFNγ-responsive element were 
evaluated via short hairpin RNAs (shRNA) knockdown of respective TF to study 
the involvement of these TFs, DNA affinity binding assay to study the in vitro 
association of these TFs with the 53-bp IFNγ-responsive element, and chromatin 
immuno-precipitation (ChIP) assay to study the association of endogenous TFs to 
the C1q gene promoters.  
3.4.2 Knockdown studies to show the involvement of TFs in the transcription 
regulation of C1qB gene by IFNγ  
To identify the TFs involved, firstly short hairpin RNAs (shRNA) targeting 
mouse IRF1 (Yu et al., 2009), IRF8 (Lee et al., 2006), PU.1 (Atar and Levi, 2005; 
Joo et al., 2008) and STAT1 (Sow et al., 2009) were created in pSUPER RNAi 
silencing vectors. For IRF8 and PU.1, two different shRNA plasmids were used. 
These shRNA-carrying vectors were co-transfected with pGL3-B273 luciferase 
plasmid and pRL-β-actin control plasmid into RAW264.7 cells to down-regulate 
the endogenous expression of respective TF. Scramble shRNA targeting non-
mammalian sequence was used as negative control.  
The knockdown effects on the protein expression levels of these TFs in their 
respective transfected RAW264.7 cells were validated by western blotting (Figure 
3.16). The knockdown effects on the IFNγ-induced promoter activity were 
evaluated via dual-luciferase assay (Figure 3.16). 
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Figure 3.16. Role of IRF1, STAT1, IRF8 and PU.1 in the IFNγ-induced 
activity of the B273 promoter. Plasmids expressing shRNA targeting mouse 
IRF1(A), STAT1(B), IRF8(IRF8-1, IRF8-2; C) and PU.1 (PU.1-1, PU.1-2; D) 
were created in pSUPER RNAi silencing vectors. Scramble shRNA targeting 
non-mammalian sequence was used as negative control. These shRNA plasmids 
were transfected with pGL3-B273 plasmid and pRL-β-actin control plasmid into 
RAW264.7 cells and harvested after 24-hour IFNγ or PBS treatment. The 
knockdown of respective TF expression was verified by western blotting (upper 
panels), with β-actin as internal control (lower panels).  Dual-luciferase assay was 
conducted using the harvested cell lysate. Relative luciferase activity was 
calculated as the ratio of firefly luciferase reading to Renilla luciferase reading. 
Data were presented as mean ± SD of triplicates. Statistical analysis was 
performed using Student’s two-sided t test. Differences were considered 
statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ represent p< 0.05, p< 
0.01, p< 0.001 and non-significance, respectively. All data are representative of at 




Knockdown of IRF1 in RAW264.7 cells showed no inhibition on the IFNγ-
stimulated activity of the B273 promoter (Figure 3.16A). On the contrary, it 
slightly but consistently increased the B273 promoter response to IFNγ. On the 
other hand, the knockdown of STAT1, IRF8 and PU.1 all markedly impaired the 
B273 promoter response to IFNγ (Figure 3.16). Therefore, these three TFs are 
required for the IFNγ-stimulated promoter activities of the C1qB gene promoter.  
3.4.3 In vitro association of TFs with the C1qB gene promoter 
In order to determine whether the STAT1, IRF8 and PU.1 directly 
interacted with the 53-bp putative IFNγ-responsive element, a double-stranded 
nucleotide oligo of this defined 53-bp fragment from -133 bp to -81 bp was 
synthesized and annealed with biotin attached at 5’ end. This oligo was defined as 
the wild-type (WT) oligo, and mutant oligos were also synthesized and named as 
A96G mutant, A102G mutant and A128G mutant (Figure 3.17). These three 
mutants were chosen, as they represented the three palindrome sequences along 
the 53-bp putative IFNγ-responsive element and were shown to abrogate the 
IFNγ-stimulated activity of the B273 promoter (Figure 3.15). 
DNA affinity binding assay was performed using this biotinylated DNA 
oligo conjugated to streptavidin-Sepharose resins as probe to pull down its 
binding partners from nuclear extract of untreated (PBS) or IFNγ-stimulated 
RAW264.7 cells. Western blotting was then performed to identify the associated 
binding partners. As a positive control, nuclear extract (10% of the input amount) 
was also included in the western blotting. Protein pulled-down by streptavidin-
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Sepharose resins without conjugated biotinylated oligos was used as negative 
control.  
 
Figure 3.17. IRF8 and PU.1 bind to the defined 53-bp IFNγ-responsive 
element. This 53-bp DNA fragment from -133 bp to -81 bp of the C1qB gene 
promoter was synthesized with 5' biotin tag, which was then immobilized on 
streptavidin-Sepharose resins. This oligo was defined as the wild-type (WT) oligo, 
and mutant oligos were also synthesized and named as A96G mutant, A102G 
mutant and A128G mutant. Nuclear extract was prepared from untreated (PBS) or 
IFNγ-stimulated RAW264.7 cells and then incubated with each respective 
immobilized DNA oligos. After washing, the protein attached to the oligos were 
eluted and analyzed by western blotting to detect IRF1, STAT1, IRF8 and PU.1 
with specific antibodies. As a positive control, nuclear extract (10% of the input 
amount) was also included in the western blotting. Protein pulled-down by 
streptavidin-Sepharose resins without conjugated biotinylated oligos was used as 
negative control. All data are representative of at least three independent 
experiments. 
From the nuclear extract of untreated RAW264.7 cells, none of the four TFs 
were pulled down by the immobilized WT oligos (Figure 3.17). When the cells 
were treated with IFNγ for 24 hours, IRF8 and PU.1 were pulled down but IRF1 
and STAT1 remained absent from the pulled-down sample (Figure 3.17). As a 
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control, the blank resins, without the WT oligo immobilized, failed to pull down 
any of these TFs. When the immobilized oligos were replaced with the A96G 
mutant, A102G mutant and A128G mutant, IRF8 and PU.1 disappeared from the 
pulled-down sample, with IRF1 and STAT1 remained absent from the pulled-
down sample (Figure 3.17).  
These results show direct interaction of IRF8 and PU.1 with the WT 53-bp 
putative IFNγ-responsive element and suggest an indirect role of STAT1 in the 
IFNγ-induced C1qB gene promoter activity. Moreover, the fact that IRF8 and 
PU.1 were absent from the precipitate when WT oligos were replaced with the 
mutant oligos suggests that the mutations abrogate the IFNγ-induced C1qB gene 
promoter activity through disrupting of the interaction between TFs and the 
putative IFNγ-responsive element.  
3.4.4. STAT1 regulates the C1qB gene promoter through the up-regulation of 
IRF8 expression 
The involvement of STAT1 in the IFNγ-induced promoter activity (Figure 
3.16) without direct binding to the 53-bp putative IFNγ-responsive element 
(Figure 3.17), is probably through regulating IRF8 or/and PU.1 which directly 
interact with this element. PU.1 was found constitutively expressed in RAW264.7 
cells, while IRF8 showed little expression unless the cells were stimulated with 
IFNγ (Figure 3.17). In fact, the involvement of STAT1 in IFNγ-stimulated 
expression of IRF8 was already shown by previous studies (Contursi et al., 2000; 
Hu and Ivashkiv, 2009; Kanno et al., 2005; Schroder et al., 2004).  
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Whether STAT1 indeed regulates IRF8 expression in RAW264.7 cells was 
verified by measuring IRF8 mRNA expression levels in the presence of STAT1 
shRNA. IRF8 was effectively up-regulated by IFNγ stimulation in the presence of 
scramble shRNA as a control (Figure 3.18). This up-regulation of IRF8 mRNA 
expression induced by IFNγ was suppressed when STAT1 shRNA was present, as 
well as when IRF8 shRNA was present as a positive control (Figure 3.18).  
 
Figure 3.18. Knockdown of STAT1 affects the IFNγ-induced up-regulation of 
IRF8 mRNA levels. RAW264.7 cells were transfected with respective shRNA 
plasmids and cultured with IFNγ and PBS respectively for 24 hours. Cells were 
harvested to isolate total RNA and reverse transcription was performed to obtain 
cDNA. The mRNA expression levels of IRF8 were quantified using real-time 
PCR and normalized to GAPDH expression as the endogenous control. All 
mRNA expression levels represent the fold increase over the mRNA expression 
levels in the scramble shRNA-transfected cells under PBS control. Data were 
presented as mean ± SD of triplicates. Statistical analysis was performed using 
Student’s two-sided t test. Differences were considered statistically significant at 
p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ represent p< 0.05, p< 0.01, p< 0.001 and non-




To examine whether IRF8 is the only crucial target of STAT1, we attempted 
to rescue the IFNγ-stimulated C1qB gene promoter activities by complementing 
the STAT1-shRNA-transfected cells with over-expression of mouse IRF8 
(mIRF8).  The over-expression of mIRF8 in either mSTAT1 shRNA- or mIRF8 
shRNA-transfected cells significantly rescued the IFNγ-induced C1qB gene 
promoter activity (Figure 3.19). These results suggest that STAT1 regulates the 
IFNγ-stimulated C1qB promoter activities through the regulation of IFNγ-induced 
up-regulation of IRF8, which binds directly to the 53-bp putative IFNγ-responsive 
element. 
 
Figure 3.19. Over-expression of mIRF8 in mSTAT1 shRNA- or mIRF8 
shRNA-transfected RAW264.7 cells significantly rescued the IFNγ-induced 
C1qB promoter activity. Mouse IRF8 over-expression plasmid were co-
transfected with respective shRNA plasmid, pGL3-B273 luciferase plasmid and 
pRL-β-actin control plasmid into RAW264.7 cells together and cultured with 
IFNγ and PBS respectively for 24 hours. Empty pcDNA plasmid was used as 
control. Dual-luciferase assay was conducted using the harvested cell lysate. 
Relative luciferase activity was calculated as the ratio of firefly luciferase reading 
to Renilla luciferase reading. Data were presented as mean ± SD of triplicates. 
Statistical analysis was performed using Student’s two-sided t test. Differences 
were considered statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ 
represent p< 0.05, p< 0.01, p< 0.001 and non-significance, respectively. All data 
are representative of at least three independent experiments. 
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3.4.5. Ex vivo association of TFs with the C1q gene promoters 
To further examine the in vivo association of IRF8 and PU.1 with the C1q 
gene promoters at the chromatin level, chromatin immunoprecipitation (ChIP) 
was performed using primary human monocyte-derived macrophages. Cells were 
treated with IFNγ or PBS for 24 hours before harvested for ChIP. After fixation, 
nuclei were isolated from macrophages, sheared, and immunoprecipitated with 
antibodies specific for IRF1, STAT1, IRF8 and PU.1. As controls, precipitation 
was also performed without antibody or with antibody against His-tag, which was 
not supposed to target any proteins in mammalian cells. DNA fragments 
associated with the proteins targeted by respective antibodies were eluted from 
respective precipitates.  
The C1qB gene promoter sequences containing the 53-bp element were 
sought from the eluted chromatin DNA fragments by PCR using primers spanning 
-167 bp and -31 bp (Figure 3.20B). The C1qA and C1qC gene promoter 
sequences, which contained respective TSS and predicted TF binding sites, were 
also sought from the eluted chromatin DNA fragments by PCR using primers 
spanning -122 bp and +79 bp on the C1qA gene promoter and spanning -110 bp 






Figure 3.20. Predicted cis-acting elements in the C1q subunit gene promoters 
and demonstration of regions amplified in ChIP PCR. The sequences of the 
C1q subunit gene promoters were analyzed via MatInspector program and the 
predicted cis-acting elements were highlighted. The regions were amplified in 
ChIP PCR experiments were indicated by pointed arrows. 
Immunoprecipitation of IRF1 and STAT1 failed to co-precipitate out any of 
the three C1q gene promoters regardless of IFNγ treatment (Figure 3.21). With 
regards to IRF8, the C1qB gene promoter was co-precipitated with IRF8, but this 
123 
 
only occurred after the macrophages were treated with IFNγ (Figure 3.21). 
However, the immunoprecipitation of IRF8 failed to co-precipitate the C1qA and 
C1qC gene promoters (Figure 3.21). This shows that, in live macrophages, IFNγ 
induces IRF8 expression enabling its binding to the C1qB gene promoter. 
Similarly, the C1qB gene promoter was also co-precipitated with PU.1, and this 
was also dependent on IFNγ induction (Figure 3.21). Regardless of IFNγ 
treatment, co-precipitation of the C1qA gene promoter with PU.1 was not 
detected (Figure 3.21). However, co-precipitation of the C1qC gene promoter 
with PU.1 was observed regardless of IFNγ treatment (Figure 3.21).  
 
Figure 3.21. Association of endogenous IRF8 and PU.1 with the C1q gene 
promoters. Primary human monocyte-derived macrophages were treated with 
IFNγ or PBS for 24 hours before harvest for ChIP. Nuclear fraction was harvested 
after fixation and sonicated to generate nuclear lysate. The sonicated nuclear 
lysate was incubated with protein G-sepharose beads with immobilized antibodies 
specific for IRF1, STAT1, IRF8 and PU.1. As negative controls, 
immunoprecipitation was also performed with anti-His antibody or without 
antibody. Precipitated chromatin fragments were eluted, and DNA was extracted 
for PCR detection of specific C1qA gene, C1qB gene and C1qC gene promoter 
regions. DNA isolated from sonicated nuclear lysate before immunoprecipitation 
was used as a positive control. PCR products were examined on 1% agarose gels. 





The knockdown of IRF1 in RAW264.7 cells showed no inhibition on the 
IFNγ-induced B273 promoter activity (Figure 3.16A). On the contrary, it slightly 
but consistently increased the B273 promoter response to IFNγ. The knockdown 
of STAT1, IRF8 and PU.1 all markedly impaired the B273 promoter response to 
IFNγ (Figure 3.16), suggesting that these three TFs are required for the IFNγ-
stimulated promoter activities of the C1qB gene promoter. 
However, in vitro DNA affinity binding assay showed that the 53-bp 
putative IFNγ-responsive element only interacted directly with IRF8 and PU.1, 
but not STAT1, and IFNγ treatment is required before the cells were harvested for 
the affinity assay (Figure 3.17). This suggests an indirect role of STAT1 in the 
IFNγ-stimulated C1qB gene promoter activities, which was shown to be through 
the regulation of IFNγ-induced IRF8 expression (Figure 3.18 and 3.19). Moreover, 
when the wild-type oligos were replaced with the mutant oligos, IRF8 and PU.1 
were no longer detected in the pulled-down sample, suggesting that the mutations 
abrogate the IFNγ-induced C1qB gene promoter activity through disrupting the 
interaction between TFs and the putative IFNγ-responsive element (Figure 3.17).  
The ChIP experiments validated the DNA pull-down results regarding the 
IFNγ-dependent interaction of IRF8 and PU.1 with the C1qB gene promoter and 
were in line with PU.1 and IRF8 being shown to mediate IFNγ-induced C1qB 
gene promoter activity. However, the question remains in how the C1qA gene 
promoter may respond to IFNγ with no shown interactions with PU.1 or IRF8.  
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3.5 Validating the involvement of myeloid-specific transcription 
factors (TFs) in the regulation of C1q genes with ectopic over-
expression of myeloid-specific TFs in non-immune cells 
3.5.1 Introduction 
C1q is preferentially, if not exclusively (Agostinis et al., 2010), produced by 
DCs and macrophages. The finding that PU.1 and IRF8 play key roles in the 
regulation of C1q gene expression helps explain DC and macrophage production 
of C1q. First, PU.1 is a key transcription factor in DCs and macrophages, which is 
required for lineage commitments and it is not significantly associated with other 
cell lineages (Nerlov and Graf, 1998; Nutt et al., 2005). Second, IRF8 is also 
strongly associated with macrophage and DC development and functions (Qi et 
al., 2009). In zebrafish, in which the three C1q genes are in a even denser cluster 
(Hu et al., 2010), IRF8 is definitive developmental switch in favor of 
macrophages over neutrophils (Li et al., 2011).  
Moreover, PU.1 functions as a bridging molecule with general TFs to 
initiate transcriptions (Aittomaki et al., 2004). The basal activity of  the FcγRI 
gene promoter was strictly dependent on PU.1, while IFNγ induction required 
both PU.1 and STAT1 (Aittomaki et al., 2002). PU.1 was also found to be able to 
trans-activate the expression of MHC class II transactivator CIITA through 
binding to its fourth promoter pIV and causing histone acetylation (Ito et al., 
2009), and similar results on its fifth promoter pV was also reported (Kitamura et 
al., 2012). These all suggest that the role of PU.1 in lineage commitment is 
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through initiating the transcription of tissue-specific genes, which decide the 
direction of cell differentiation. 
Therefore, to validate the involvement of PU.1 and IRF8 in the C1q gene 
transcriptional regulation, human PU.1 and IRF8 were cloned to verify whether 
the over-expression of these two TFs are sufficient to initiate the transcriptional 
activities of the C1q gene promoters. HEK293 cells were used in this over-
expression study, as they are human embryonic kidney cells and no PU.1, IRF8 or 
C1q is expressed in these cells (Graham et al., 1977). 
3.5.2 C1q gene promoter activities in non-immune cells with ectopic over-
expression of myeloid-specific TFs  
The coding sequences of human PU.1 and IRF8 were cloned into 
pcDNA3.1 plasmid under the control of the CMV (cytomegalovirus) promoter for 
constitutive over-expression in mammalian cells. The expression plasmids were 
co-transfected with pGL3-A231, pGL3-B273 or pGL3-C258 and pRL-CMV 
control plasmids into HEK293 cells.  
PU.1 significantly increased the basal promoter activities of the all three 
C1q genes with various levels (Figure 3.22). The basal activities were further 
increased with the addition of IRF8, however, the over-expression of IRF8 itself 
was not able to increase the basal activities of the C1q gene promoters (Figure 
3.22). Regarding the response to IFNγ, when both PU.1 and IRF8 were over-
expressed, all three C1q gene promoters were able to response to IFNγ, though 
the degree varied (Figure 3.22). The induction by IFNγ on the C1qB gene 
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promoter activity was completely restored with the over-expression of both PU.1 
and IRF8 (Figure 3.22). The inhibition effects by IFNγ on the C1qA and C1qC 
gene promoters were also restored under the over-expression of both PU.1 and 
IRF8, however, both basal and IFNγ-inhibited activities for the C1qA promoter 
were much lower than that in RAW264.7 cells (Figure 3.22).  
 
Figure 3.22. The over-expression of hPU.1 and hIRF8 in HEK293 cells 
significantly restored both basal and IFNγ-induced C1q gene promoter 
activities. Human PU.1 or/and IRF8 over-expression plasmid were co-transfected 
with respective promoter luciferase plasmid and pRL-CMV control plasmid into 
HEK293 cells and cultured with IFNγ and PBS respectively for 24 hours. Empty 
pcDNA plasmid was used as control. Dual-luciferase assay was conducted using 
the harvested cell lysate. Relative luciferase activity was calculated as the ratio of 
firefly luciferase reading to Renilla luciferase reading. Data were presented as 
mean ± SD of triplicates. Statistical analysis was performed using Student’s two-
sided t test. Differences were considered statistically significant at p < 0.05. ‘*’, 
‘**’, ‘***’ and ‘n.s’ represent p< 0.05, p< 0.01, p< 0.001 and non-significance, 




3.5.3 Effects of the ectopic expression of myeloid-specific TFs in HEK293 
cells  
Over-expression of PU.1 increased both basal and IFNγ-induced activities 
of the C1qB promoter in HEK293 cells (Figure 3.22). PU.1 and IRF8 were also 
found to cooperate to initiate the transcription of a number of myeloid-specific 
genes (Tamura et al., 2000; Tamura and Ozato, 2002). Moreover, PU.1 and 
multiple IRFs synergized to control the transcription of human IL-1β, and 
endogenous IL-1β was activated in HEK293 cells when these TFs were over-
expressed (Marecki et al., 2001). This suggests that over-expression of PU.1 
alone or co-expression with IRF8 could possibly initiate the endogenous C1q 
gene expression in non-C1q-producing cells.  
PU.1 and/or IRF8 over-expression plasmids were transfected into HEK293 
cells and treated with IFNγ or PBS as control for 24 hours. These cells were 
harvested for total RNA. The isolated total RNA was quantified and converted to 
cDNA. The cDNA was used to perform normal PCR to detect the mRNA levels 
of C1q subunit genes. Human macrophage cDNA was used as a positive control. 
GAPDH mRNA levels were also detected as an internal control.  
However, the mRNA levels of C1q subunit genes were not detected in 
HEK293 cells regardless of which TF was transfected into the cells (Figure 3.23), 
although similar experimental setup successfully induced the endogenous 
expression of human IL-1β (Marecki et al., 2001).  
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Moreover, as an important regulator in myeloid development, PU.1 
regulates the expression of numerous genes including the genes encoding 
developmentally important cytokine receptors for GM-CSF and M-CSF (Dakic et 
al., 2007; DeKoter et al., 1998; Gangenahalli et al., 2005). However, the M-CSF 
receptor (MCSF-R) mRNA was also not detected as well, although it was 
reported that PU.1 directs the tissue-specific expression of MCSF-R (Zhang et al., 
1994). 
 
Figure 3.23. Endogenous C1q mRNA levels in HEK293 cells with transient 
transfection of ectopic PU.1 and IRF8. Human PU.1 or/and IRF8 over-
expression plasmids were transfected into HEK293 cells, respectively. Empty 
pcDNA plasmid was used as control. Cells were cultured with IFNγ and PBS 
respectively for 24 hours. Cells were harvested to isolate total RNA and reverse 
transcription was performed to obtain cDNA. The mRNA expression levels of 
C1q subunit genes were detected by PCR and GAPDH mRNA expression levels 
were also detected as the endogenous control. All data are representative of at 
least three independent experiments. 
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This suggests that the transient expression of ectopic myeloid-specific PU.1 
and IRF8 was not able to initiate the transcription of the endogenous C1q subunit 
genes. As reviewed in a number of papers, the function of PU.1 on cell-fate 
decisions is dose-dependent and PU.1 is highly expressed throughout the 
development of myeloid cells, from hematopoietic stem cells to lineage 
commitment of myeloid lineage (Nutt et al., 2005; Olson et al., 1995). Upon 
lineage commitment, PU.1 is only highly expressed in myeloid cells and this 
feature was not observed in any other cell lineages (Nutt et al., 2005; Olson et al., 
1995). Thus the prolonged expression of these myeloid-specific factors, especially 
PU.1, could be required for the transcription initiation of C1q subunit genes.  
Therefore, we proposed that the transcription initiation of the C1q subunit 
genes requires prolonged exposure of PU.1, which possibly induces other 
myeloid-specific factors that are important for the transcription initiation of the 
C1q subunit genes. Thus stable transfection of hPU.1 was conducted on HEK293 
cells, and cultured under G-418 selection for 6 to 7 weeks. Colonies that have 
survived from G-418 selection were stable-transfected, and were isolated and 
cultured separately.  
Three clones of PU.1 stable-transfected cells were selected and cultured. 
The total cell lysate of these clones were harvested for western blotting to verify 
the protein expression levels of PU.1. Total cell lysate of non-transfected 
HEK293 cells was also included as a negative control. The protein expression 
levels of PU.1 were detected in both PU.1 clone 1 and PU.1 clone 3, but not in 




Figure 3.24. The protein expression levels of PU.1 and IRF8 in stable-
transfected HEK293 cells. Linearized pcDNA-hPU.1 plasmids or linearized 
pcDNA-IRF8 plasmids were transfected into HEK293 cells. The transfected cells 
were treated with G-418 selection drug for 6 to 7 weeks to kill any non-
transfected HEK293 cells. Clones, that survived the G-418 selection, were 
isolated and cultured separately. Total cell lysate was harvested from cells of 
individual clones and subjected to western blotting to detect PU.1or IRF8 with 
their specific antibodies, respectively. Total cell lysate of non-transfected 
HEK293 cells was also included as a negative control. All data are representative 
of at least three independent experiments. 
After the stable expression of PU.1 was validated, the mRNA expression 
levels of C1q subunit genes in these cells were examined. The PU.1 clone 1 cells 
were transfected with IRF8 or pcDNA as control. The cells were then treated with 
IFNγ or PBS for 24 hours, before they were harvested for total RNA isolation. 
However, the mRNA levels of the C1q subunit genes were still not observed in 
HEK293 cells with stable-transfected PU.1 (Figure 3.25), despite that high level 
of PU.1 is a feature of myeloid lineage differentiation (Nutt et al., 2005; Olson et 
al., 1995) Moreover, the MCSF-R mRNA was still not detected as well, although 
it was reported to be directed PU.1 (Zhang et al., 1994). These results suggest that 
PU.1 is not sufficient for the transcription initiation of C1q subunit genes and 




Figure 3.25. Endogenous C1q mRNA levels in HEK293 cells with stable-
transfected PU.1. The PU.1 clone 1 cells were transfected with IRF8 or pcDNA 
as control. The cells were then treated with IFNγ or PBS for 24 hours, before they 
were harvested for total RNA isolation. Reverse transcription was performed to 
obtain cDNA. The mRNA expression levels of C1q subunit genes were detected 
by PCR and GAPDH mRNA expression levels were also detected as the 
endogenous control. All data are representative of at least three independent 
experiments. 
However, this could also be due to the low pluripotency of HEK293 cells. 
Most of the studies involving myeloid cell development using ectopic expression 
of PU.1 were conducted in either multipotent hematopoietic progenitors (Nerlov 
and Graf, 1998) or progenitor cells of other immune cell types, like T cell 
progenitors (Laiosa et al., 2006). The study in the expressional regulation of 
MCSF-R by PU.1 only showed the promoter activity was up-regulated by the 
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ectopic expression of PU.1 in HeLa cells, but not the endogenous mRNA levels 
(Zhang et al., 1994). Thus a more pluripotent cell type is needed for further 
experiment of this project.  
3.5.4 Summary 
In the non-immune HEK293 cells, the ectopic expression of myeloid-
specific TFs, PU.1 and IRF8, have successfully restored both basal and IFNγ-
induced activities of the three C1q gene promoters with various levels (Figure 
3.22). However, the endogenous mRNA expression levels of C1q subunit genes 
were not detected in HEK293 cells with either transient-transfection or stable-
transfection of PU.1 and IRF8 (Figure 3.23 and 3.25), although similar 
experimental setup successfully induced the endogenous expression of human IL-
1β (Marecki et al., 2001). Moreover, as a developmentally important cytokine 
receptor, MCSF-R mRNA levels were also not detected, although PU.1 was 
reported to initiate its expression (Dakic et al., 2007; DeKoter et al., 1998; 
Gangenahalli et al., 2005). 
Two possible explanations were proposed. It could require additional 
myeloid-specific factors, other than PU.1, for the transcription initiation of C1q 
subunit genes. However, it could also be due to the low pluripotency of HEK293 
cells and its potential to be reprogrammed is limited, as they were isolated from 
fetus kidney, which is mostly composed of differentiated cells (Graham et al., 




3.6 C1q gene promoter activities across species 
3.6.1 Introduction 
As showed previously, the endogenous C1q genes were coordinately 
expressed in a synchronized manner in DCs and macrophages (Figure 3.2). 
However, the isolated C1q gene promoters displayed varying levels of basal 
activities and behaved differently in response to IFNγ stimulation (Figure 3.4, 3.5 
and 3.6). The isolated C1qB gene promoter is highly inducible by IFNγ, while the 
isolated C1qA and C1qC gene promoters were inhibited, instead of induced by 
IFNγ (Figure 3.4, 3.5 and 3.6). The insertion of the B273 promoter at the 3' end 
across the luciferase gene rendered the C1qA and C1qC gene promoters to 
respond positively to IFNγ stimulation (Figure 3.8). A highly conserved 53-bp 
region within the C1qB gene promoter was identified as the IFNγ-responsive 
element and potentially regulates the synchronized response to IFNγ of all the 
three genes from the center of the gene cluster (Chapter 3.3).  
At genomic level, the C1q genes are highly clustered in tandem on a stretch 
of 25 Kb fragment on human chromosome 1 in the order of C1qA-C1qC-C1qB 
(Sellar et al., 1991). This conserved genomic organization was also observed from 
the mouse C1q genes on mouse chromosome 4 (Petry et al., 1996) and the 
zebrafish C1q genes on zebrafish chromosome 21 (Hu et al., 2010). Moreover, 
several other gene cluster loci on different chromosomes were characterized and 
evolutionary conserved among mammals and zebrafish, including those in the 
innate immune system (Aggad et al., 2010; Dumoutier et al., 2000; Igawa et al., 
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2006; Lutfalla et al., 2003). Moreover, among these evolutionarily conserved 
gene clusters, a number of genes within the same cluster were reported to be 
associated with certain diseases (Igawa et al., 2006; Kotenko, 2002; Vilcek, 2003). 
Furthermore, with regards to the transcription regulation, the evolutionary 
conservations and changes in cis-regulatory regions has been shown to be 
important for conservation of critical cell functions and evolutionary changes, in 
addition to those in the protein coding regions (Wray, 2007; Wray et al., 2003). 
Thus the study of the transcriptional regulation of the C1q gene cluster could 
increase understanding of the evolution of gene clusters.  
Chimpanzee, mouse, dog, cattle, chicken and zebrafish were chosen as 
representatives of non-human primates, rodents, carnivores, herbivores, birds and 
fish, respectively, as the C1q gene cluster is conserved in these species (Figure 
1.3B). The putative C1q gene promoter regions of these species were cloned into 
pGL3 luciferase vectors. The C1q gene promoters of chimpanzee, mouse and dog 
were cloned from genomic DNA extracted from the blood of each respective 
species, while the C1q gene promoters of cattle, chicken and zebrafish were 
cloned from bacteria artificial chromosome (BAC) clones (cattle: CH240-54M10, 
chicken: CH261-29N4, and zebrafish: CH211-238N12), which contain the entire 
respective C1q gene cluster. The plasmids containing respective promoters were 
then transfected into RAW246.7 cells together with the pRL-β-actin control 





3.6.2 The C1q gene promoter activities of selected mammalian species 
Firstly, the promoter activities of the C1q genes from selected mammalian 
species (chimpanzee, mouse, dog and cattle) were examined. The promoter region 
spanning the TSS of each gene includes 1000 bp to 2500 bp region to 5' end of the 
TSS. Respective promoter was cloned into pGL3 luciferase vectors and 
transfected into RAW264.7 cells together with pRL-β-actin control plasmids. 
Cells were treated with IFNγ for 24 hours before they were harvested for 
luciferase assay. 
In the transfected RAW246.7 cells, these C1q gene promoters also revealed 
basal promoter activities and various degrees of response to IFNγ, but the mode of 
responses varies (Figure 3.26). The C1q gene promoters of chimpanzee and 
mouse showed similar basal and IFNγ-stimulated activities as their human 
counterparts (Figure 3.26A and 3.26B). The dog C1qB gene promoter exhibited 
exactly the same activity pattern as its human counterpart (Figure 3.26C), though 
the 53bp IFNγ-responding element is least conserved in dog (Figure 3.13). 
However, the C1qA and C1qC promoters showed no response to IFNγ stimulation 
(Figure 3.26C). On the contrary, all the three C1q gene promoters of cattle were 
inhibited by IFNγ (Figure 3.27D), despite the 53bp IFNγ-responding element 
being conserved in the cattle C1qB gene promoter as well (Figure 3.13). The 
different modes of response to IFNγ of the dog C1qA and C1qC gene promoters 
and the cattle C1qB gene promoter is probably due to the incompatibility of the 
cis-acting elements of dog and cattle to the mouse trans-acting system, as the 





Figure 3.26. Activities of the putative C1q gene promoters across selected 
mammalian species. Chimpanzee, mouse, dog and cattle were chosen as 
representatives of non-human primates, rodents, carnivores and herbivores, 
respectively. The promoter region spanning the TSS of each gene includes 1000 
bp to 2500 bp region to 5' end of the TSS. Respective promoter regions were 
cloned into pGL3 luciferase vectors and transfected into RAW264.7 cells together 
with pRL-β-actin control plasmids. Cells were treated with IFNγ for 24 hours 
before they were harvested for luciferase assay. Dual-luciferase assay was 
conducted using the harvested cell lysate. Relative luciferase activity was 
calculated as the ratio of firefly luciferase reading to Renilla luciferase reading. 
Data were presented as mean ± SD of triplicates. Statistical analysis was 
performed using Student’s two-sided t test. Differences were considered 
statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ represent p< 0.05, p< 
0.01, p< 0.001 and non-significance, respectively. All data are representative of at 




3.6.3 The C1q gene promoter activities in selected early vertebrate species 
As representatives of early vertebrates, the putative promoter regions of 
chicken and zebrafish C1q genes were also cloned into luciferase vectors and 
transfected into RAW264.7 cells together with pRL-β-actin control plasmids. 
Cells were treated with IFNγ for 24 hours before they were harvested for 
luciferase assay.  
Surprisingly, the chicken C1qA gene promoter exhibited relatively high 
basal activity and was inhibited by IFNγ similar to its human counterpart. 
However, the basal activities of chicken C1qB and C1qC gene promoters were 
quite low and did not respond to IFNγ stimulation (Figure 3.27A). The 
incompatibility of the cis-acting elements of chicken to the mouse trans-acting 
system might account for the low basal and no response to IFNγ of the chicken 
C1qB and C1qC gene promoters. The high basal activity of the chicken C1qA 
gene promoter and its inhibition by IFNγ in the mouse cells were unexpected and 
require further studies to understand the underlying mechanisms. 
The zebrafish C1qA and C1qB gene promoters exhibited low basal 
activities similar to the pGL3 basic plasmid control, while zebrafish C1qC gene 
promoter exhibited higher basal activities than the negative control, but still much 
lower than that of other species (Figure 3.27B). As an evolutionarily distant 
species to mammalian species, the low basal and no response to IFNγ of the 
zebrafish C1q gene promoters in the mouse cells were expected, as evolutionary 
changes took place in both cis- and trans- elements in the transcription regulation 
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system (Wray et al., 2003). To verify whether this is really due to the 
evolutionary differences in the transcription regulation system of different species, 
a zebrafish origin transfection system is required for further studies on the 
zebrafish C1q gene promoters. 
  
Figure 3.27. Activities of putative C1q gene promoters of early vertebrate 
species. Chicken and zebrafish were chosen as representatives of birds and fish, 
respectively. The promoter region was defined as 1000bp to 2500bp DNA 
fragments 5' to the first exon of the specific subunit gene and spans the 
transcription start site (TSS). Respective promoter regions were cloned into pGL3 
luciferase reporter plasmids and transfected into RAW264.7 cells together with 
pRL-β-actin control plasmids. Cells were treated with IFNγ for 24 hours before 
they were harvested for luciferase assay. Dual-luciferase assay was conducted using 
the harvested cell lysate. Relative luciferase activity was calculated as the ratio of 
firefly luciferase reading to Renilla luciferase reading. Data were presented as mean 
± SD of triplicates. Statistical analysis was performed using Student’s two-sided t 
test. Differences were considered statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ 
and ‘n.s’ represent p< 0.05, p< 0.01, p< 0.001 and non-significance, respectively. 
All data are representative of at least three independent experiments. 
3.6.4 Summary 
In the transfected RAW246.7 cells, the C1q gene promoters of selected 
mammalian species exhibited various levels of basal activities and different 
140 
 
modes of response to IFNγ (Figure 3.26). Among these promoters examined, the 
C1q gene promoters of chimpanzee and mouse showed similar basal and IFNγ-
stimulated activities as their human counterparts (Figure 3.26A and 3.26B). 
However, for dog, only the C1qB gene promoter exhibited the same activity 
pattern as its human counterpart, while its C1qA and C1qC promoters showed no 
response to IFNγ stimulation (Figure 3.26C). On the contrary, the activity patterns 
the C1qA and C1qC gene promoters of cattle were similar to that of human 
(Figure 3.26D), but the C1qB gene promoter was inhibited by IFNγ (Figure 
3.26D), although the 53bp IFNγ-responsive element was shown to be conserved 
(Figure 3.13). The basal activities of chicken C1qB and C1qC gene promoters 
were quite low and no response to IFNγ was observed (Figure 3.27A). However, 
relatively high basal activity of the chicken C1qA gene promoter was observed 
and was inhibited by IFNγ. For zebrafish, all the three C1q gene promoters 
exhibited negligible levels of basal activity and did not respond to IFNγ in 
RAW264.7 cells (Figure 3.27B).  
The major limitation of this study is the use of the mouse macrophage 
RAW264.7 cells, as evolutionary changes took place in both cis- and trans- 
elements in the transcription regulation system (Wray et al., 2003). The 
incompatibility of the cis-acting elements in the promoters of other species to the 
mouse trans-acting system might account for the low basal activity of the chicken 
and zebrafish C1q gene promoters and the different modes of responses to IFNγ 




3.7 Promoter activities of zebrafish C1q subunit genes 
3.7.1 Introduction 
The classical pathway was only established after the emergence of jawed 
vertebrates (Dodds and Matsushita, 2007) and C1q was demonstrated to act as 
lectins and only involved in innate immunity in lower vertebrates, such as 
lamprey (Matsushita et al., 2004) and amphioxus (Yu et al., 2008). As an 
evolutionary linker between lower vertebrates and higher vertebrates, zebrafish is 
the most commonly used model in evolutionary studies in vertebrates. Study on 
the zebrafish C1q promoters would enhance the understanding on the 
revolutionary changes in the regulation of C1q gene cluster. 
Previously, the zebrafish C1q gene promoters were shown to exhibit 
negligible basal activities and did not respond to IFNγ in the mouse macrophage 
RAW264.7 cells (Figure 3.27B). The incompatibility of the zebrafish promoters 
to the mouse system due to the evolutionary changes in the transcription system 
(Wray et al., 2003) might account for these observations. This could be verified 
by studying the promoters in the transcription system of the same species.  
In order to verify the above doubt and to further study the activity patterns 
of the zebrafish C1q gene promoters, the zebrafish embryonic fibroblast PAC-2 
cells were obtained from Professor Nicholas S. Foulkes (Karlsruhe Institute of 
Technology, Universität Heidelberg, Germany) (Vallone et al., 2007). However, 
as PAC-2 cells are embryonic fibroblasts, the expression of zebrafish PU.1 and 
IRF8 were not observed in these cells (data not shown). Previously, PU.1 and 
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IRF8 were shown to participate in the IFNγ-induced human C1q gene promoter 
activities (Chapter 3.4), and their ectopic expression in HEK293 cells successfully 
restored both basal and IFNγ-induced activities of the three human C1q gene 
promoters with various levels (Chapter 3.5). Moreover, the functions of PU.1 and 
IRF8 in myeloid cell development were well conserved in zebrafish (Jin et al., 
2012; Li et al., 2011). Therefore, the zebrafish PU.1 (zPU.1) and IRF8 (zIRF8) 
was cloned into pcDNA over-expression plasmid for their ectopic expression in 
PAC-2 cells for the study of the zebrafish C1q gene promoters. 
3.7.2 Zebrafish C1q gene promoter activities in PAC-2 cells with ectopic 
over-expression of zebrafish TFs 
The coding sequences of zPU.1 and zIRF8 were cloned from zebrafish 
cDNA library and inserted into pcDNA over-expression plasmids. The zebrafish 
C1q gene promoter plasmids were then co-transfected with the zPU.1 and zIRF8 
plasmids, as well as the pRL-CMV control plasmids into PAC-2 cells. Empty 
pcDNA plasmid was used as control. The cells were harvested for luciferase assay 
24 hours after transfection.  
The over-expression of zPU.1 and zIRF8 significantly increased the basal 
activities of the three zebrafish C1q gene promoters in PAC-2 cells (Figure 3.28). 
An approximately 7-fold increase was observed in the basal activity of the 
zebrafish C1qA gene promoter, when both zPU.1 and zIRF8 were over-expressed 
(Figure 3.28). However, only a two to three-fold increase was observed in the 
basal promoter activities of the zebrafish C1qB and C1qC gene promoters.  
143 
 
The basal activities of the zebrafish C1q gene promoters in the zebrafish 
cells are significantly higher than that in the mouse cells. These results suggest 
that the incompatibility of the C1q gene promoters from other species in the 
mouse transcription system could account for the low basal activity and the 
different modes of responses to IFNγ observed in the previous results.  
 
Figure 3.28. Over-expression of zPU.1 and zIRF8 in zebrafish PAC-2 cells 
significantly restored the basal activities of the zebrafish C1q gene promoters. 
Zebrafish PU.1 and IRF8 plasmids were co-transfected with respective promoter 
luciferase plasmid and pRL-CMV control plasmid into PAC-2 cells and cultured 
for 24 hours. Empty pcDNA plasmid was used as control. Dual-luciferase assay 
was conducted using the harvested cell lysate. Relative luciferase activity was 
calculated as the ratio of firefly luciferase reading to Renilla luciferase reading. 
Data were presented as mean ± SD of triplicates. Statistical analysis was 
performed using Student’s two-sided t test. Differences were considered 
statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ represent p< 0.05, p< 
0.01, p< 0.001 and non-significance, respectively. All data are representative of at 
least three independent experiments. 
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3.7.3 The zebrafish C1q gene promoter activities with zebrafish IFNγ 
stimulation 
The conservation of the response to IFNγ of the zebrafish C1q gene 
promoters was also investigated using zebrafish IFNγ to stimulate the PAC-2 cells 
transfected with respective promoter luciferase vectors. Different from the single 
mammalian IFNγ gene, there are two zebrafish IFNγ genes reported within the 
same genomic cluster as its mammalian counterparts, namely zebrafish IFNγ1 
(zIFNγ1) and zebrafish IFNγ2 (zIFNγ2), with zIFNγ2 sharing higher percentage 
of amino acid identity with IFNγ of higher vertebrates (Igawa et al., 2006). Both 
zIFNγ1 and zIFNγ2 were shown to be able to induce the same set of genes and 
were functionally equivalent to the mammalian IFNγ (Sieger et al., 2009). Later 
reports showed zIFNγ1 was more potent in inducing pro-inflammatory genes than 
zIFNγ2 (Lopez-Munoz et al., 2011) and they seemed to signal through different 
receptor complexes (Aggad et al., 2010). Thus it is necessary to find out which 
zebrafish IFNγ is the one that plays a role in the expression of zebrafish C1q. 
Due to the lack of the commercial source of zebrafish IFNγ, the over-
expression constructs pCS2-zIFNγ1 and pCS2-zIFNγ2 were obtained from 
Professor Maria Leptin (European Molecular Biology Laboratory, Heidelberg, 
Germany) (Sieger et al., 2009) and transfected into PAC-2 cells. The culture 
medium of these transfected cells were collected and used as the IFNγ stimuli. 
Respective promoter luciferase plasmids were co-transfected with pRL-CMV 
control plasmids into PAC-2 cells together with zPU.1 or/and zIRF8 expression 
plasmids, or pcDNA plasmid as control. The transfected cells were then treated 
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with the culture medium collected from zIFNγ1 or/and zIFNγ2 transfected PAC-2 
cells for 24 hours before they were harvested for luciferase assay. The culture 
medium collected from pcDNA transfected cells were used for control.  
 
Figure 3.29. Zebrafish C1qA gene promoter exhibited relatively high basal 
activity with zPU.1 over-expression and the activity was enhanced by 
zebrafish IFNγ2. Zebrafish C1qA gene promoter luciferase plasmid was co-
transfected with pRL-CMV control plasmid into PAC-2 cells together with of 
zPU.1 or/and zIRF8 expression plasmids, or pcDNA plasmids as control. The 
transfected cells were treated with the medium collected from zIFNγ1 or/and 
zIFNγ2 transfected PAC-2 cells, or pcDNA transfected cells as control for 24 
hours before they were harvested for luciferase assay. Relative luciferase activity 
was calculated as the ratio of firefly luciferase reading to Renilla luciferase 
reading. Data were presented as mean ± SD of triplicates. Statistical analysis was 
performed using Student’s two-sided t test. Differences were considered 
statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ represent p< 0.05, p< 
0.01, p< 0.001 and non-significance, respectively. All data are representative of at 
least three independent experiments. 
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The basal promoter activity of zebrafish C1qA gene was increased by the 
over-expression of zPU.1 alone, but not zIRF8 (Figure 3.29). However, over-
expression of zIRF8 further enhanced the increase in the basal activities of the 
zebrafish C1qA gene promoter by zPU.1 (Figure 3.29). The stimulation by 
zIFNγ2 had successfully increased the activity of the zebrafish C1qA gene 
promoter, while zIFNγ1 did not show any influence on the zebrafish C1qA gene 
promoter activity (Figure 3.29).  
Interestingly, zIFNγ2 induced the zebrafish C1qA gene promoter activity 
even in the absence of the over-expression of zPU.1 (Figure 3.29). Thus the 
zPU.1 and zIRF8 are only necessary for the basal promoter activity, but not the 
IFNγ-induced promoter activity for the zebrafish C1qA gene promoter. This 
suggests the regulation pattern on the C1qA gene promoter of zebrafish is 
different from that of human. 
Similarly, the basal activity of the zebrafish C1qB gene promoter was also 
increased by zPU.1 over-expression, but not zIRF8, and the addition of zIRF8 
enhanced the zPU.1-induced increase in the basal activity of the zebrafish C1qB 
gene promoter (Figure 3.30). However, the increased basal activity was still much 
lower than that of the zebrafish C1qA gene promoter (Figure 3.29 and 3.30). 
Regarding the IFNγ-induced promoter activities, the zebrafish C1qB gene 
promoter activity was enhanced by zIFNγ2, only when both zIRF8 and zPU.1 
were co-transfected, while zIFNγ1 consistently had no effects on the zebrafish 




Figure 3.30. Zebrafish C1qB gene promoter exhibited relatively low basal 
activity with zPU.1 over-expression and the activity was enhanced by 
zebrafish IFNγ2 only when both zIRF8 and zPU.1 were over-expressed. 
Zebrafish C1qB gene promoter luciferase plasmids were co-transfected with pRL-
CMV control plasmids into PAC-2 cells together with of zPU.1 or/and zIRF8 
expression plasmids, or pcDNA plasmids as control. The transfected cells were 
treated with the medium collected from zIFNγ1 or/and zIFNγ2 transfected PAC-2 
cells, or pcDNA transfected cells as control for 24 hours before they were 
harvested for luciferase assay. Relative luciferase activity was calculated as the 
ratio of firefly luciferase reading to Renilla luciferase reading. Data were 
presented as mean ± SD of triplicates. Statistical analysis was performed using 
Student’s two-sided t test. Differences were considered statistically significant at 
p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ represent p< 0.05, p< 0.01, p< 0.001 and non-
significance, respectively. All data are representative of at least three independent 
experiments. 
The basal activity of the zebrafish C1qC gene promoter was also increased 
with zPU.1 over-expression and further enhanced by zIRF8, while zIRF8 itself 
did not have any effects on the zebrafish C1qC gene promoter (Figure 3.31). 
However, different from the promoters of the zebrafish C1qA and C1qB genes, 
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the zebrafish C1qC gene promoter activity was inhibited by zIFNγ2 to around 
50%, while zIFNγ1 consistently had no effects on the zebrafish C1qC gene 
promoter activity (Figure 3.31).  
 
Figure 3.31. Zebrafish C1qC gene promoter exhibited relatively high basal 
promoter activities with zPU.1 co-transfection and the activities were 
inhibited by zebrafish IFNγ2. Zebrafish C1qC gene promoter luciferase 
plasmids were co-transfected with pRL-CMV control plasmids into PAC-2 cells 
together with of zPU.1 or/and zIRF8 expression plasmids, or pcDNA plasmids as 
control. The transfected cells were treated with the medium collected from 
zIFNγ1 or/and zIFNγ2 transfected PAC-2 cells, or pcDNA transfected cells as 
control for 24 hours before they were harvested for luciferase assay. Relative 
luciferase activity was calculated as the ratio of firefly luciferase reading to 
Renilla luciferase reading. Data were presented as mean ± SD of triplicates. 
Statistical analysis was performed using Student’s two-sided t test. Differences 
were considered statistically significant at p < 0.05. ‘*’, ‘**’, ‘***’ and ‘n.s’ 
represent p< 0.05, p< 0.01, p< 0.001 and non-significance. All data are 





3.7.4 Sequence alignment of putative IFNγ-responsive element across species 
The zebrafish C1qA gene promoter was more potently induced by zIFNγ2 
than the zebrafish C1qB gene promoter. Therefore, the conserved 53-bp IFNγ-
responsive element in mammalian species is possibly residing in the zebrafish 
C1qA gene promoter, as it was not found in the zebrafish C1qB gene promoter 
previously (Figure 3.13). The zebrafish C1qA gene promoter region was analyzed 
using MatInspector software (Genomatix) and the predicted cis-acting elements 
were indicated (Figure 3.32). A TSS-proximal chimeric GAS-ISRE sequence was 
revealed 55 bp upstream of the zebrafish C1qA gene TSS (Figure 3.32).  
 
Figure 3.32. Predicted cis-acting elements in the zebrafish C1qA promoter 
region. The sequence of zebrafish C1qA promoter was analyzed via MatInspector 
program and the predicted cis-acting elements were highlighted. The TSS was 
indicated in bold font. 
Furthermore, sequence alignment of the zebrafish C1qA gene promoter with 
the conserved 53-bp sequence revealed that the core sequence "TTGCAGAAAT" 
is well conserved from zebrafish to human (Figure 3.33), despite that the 
sequence is in the C1qA gene promoter of zebrafish, but in the C1qB gene 
promoters of mammalian species. These results suggest that there were 
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evolutionary changes in the transcription regulation of C1q gene promoters, 
although the genomic organization of the three C1q subunit genes were well 
conserved from zebrafish to human. 
 
Figure 3.33. The alignment of the putative IFNγ-responsive element in the 
zebrafish C1qA gene promoter with its counterparts in the C1qB gene 
promoter across mammalian species. The sequence of the putative IFNγ-
response element within the putative zebrafish C1qA gene promoter region 
(NC_007132.5) was aligned with corresponding sequences in the C1qB gene 
promoters of human (NC_000001.10), chimpanzee (NC_006468.3), mouse 
(NC_000070.5), rat (NC_005104.2), dog (NC_006584.2), cattle (NC_007300.4), 
and chicken (NC_006108.2). Alignment was performed via clustalX version 2 
(http://www.clustal.org/clustal2) (Larkin et al., 2007) and presented using Jalview 
(http://www.jalview.org/webstart/jalview.jar) (Waterhouse et al., 2009). The 
identified TF binding sites and well conserved region were highlighted. 
3.7.5 Summary 
In the mouse RAW264.7 cells, the zebrafish C1q gene promoters exhibited 
negligible levels of basal activity and did not respond to IFNγ (Figure 3.27B). 
However, when the experiments were conducted in the zebrafish PAC-2 cells, all 
the three zebrafish C1q gene promoters exhibited different levels of basal 
activities with the over-expression of ectopic zPU.1, and the promoter activities 
were further enhanced with the over-expression of ectopic zIRF8 (Figure 3.28). 
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These results suggest that the incompatibility of the C1q gene promoters from 
other species in the mouse transcription system could account for the low basal 
activity and the different modes of responses to IFNγ observed in the previous 
results. But due to the lack of relevant cell lines suitable for each species, it is 
difficult to conduct further studies on those promoters. 
Despite of the existence of two zebrafish IFNγ genes (Igawa et al., 2006) 
and both were shown to induce the same set of genes and are functionally 
equivalent to mammalian IFNγ (Sieger et al., 2009), only zIFNγ2 is able to affect 
the zebrafish C1q gene promoter activities (Figure 3.29, 3.30 and 3.31). The 
stimulation by zIFNγ2 had successfully increased the activity of the zebrafish 
C1qA and C1qB gene promoters, but the C1qC gene promoter was inhibited by 
zIFNγ2 (Figure 3.29, 3.30 and 3.31). However, the IFNγ-induced activity was 
stronger for the zebrafish C1qA gene promoter than that of the C1qB gene 
promoter (Figure 3.29 and 3.30).  
Further investigation on the zebrafish C1qA gene promoter revealed that the 
conserved 53-bp element in the mammalian C1qB gene promoters is residing in 
the zebrafish C1qA gene promoter. These results suggest that there are 
evolutionary changes in the transcription regulation of C1q gene promoters, 
although the genomic organization of the three C1q subunit genes is well 




3.8 The development of a C1q transgenic mouse model 
3.8.1 Introduction 
The previous results of this project all support the second hypothesis that 
the synchronized expression of the three C1q subunit genes is achieved through a 
core cis-acting element in the form of a gene cluster. However, the investigations 
were all conducted in the in vitro or ex vivo system. In order to further validate the 
hypothesis in vivo, a transgenic mouse model was proposed to investigate the 
natural expression regulation patterns. 
Basically, transgenesis is to introduce foreign genetic material into the 
genome so that the foreign DNA is incorporated into the genome and inherited by 
the offspring (Fu et al., 1998). The primary usage of transgenic animal models is 
the in vivo study of gene functions and they are also widely used in disease 
progression study, evaluation of therapeutic strategies, and a number of other 
commercial applications (Gama Sosa et al., 2010). The first transgenic mouse was 
generated by infecting pre-implantation embryos with Moloney leukemia virus, 
leading to germline integration of viral genomic DNA (Jaenisch, 1976). 
Subsequently, foreign genetic materials of bacterial (Gordon et al., 1980), viral 
(Harbers et al., 1981), and mammalian (Wagner et al., 1981) origin were reported 
to be incorporated into the mouse genome through pronuclear injection into 
fertilized mouse oocytes. Since then, transgenic mouse models became the most 
popular models for human diseases and various advanced technologies were 
introduced to generate transgenic mice. 
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In this transgenic mouse model, fluorescent reporter genes would be 
expressed under the control of C1q gene promoters. This would enable the 
assessment of the regulatory effects through monitoring the expression of the 
reporter genes.  
3.8.2 Design of transgenic mice  
The rationale of this study is to investigate the transcriptional control of the 
C1q gene expression in vivo using transgenic mice. Thus the transgenic mice were 
designed to have transgenic reporter genes under the control of C1q gene 
promoters. As the previous results support the hypothesis that the three C1q genes 
are coordinately regulated as a gene cluster, the reporter genes would be inserted 
into each C1q gene in the context of the whole gene cluster. Thus a large DNA 
construct is required to carry the whole C1q gene cluster and the regions flanking 
both end of the gene cluster.  
There are various types of transgenic vectors. They are derived from 
plasmids (Gordon et al., 1980), yeast artificial chromosome (YAC) (Burke et al., 
1987), P1 bacteriophage (Sternberg, 1990), bacteria artificial chromosome (BAC) 
(Shizuya et al., 1992), and P1 bacteriophage-derived artificial chromosome (PAC) 
(Ioannou et al., 1994). Among them, P1 bacteriophage, YAC, BAC and PAC all 
allow the insertion of large DNA fragments. However, YAC clones are unstable 
and tend to delete inserted sequences spontaneously (Neil et al., 1990). P1 
bacteriophage system requires an extra in vitro packaging step (Sternberg, 1990). 
Therefore, BAC and PAC are the most suitable transgenic vector systems for this 
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project. Since the BAC clones of the mouse genome are commercially available 
from the BACPAC resource center (Oakland, CA, USA), the BAC clone, 
containing the whole C1q gene cluster and the regions flanking both end of the 
gene cluster, would be used to generate the transgenic mice.  
To insert the reporter gene into the C1q gene cluster, the second exon of 
each C1q gene was chosen to be replaced with the reporter gene, as it contains the 
translation start site. The insertion of the reporter gene would disrupt the 
expression of the original C1q gene, but allow the integrity of the C1q gene 
cluster to be retained. The reporter gene would be accompanied by a mammalian 
selection marker, which allows the selection of positive clones. The transgenic 
BAC clone would be introduced into mouse embryonic stem (ES) cells via 
electroporation. Successful clones of transgenic ES cells would be injected into 
blastocysts, which are subsequently transferred into the uterus of pseudo-pregnant 
mice. Subsequently, the successful chimeric mice from these chimeric blastocysts 








3.8.3 Construction of transgenic bacterial artificial chromosome (BAC) with 
enhanced green fluorescent protein (egfp) reporter gene under the control of 
the C1qA gene promoter 
To search for the most suitable BAC clone, that carries the whole mouse 
C1q gene cluster and the regions flanking both end of the gene cluster, the Clone 
DB database from NCBI (www.ncbi.nlm.nih.gov/clone/) was used. The BAC 
clone, RP24-114O15, was chosen as the template for this transgenic study, as it 
contains the whole mouse C1q gene cluster with 165 Kb flanking sequences 
upstream of the C1qA gene and 20 Kb downstream of the C1qB gene (Figure 
3.34). The BAC clone, RP24-114O15, contains C1qB, C1qC, C1qA, Epha8 and 
Zbtb40 genes, in 5' to 3' order, as the mouse C1q genes are on the negative strand 
of the mouse chromosome 4 (Figure 3.34). 
 
Figure 3.34. Demonstration of BAC clone RP24-114O15. The BAC clone, 





The first transgenic BAC vector was constructed by replacing the second 
exon of the C1qA gene with the enhanced green fluorescent protein (egfp) as the 
reporter gene. The C1qA gene was chosen as the first target to be used as a 
platform to study the natural expression patterns of C1q in mice. Follow-up 
studies of this transgenic mouse model would introduce mutations to the C1qB 
core promoter to study the coordinated transcriptional control as a gene cluster.  
The GFP gene was PCR-amplified by my colleague from pEGFP-C1 
plasmid (Clontech, Mountain View, CA, USA) (Tan, unpublished data). It 
contains the kozak sequence for the start of translation (Kozak, 1987), the coding 
sequence of GFP and the SV40 early mRNA polyadenylation signal. The 




) gene, flanked by FLP recombinase 
target (FRT) sites, was PCR-amplified from FRT-PGK-gb2-neo-FRT selection 
cassette (Gene Bridges, Germany) as the selection marker (Tan, unpublished data). 
The recombination between the two flanking FRT sites allows the removal of the 
selection marker by crossing with mouse strain expressing FLP recombinase 
(Kilby et al., 1993; Rodriguez et al., 2000; Sadowski, 1995). The two PCR 
amplicons were subsequently used as templates in a fusion PCR, and the fusion 
PCR product was inserted into pCR2.1-TOPO TA cloning vector (Tan, 
unpublished data). The insert sequence was verified by sequencing and PCR-
amplified using primers containing 50 bp homologous sequence of the C1qA gene 
exon two (Tan, unpublished data). These PCR products were used as the 
transgene cassette (Figure 3.35). 
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To insert the transgene cassette into the second exon of the C1qA gene in 
the BAC clone, the homologous recombination method was employed via the 
Red/ET recombination system (Gene Bridges) (Figure 3.35). This system makes 
use of a λ phage system mediated by Redα and Redβ recombinase pair for 
homologous recombination (Muyrers et al., 2000). 
 
Figure 3.35. Design of the transgene cassette and demonstration of the 
homologous recombination. The transgene cassette is composed of the egfp gene 
and the FRT-flanked-neo
r
 gene driven by Pgk/gb2 promoter. Both ends of the 
transgene cassette contain the 50-bp homologous sequences to the 5' and 3' of the 
C1qA gene exon two, respectively (grey shades). Homologous recombination was 
performed via the Red/ET recombination system between the C1qA gene exon 
two and the transgene cassette (depicted by the red double arrows).  
Briefly, to express the Redα and Redβ recombinase pair, the pRedET 
plasmid (Gene Bridges) was transformed into the BAC-bearing E. coli by 
electroporation (Tan, unpublished data). Subsequently, the bacteria were 
electroporated with the PCR products of the transgene cassette (Tan, unpublished 
data). After the homologous recombination took place, the successful clones were 
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selected in the presence of both chloramphenicol (for BAC) and kanamycin (for 
the transgene cassette) (Tan, unpublished data). The successful clones were 
verified by sequencing and linearized for subsequent electroporation to transfect 
the BAC into the mouse ES cells (Tan, unpublished data). 
3.8.4 Generation and screening for positive transgenic mouse embryonic 
stem (ES) cell clones 
The successful clone of the transgenic BAC was linearized with a homing 
endonuclease, PI-SceI and transfected into mouse ES cells via electroporation by 
collaborator lab (Dr. Md. Zakir Hossain's lab, Cancer science institute, Singapore). 
The successfully transfected ES cell clones were selected in the presence of G-
418 selection drug and cultured in isolated wells. Different clones were screened 
through PCR analysis on the integrity of the transgene cassette and its integration 
with the C1q gene cluster (Tan, unpublished data). The pairs of primers used for 
the screening PCR were demonstrated in Figure 3.36. The C1qA-107-F forward 
primer was paired with the ES-GFP-R reverse primer to check the integration of 
the transgene cassette with the C1qA gene promoter, and they were labeled as the 
primer set A (Figure 3.36). The ES-GFP-F forward primer was paired with the 
ES-NEO-R reverse primer to check the integrity of the transgene cassette, and 
they were labeled as the primer set B (Figure 3.36). The Fabp1 forward and 
reverse primers were used as the internal control for mouse genome and they were 
labeled as the primer set C (Figure 3.36). The same sets of primers were used for 
subsequent PCR screening on the transgenic chimeric mice.  
159 
 
Three mouse ES cell clones (B8, C1 and E10) were identified as the 
successful clones through the screening by the three sets of primers and used for 
the generation of the transgenic chimeric mice (Tan, unpublished data). 
 
Figure 3.36. Demonstration of the primers used for the screening of the 
transgenic mouse ES cell clones and the transgenic chimeric mice. The C1qA-
107-F forward primer was paired with the ES-GFP-R reverse primer to check the 
integration of the transgene cassette with the C1qA gene promoter, and they were 
labeled as the primer set A (green arrows). The ES-GFP-F forward primer was 
paired with the ES-NEO-R reverse primer to check the integrity of the transgene 
cassette, and they were labeled as the primer set B (red arrows). The Fabp1 
forward and reverse primers were used as the internal control for mouse genome 
and they were labeled as the primer set C. The same sets of primers were used for 







3.8.5 Generation and screening for positive transgenic chimeric mice 
The three successful transgenic mouse ES cell clones, B8, C1 and E10, were 
sent to the collaborator lab (Dr. Md. Zakir Hossain's lab, Cancer science institute, 
Singapore) for the generation of the transgenic chimeric mice. The transgenic ES 
cells were injected into blastocysts, which were subsequently transferred into the 
uterus of pseudo-pregnant mice. Briefly, 20 chimeric blastocysts were transferred 
into the uterus of pseudo-pregnant mice and 11 of them were successfully born 
alive. Among all the 11 chimeric mice, there were five male and six female mice. 
The five male chimeric mice were chosen to mate with normal mice to give rise to 
heterozygotes, as they could mate with a few female mice without break. They 
were assigned to cage BR1 to BR5, respectively (Table 3.1) and undergone the 
screening for the transgene cassette and its integration with the C1qA gene locus 
(Figure 3.37). As shown in Figure 3.37, all the five male chimeric mice were 
positive for the transgene cassette and its integration with the C1qA gene locus. 
Thus all of them were chosen to mate with normal mice to give rise to 
heterozygous F1 generation. 
Table 3.1. List of the chimeric mice generated in this study. 
Cage No. Strain D.O.B Gender 
BR1 A-gfp-BAC-C1-1 6/5/2013 Male 
BR2 A-gfp-BAC-C1-2 6/5/2013 Male 
BR3 A-gfp-BAC-B8-1 3/5/2013  Male 
BR4 A-gfp-BAC-B8-2 22/4/2013 Male 
BR5 A-gfp-BAC-E10 3/5/2013  Male 




Figure 3.37. Screening for the transgene cassette and its integration with the 
C1qA gene locus of the five male chimeric mice. The tail tips of the five male 
chimeric mice were snapped, respectively, and lysed for genomic DNA isolation. 
The isolated genomic DNA were screened for the transgene cassette and its 
integration with the C1qA locus via PCR using the primer set A (left), set B 
(middle) and set C (right) as internal control. The PCR products were analyzed on 
1% agarose gel. Genomic DNA from normal mice was used as a negative control 
(lane 1 of each panel). The five chimeric mice from cage BR1 to BR5 were run on 
lane 2 to lane 6 for each pair of primers, respectively. No template PCR control 
was run at lane 7 for each pair of primers.  
3.8.6 Breeding for F1 generation to get heterozygote transgenic mice 
The mouse ES cells were derived from 129 mice to generate the transgenic 
ES cells in this study. The 129 mice carry genes that result in a black agouti 
(brown) coat color and this brown coat color is dominant to the black coat color 
of C57BL/6 mice. Therefore, the injection of 129 ES cells into C57BL/6 recipient 
blastocysts results in the chimera with patches of brown and patches of black. 
Thus when these 129/B6 mix chimeras mate with C57BL/6 mice, progeny would 
be either brown when the 129 ES cells have contributed to the germline; or 
progeny would be black when cells from the C57BL/6 recipient blastocysts have 
contributed to the germline. All the brown offspring should then be genotyped to 
find out which ones have received the targeted allele.  
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Each of the five male chimeric mice was mated with C57BL/6 female mice. 
The offspring litters were kept in separated cages and listed in Table 3.2. The 
record of these F1 generation mice is as recent as 04/12/2013.  
Table 3.2. List of F1 generation mice. 
Cage No. Father D.O.B Gender Fur color No. of mice 
M1 BR1 8/8/2013 Male Black 3 
F1 BR1 8/8/2013 Female Black 4 
M2 BR2 10/8/2013 Male Black 5 
F2 BR3 10/8/2013 Female Black 2 
M3 BR3 10/8/2013 Male Black 3 
M4 BR3 10/8/2013 Male Black 3 
M5 BR4 10/8/2013 Male Black 3 
F3 BR4 10/8/2013 Female Black 2 
F4 BR4 5/9/2013 Female Black 3 
F5 BR2 5/9/2013 Female Black 1 
M6 BR3 5/9/2013 Male Black 5 
F6 BR3 5/9/2013 Female Black 4 
M7 BR4 5/9/2013 Male Black 3 
F7 BR2 17/9/2013 Female Black 3 
M8 BR2 17/9/2013 Male Black 3 
M9 BR2 17/9/2013 Male Black 3 
F8 BR1 19/9/2013 Female Black 3 
F9 BR1 19/9/2013 Female Black 3 
M10 BR1 19/9/2013 Male Black 3 
F10 BR5 19/9/2013 Female Brown 1 
M11 BR1 19/9/2013 Male Black 3 
F11 BR4 28/9/2013 Female Black 2 
M12 BR4 28/9/2013 Male Black 4 
F12 BR3 16/10/2013 Female Black 3 
M13 BR3 16/10/2013 Male Black 4 
F13 BR2 26/10/2013 Female Black 3 
F14 BR2 26/10/2013 Female Black 3 
M14 BR2 26/10/2013 Male Black 3 
M15 BR5 7/11/2013 Male Brown 2 
F15 BR5 7/11/2013 Female Brown 3 
M16 BR1 13/11/2013 Male Black 4 
F16 BR1 13/11/2013 Female Black 4 
F17 BR1 13/11/2013 Female Black 3 
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M17 BR3 13/11/2013 Male Black 4 
F18 BR3 13/11/2013 Female Black 1 
M18 BR5 13/11/2013 Male Black 3 
F19 BR5 13/11/2013 Female Black 1 
M19 BR4 14/11/2013 Male Black 5 
M20 BR4 14/11/2013 Male Black 3 
F20 BR4 14/11/2013 Female Black 1 
Only the male chimeric mouse in cage BR5 has given rise to brown coat 
color offspring, while the rest four male chimeric mice have only given rise to 
black offspring. These results suggest that the 129 transgenic ES cells have 
contributed to the germline of the male chimeric mouse in BR5, while no sign of 
germline transmission of 129 transgenic ES cells in the male mice in BR1 to BR4.  
The single brown mouse (Cage F10) was tail-snapped and its genomic DNA 
was isolated to screen for the transgene cassette and its integration with the C1qA 
gene locus. However, the screening results showed that it is negative for the 
transgene cassette (Figure 3.38). The male chimeric mouse in BR5 has given rise 
to more brown litters and they will be screened for the transgene cassette, once 





Figure 3.38. Screening for the transgene cassette and its integration with the 
C1qA gene locus of the single brown mouse in cage F10. The tail tip of the 
brown offspring mouse was snapped and lysed for genomic DNA isolation. The 
isolated genomic DNA was screened for the transgene cassette and its integration 
with the C1qA locus via PCR using the primer set A (left), set B (middle) and set 
C (right) as internal control. The PCR products were analyzed on 1% agarose gel. 
The genomic DNA from the male chimeric mouse in cage BR5 was used as a 
positive control (lane 1 of each panel). Normal mice genomic DNA was used as a 
negative control (lane 3 of each panel). No template PCR control was run at lane 











A transgenic BAC construct with the egfp gene under the control of the 
mouse C1qA gene promoter was constructed via homologous recombination and 
used for mouse ES cell-mediated generation of transgenic mice. The male 
chimeric mice were screened for the presence and integration of the transgene 
cassette with the C1qA gene locus. All of them were shown to be positive for the 
screening. The five male chimeric mice have mated with normal C57BL/6 mice to 
give rise to the F1 generation mice. However, most of the F1 generation offspring 
were black in color, which means they do not contain the genomic materials from 
the transgenic 129 ES cells. Moreover, the single brown offspring from the male 
chimeric mouse in cage BR5 was also shown to be negative for the transgene 
cassette. But more brown litters were born with the male chimeric mice in BR5 as 
their father. They will be screened when they were ready for the tail-snapping to 
isolate their genomic DNA.  
Follow-up studies of the transgenic mouse model would introduce 
mutations to the C1qB gene core promoter to study its influence in the expression 







Chapter 4 - Discussion 
4.1 Significance of the study 
The rationale of the study is to understand the mechanisms underlying the 
transcriptional control of the complement protein C1q. A number of reasons 
warrant the importance of this study. 
4.1.1 C1q and its role in systemic lupus erythematosus (SLE) 
The genetic deficiency of C1q, which impairs the production of functional 
C1q, has profound impact on the immune system, as it almost certainly cause the 
autoimmune disease, systemic lupus erythematosus (SLE) (Carneiro-Sampaio et 
al., 2008; Schejbel et al., 2011). Although the genetic C1q deficiency is relatively 
rare, acquired C1q deficiency is more frequently observed in SLE patients, which 
would contribute to SLE pathogenesis (Edelbauer et al., 2011; Wu et al., 2011). 
Deficiency in C1q leads to impaired clearance and accumulation of apoptotic cells 
and immune complexes, resulting in the exposure of autoantigens to the immune 
system (Carneiro-Sampaio, 2008; Casciola-Rosen et al., 1994; Mevorach et al., 
1998; Schifferli et al., 1986; Truedsson et al., 2007). Moreover, reduced C1q 
levels could result in increased plasmacytoid DCs (pDCs) IFNα production, 
which could contribute to SLE pathogenesis (Lood et al., 2009), and functional 
C1q was found to induce the tolerogenic properties of developing DCs (Teh et al., 
2011). These together suggest that C1q plays a protective role in SLE and its 
deficiency is a strong risk factor for the disease pathogenesis.  
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4.1.2 Possible mechanism leading to C1q deficiency in SLE 
In SLE patients without apparent genetic C1q deficiency, acquired C1q 
deficiency is frequently observed, and the most well-known explanation for the 
acquired C1q deficiency is the excessive C1q consumption by immune complexes 
and anti-C1q autoantibodies (Gordon et al., 2000; Greisman et al., 1987). 
However, the expression of C1q is versatile and affected by diverse microbial 
stimuli, cytokines, hormones and drugs, though C1q is consistently produced DCs 
and macrophages (Lu et al., 2008). Thus defects in the regulation of C1q 
expression at the transcriptional level could also contribute to the C1q deficiency 
in SLE patients (Figure 1.2). In fact, it was already reported that reduced C1q 
mRNA expression and impaired up-regulation of C1q production in response to 
stimulation were observed in cultured monocytes from the peripheral blood of 
some SLE patients without apparent genetic C1q deficiency (Moosig et al., 2006). 
However, the mechanisms underlying the dysregulation of C1q expression at the 
transcription level were not determined.  
Similar to single nucleotide polymorphisms (SNPs) in the protein coding 
sequence of the C1q genes, which could be the potential cause of genetic C1q 
deficiency, SNPs were also revealed at the 5' vicinity of the three C1q subunit 
genes on human chromosome 1, through searching the NCBI dbSNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP) (Data not shown). However, unlike 
the SNPs in the protein coding sequence, which were well studied (Schejbel et al., 
2011), SNPs in the non-coding regions have not been studied and have the 
potential to contribute to the dysregulation of C1q expression at the transcription 
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level. In fact, in one of the murine C1q gene study, polymorphism in the C1q 
gene regulatory region was found to down-regulate murine C1q protein levels and 
this was linked to lupus nephritis (Miura-Shimura et al., 2002). 
4.1.3 C1q gene cluster and its implication in gene cluster study  
C1q is precisely assembled from 18 subunits, equally produced from three 
different genes. The three C1q subunit genes are highly clustered (C1qA-C1qB-
C1qC) within a genomic region of ~25 kb on human chromosome 1 (Sellar et al., 
1991). Deficiency in a single subunit gene could abolish the production of the 
entire C1q molecule (Botto et al., 1998; Schejbel et al., 2011). This 
interdependent production of the three subunits demands the transcriptional 
synchronization.  
Moreover, this specific feature of gene organization is conserved across 
multiple divergent species from zebrafish to human (Figure 1.4B). The 
conservation of the C1q gene organization suggests that the transcriptional 
regulation of the C1q genes is also conserved and probably under the same set of 
regulatory scheme in C1q-expressing cells. Thus it is important to investigate how 
the three C1q genes are coordinately expressed and use it as a genomic template 
for understanding synchronized gene transcription in gene clusters. Furthermore, 
the study on the evolution of C1q gene cluster may provide more insights into the 
evolution of transcriptional regulation of gene clusters. 
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4.2 The synchronized transcriptional regulation of the three 
human C1q subunit genes  
4.2.1 The interdependency of the three C1q subunit genes 
The fact that C1q is assembled in 1:1:1 ratio from its C1qA, C1qB and 
C1qC subunits (Reid and Porter, 1976) suggests synchronized transcription of the 
three subunit genes. The mRNA expression profile of the three C1q subunit genes 
(C1qA, C1qB and C1qC) revealed the synchronization in both basal and IFNγ-
stimulated transcription for all the three genes (Figure 3.2). This suggests the 
apparently independent C1q subunit genes were under the same mechanism of 
transcriptional regulation in a coordinated manner.  
To investigate the transcriptional regulation of the three C1q subunit genes, 
two hypotheses were proposed: 1) the three C1q gene promoters contain 
replicated cis-acting elements so as to respond to common regulatory signals that 
are unique to DCs and macrophages; 2) the three C1q genes lack independent 
promoters and the synchronization is achieved through a superseding core 
promoter inside the C1q cluster. 
The three individual C1q gene promoters were cloned into luciferase 
reporter plasmids to examine their activities using dual-luciferase assay. The three 
isolated promoters displayed varying levels of basal activity with the C1qA gene 
promoter and the C1qB gene promoter being much stronger than the C1qC gene 
promoter (Figure 3.4, 3.5 and 3.6). Although, the isolated C1qB gene promoter 
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was highly inducible by IFNγ (Figure 3.5) as its endogenous counterpart (Figure 
3.2), the isolated C1qA and C1qC gene promoters were suppressed by IFNγ 
(Figure 3.4 and 3.6). These results showed that only the C1qB gene promoter 
exhibited similar patterns of basal and IFNγ-induced activities as its endogenous 
counterpart, while the C1qA and C1qC gene promoters departed from their 
endogenous counterparts. This rules out the first hypothesis that the synchronized 
transcription is achieved by have the relevant cis-acting elements replicated in the 
three independent C1q subunit gene promoters. 
As the only responding promoter to IFNγ stimulation, the minimal C1qB 
gene promoter, the B273 promoter was reckoned as the shared core cis-acting 
element in the second hypothesis. The insertion of the B273 promoter to the 3' 
end across the luciferase gene rendered the 5' C1qA and C1qC gene promoter to 
respond positively to IFNγ (Figure 3.8). This suggests that the B273 promoter acts 
as the core cis-acting element and regulates the C1qA gene and the C1qC gene 
promoters to synchronize the IFNγ-induced expression of the three C1q genes in 
vivo. This core promoter concept reconciles with the high conserved clustering of 
the three C1q genes (Hu et al., 2010; Petry et al., 1996; Sellar et al., 1991).  
In the studies of several other gene clusters, the sharing of regulatory sites 
to coordinate the expression of multiple genes has also been reported and multiple 
genes were affected when the shared regulatory element was altered or mutated 
(Gould et al., 1997; Li et al., 2002; Uusi-Oukari et al., 2000; Xu et al., 2006). 
These studies all revealed the presence of cross-talking between genes within the 
same gene cluster, and the coordination was achieved through the shared 
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regulatory element within the gene cluster. The coordinated regulation of C1q 
gene promoters through the core B273 promoter is consistent with the gene 
cluster studies by other groups and reinforces the second hypothesis.  
However, these data are insufficient to understand how the basal expression 
of the three C1q genes is coordinated, though the synchronized induction of the 
three C1q genes by IFNγ is explained by the core cis-acting IFNγ-responsive 
element. The ability of a 3' C1qB gene promoter to regulate the activities of the 
C1qA and C1qC gene promoters implies that the C1qB gene promoter also 
synchronized the basal expression of the three C1q genes. The mechanisms 
underlying the synchronized basal expression of the three C1q genes require 
further investigations.  
Moreover, this study focused on the transcriptional control of the C1q genes 
and did not take the post-transcriptional events into consideration, which include 
RNA stability, processing and regulation. Among them, the miRNA-triggered 
post-transcriptional regulation has provoked an explosive field of research and the 
3' untranslated region of the mRNA is responsible for the regulation by miRNA 
(Bartel, 2004). However, in this study, the reporter gene lacks the 3' untranslated 
region, so that the results did not provide the full picture of the transcriptional 
control of the human C1q genes. Thus in further studies, miRNA profiling is 
required to understand the post-transcriptional regulation via large-scale parallel 
sequencing approaches with custom computational pipelines including miRNA 
microarray (Liu et al., 2004), deep-sequencing method (Bar et al., 2008), etc. 
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4.2.2 The novel IFNγ-responsive element identified in the C1qB gene 
promoter 
The promoter activity profiles of the three C1q genes revealed that only the 
C1qB gene promoter contains the relevant cis-acting element responsible for the 
IFNγ-induced promoter activity. Furthermore, the B273 promoter was shown to 
act as the core cis-acting element, which regulates the C1qA and C1qC gene 
promoters to synchronize the IFNγ-induced expression of the three C1q genes. 
Further progressive deletions from both 5' and 3' ends on the C1qB gene promoter 
identified a 53-bp DNA fragment that is responsible for the IFNγ-induced C1qB 
gene promoter activity.  
This putative IFNγ-responsive element is also well conserved in mammals 
and the conserved regions along the 53-bp fragment are either symmetric or 
imperfect symmetric palindrome sequences centered at -96 bp, -105 bp and -124 
bp (Figure 3.13). The symmetric or imperfect symmetric palindrome sequences 
were shown as putative TF binding sites and important components of the cis-
acting element consensus sequences by a number of studies (Berry et al., 1989; 
Chang and Murialdo, 1990; Cho-Chung, 1998; Orchard et al., 1990; Shibata-
Sakurai et al., 1993).  
The palindrome sequences centered at -96 bp and -105 bp were predicted as 
the novel GAS-ISRE chimeric element and fits in the consensus of a known GAS-
ISRE chimeric sequence (Kaneko et al., 2006) and various composite cis-acting 
elements found in promoters of IFNγ-responsive genes (Kanno et al., 2005). 
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These composite elements are normally formed as the chimera of Ets and IRF 
binding sites, including modified GAS element (Contursi et al., 2000; Decker et 
al., 1997), Ets/IRF composite element (EICE) (Marecki et al., 2001; Schroder et 
al., 2007), Ets/IRF response element (EIRE) (Meraro et al., 2002) and IRF-Ets 
composite site (IECS) (Tamura et al., 2005). Though these cis elements are 
named differently, there are only subtle differences between these elements 
(Kanno et al., 2005; Marecki and Fenton, 2000).  
Mutations at these conserved sequences revealed that the integrity of the 
identified 53-bp DNA fragment is essential for the IFNγ-induced C1qB gene 
promoter activity. Interestingly, although A96G mutation completely inactivated 
this element, the mutations at the flanking nucleotides, i.e. C95T and G97A, 
substantially increased the basal activity of this promoter without compromising 
the IFNγ-induced activity (Figure 3.15). This implies that the palindrome 
sequence centered at -96 bp is not only responsible for the stimulated activity in 
response to IFNγ, but also has a potent regulatory role in the control of basal 
activity of the C1qB gene promoter. This ensures that the expression level of 
C1qB is well controlled to match the expression levels of the other two subunits.  
The palindrome sequence centered at -124 bp was neither predicted nor 
found in literature, although it is highly conserved in all selected mammalian 
species (Figure 3.13). However, the deletion of the 5' half (-133 bp to -125 bp) of 
this palindrome sequence totally abrogated the IFNγ-induced C1qB gene 
promoter activity (Figure 3.11), although the integrity of the predicted GAS-ISRE 
sequence was still maintained. Moreover, the mutations at this region also 
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completely abrogated the IFNγ-induced C1qB gene promoter activity. Further 
short sequence search of this novel palindrome sequence in the NCBI database 
was also conducted; however, there was no homologous sequences found from 
the human genomic sequence in the NCBI database. This implies the novelty and 
uniqueness of this palindrome sequence centered at -124 bp. 
These results suggest that the integrity of the whole 53-bp element is 
essential for the IFNγ-induced C1qB gene promoter activity and the putative 
GAS-ISRE region is necessary but not sufficient for the response of C1qB gene 
promoter to IFNγ stimulation. Further studies on the palindrome sequence 
centered at -124 bp are required to fully understand this novel IFNγ-responsive 
element. 
4.2.3 The transcription factors (TFs) involved in the IFNγ-induced C1q gene 
promoter activity 
The predicted GAS-ISRE chimeric sequence, which forms an essential 
region of the 53-bp IFNγ-responsive element (Figure 3.13), is a well-defined 
IFNγ-responsive element (Kanno et al., 2005; Marecki and Fenton, 2000; 
Marecki et al., 2001). It appears as either chimeric sequences of GAS and ISRE, 
or other Ets/IRF composite sequences (Contursi et al., 2000; Decker et al., 1997; 
Kaneko et al., 2006; Kanno et al., 2005; Marecki et al., 2001; Meraro et al., 2002; 
Mirkovitch et al., 1992; Schroder et al., 2007; Tamura et al., 2005).  
Based on the known interactions of these elements to transcription factors 
(TFs), IRF1, STAT1, IRF8 and PU.1 were chosen as the candidates to study the 
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interactions between the 53-bp IFNγ-responsive element and its related TFs. They 
were chosen based on the following evidences that IRF1 is highly up-regulated by 
IFNγ and binds to ISRE element (Kanno et al., 2005; Ramsauer et al., 2007); 
STAT1 dimer binds to GAS element after the activation of Jak-STAT signaling 
pathway.  In most of the cases, there is a second wave of transcription activation 
post the Jak-Stat pathway, and it is normally through the binding of the IRF8-
PU.1 complex to the GAS elements (Decker et al., 1997; Kanno et al., 2005; 
Shuai and Liu, 2003). But this only happens in GAS elements with the Ets/IRF 
chimeric motif (TTTCNNGGAA), and some of these GAS elements only recruit 
Ets/IRF complexes, but not STAT1 dimers (Decker et al., 1997; Kanno et al., 
2005).  
The knockdown of IRF1 in RAW264.7 cells showed no inhibition on the 
IFNγ-stimulated activity of the B273 promoter (Figure 3.16A). On the contrary, it 
slightly but consistently increased the B273 promoter response to IFNγ. The 
knockdown of STAT1, IRF8 and PU.1 all markedly impaired the B273 promoter 
response to IFNγ (Figure 3.16), suggesting that these three TFs are required for 
the IFNγ-stimulated promoter activities of the C1qB gene promoter. 
However, in vitro DNA affinity binding assay showed that the 53-bp 
putative IFNγ-responsive element only interacted directly with IRF8 and PU.1, 
but not STAT1, and IFNγ treatment is required for the interaction (Figure 3.17). 
This suggests an indirect role of STAT1 in the IFNγ-stimulated C1qB gene 
promoter activities, which was shown to be through the regulation of IFNγ-
induced IRF8 expression (Figure 3.18 and 3.19). Moreover, when the wild-type 
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oligos were replaced with the mutant oligos, IRF8 and PU.1 were no longer 
detected in the precipitate (Figure 3.17). Notably, the mutation T128C, which is 
inside the palindrome sequence at -124 bp, also abrogated the in vitro binding of 
PU.1 and IRF8 to the 53-bp DNA fragment. This suggests that the mutations 
abrogate the IFNγ-induced C1qB gene promoter activities through the disruption 
of TF binding to the putative IFNγ-responsive element, and the palindrome 
sequence at -124 bp is also required for the binding of PU.1 and IRF8 to the 53-bp 
DNA fragment.  
There are two possible explanations on how the palindrome sequence 
centered at -124 bp participates in the TF-DNA interaction. It is either part of the 
binding site of PU.1/IRF8 complex, or a binding site for another TF that is not 
revealed in this study, but participate in the IFNγ-stimulated promoter activities 
through forming complex with the PU.1/IRF8 complex. Further studies are 
required to fully understand the role of the palindrome sequence centered at -124 
bp and the possible involvement of other TFs. 
The ChIP experiments validated the DNA pull-down results regarding 
IFNγ-dependent interaction of IRF8 and PU.1 with the C1qB gene promoter. On 
the other hand, the co-precipitation of the C1qC gene promoter with PU.1 was 
also observed regardless of IFNγ treatment (Figure 3.21). This result validated the 
software prediction on the C1qC promoter that a PU.1 binding site is residing next 
to the TSS of the C1qC gene. This also suggests a potential role of PU.1 in the 
regulation of C1qC promoter activity and its possible participation in the 3' 
regulation by the C1qB gene promoter to the C1qC gene promoter.  
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However, the question remains in how the C1qA gene promoter may 
respond to IFNγ with no shown interactions with PU.1 or IRF8. Based on the 
results on the IFNγ-induced endogenous C1qA mRNA levels (Figure 3.2) and the 
IFNγ-induced C1qA gene promoter activity with 3' B273 regulation (Figure 3.8), 
we could conclude that the C1qA gene promoter is the least inducible by IFNγ, as 
its fold of induction by IFNγ is much lower than that of the C1qB and C1qC 
promoters. This suggests that the regulation on the IFNγ-induced C1qA gene is 
probably through a much weaker interaction between the cis-acting elements and 
the TF complexes. In fact, the ChIP experiments were shown to be incapable of 
capturing the interactions between DNA and its associated proteins, if the 
interactions are weak and transient (Schmiedeberg et al., 2009). This weak 
induction on the C1qA gene promoter by IFNγ is physiologically relevant. This 
weak one-to-two-fold induction on the C1qA gene expression by IFNγ is 
sufficient to match the 5-to-7-fold induction on the C1qC gene expression, as the 
basal activity of the C1qA gene promoter is at a much higher level than that of the 
C1qC gene promoter (Figure 3.9). This control of excessive induction could also 
be seen from the mutation study on the C1qB gene promoter, that when the C95T 
and G97A mutations were introduced to the C1qB gene promoter, the basal 
activity was substantially increased without compromising the IFNγ-induced 
activity (Figure 3.15). However, more investigations on the C1qA gene promoter 
are required to better understand the intricate up-regulation mechanism of C1qA 
gene by IFNγ. 
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4.2.4 Proposed model for the mechanism underlying the IFNγ-induced C1q 
gene promoter activities 
The regulation pattern of the synchronized IFNγ-induced C1q gene 
promoter activities is summarized and demonstrated in Figure 4.1. At the basal 
level, the C1qA and C1qB gene are transcribed at higher levels than the C1qC 
gene, which makes the C1qC levels as the limiting factor for the assembly of the 
complete C1q molecule in 1:1:1 ratio of the three subunits. In the case of viral 
infections, etc., IFNγ in the microenvironment starts to stimulate the C1q-
producing cells through activating STAT1, which subsequently activates the first 
wave of IFNγ-inducible genes including IRF8 (Figure 4.1). IRF8 complexes with 
PU.1 and other possible TFs and the TF complex binds to the IFNγ-responsive 
element in the C1qB gene promoter, which directly increases the C1qB gene 
promoter activity and at the same time increases the C1qA and C1qC gene 
promoter activities through the spatial interaction between the TF complexes 




Figure 4.1. Proposed model for the mechanism underlying the IFNγ-induced 
C1q gene promoter activities. At the basal level, the C1qA and C1qB gene are 
transcribed at higher levels than the C1qC gene, which makes the C1qC levels as 
the limiting factor for the assembly of the complete C1q molecule in 1:1:1 ratio of 
the three subunits. In the case of viral infections, etc., IFNγ in the micro-
environment starts to stimulate the C1q-producing cells through activating 
STAT1, which subsequently activates the first wave of IFNγ-inducible genes 
including IRF8. IRF8 complexes with PU.1 and other possible TFs and the TF 
complex binds to the IFNγ-responsive element in the C1qB gene promoter, which 
directly increases the C1qB gene promoter activity and at the same time increases 
the C1qA and C1qC gene promoter activities through the spatial interaction 
between the TF complexes bound to the three C1q gene promoters. The open 
arrows with dotted line represent the transcription of the three genes at the basal 
level. The open arrows with solid line represent the IFNγ-induced transcription of 




4.3 Ectopic expression of myeloid-specific TFs in non-immune 
cells 
C1q is preferentially, if not exclusively (Agostinis et al., 2010), produced by 
DCs and macrophages. The finding that PU.1 and IRF8 play key roles in the 
regulation of C1q gene expression helps to explain the DC and macrophage 
production of C1q. First, PU.1 is a key transcription factor in DCs and 
macrophages, which is required for lineage commitments and it is not 
significantly associated with other cell lineages (Nerlov and Graf, 1998; Nutt et 
al., 2005). Second, IRF8 is also strongly associated with macrophage and DC 
development and functions (Qi et al., 2009). In zebrafish, in which the three C1q 
genes are in a even denser cluster (Hu et al., 2010), IRF8 is definitive 
developmental switch in favor of macrophages over neutrophils (Li et al., 2011).  
PU.1 was also shown to function as a bridging molecule with general TFs to 
initiate transcriptions (Aittomaki et al., 2004). The basal activity of  the FcγRI 
gene promoter was strictly dependent on PU.1, while IFNγ induction required 
both PU.1 and STAT1 (Aittomaki et al., 2002). Moreover, PU.1 was also found to 
be able to trans-activate the expression of MHC class II transactivator CIITA in 
cooperation with IFNγ through binding to its fourth promoter pIV and causing 
histone acetylation (Ito et al., 2009), and similar results on its fifth promoter pV 
was also reported (Kitamura et al., 2012). These all suggest that the role of PU.1 
in myeloid lineage commitment is through initiating the expression of tissue-
specific genes, which decide the direction of cell differentiation. 
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Therefore, to validate the involvement of PU.1 and IRF8 in the C1q gene 
transcriptional regulation, human PU.1 and IRF8 were cloned to verify whether 
ectopic expression of these two TFs are sufficient to initiate the transcription of 
the C1q genes. HEK293 cells were used, as they are human embryonic kidney 
cells and no PU.1, IRF8 or C1q is expressed in these cells (Graham et al., 1977). 
Moreover, the transcription of endogenous IL-1β was initiated in HEK293 cells 
when ectopic PU.1 and IRF8 were over-expressed (Marecki et al., 2001). 
In the non-immune HEK293 cells, the ectopic expression of myeloid-
specific TFs, PU.1 and IRF8, have successfully restored both basal and IFNγ-
induced activities of the three C1q gene promoters with various levels (Figure 
3.22). However, the endogenous mRNA expression levels of C1q subunit genes 
were not detected in HEK293 cells with either transient-transfection or stable-
transfection of PU.1 and IRF8 (Figure 3.23 and 3.25), although similar 
experimental setup successfully induced the endogenous expression of human IL-
1β (Marecki et al., 2001). Moreover, as a developmentally important cytokine 
receptor, MCSF-R mRNA levels were also not detected, although PU.1 was 
reported to initiate its expression during the early stages of myeloid differentiation 
(Dakic et al., 2007; DeKoter et al., 1998; Gangenahalli et al., 2005). 
One of the proposed reasons could be that additional myeloid-specific 
factors, other than PU.1, are required for the transcription initiation of C1q 
subunit genes. To initiate the transcription of a gene, the promoter DNA 
sequences need to be released from the condensed chromatin structure and this is 
normally done by chromatin modification involving mainly histone acetylation 
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(Allfrey et al., 1964; Serrano et al., 2013). Although PU.1 was shown to be able 
to initiate gene transcriptions through facilitating histone acetylation (Ito et al., 
2009; Kitamura et al., 2012) and function as bridging molecules for general TFs 
(Aittomaki et al., 2002). The results suggest that additional myeloid-specific or 
hematopoietic progenitor-specific factors are required to initiate the transcription 
of C1q genes. 
However, it could also be due to the low pluripotency of HEK293 cells and 
its potential to be reprogrammed is limited, as they were isolated from fetus 
kidney, which is mostly composed of differentiated cells (Graham et al., 1977). 
Other early hematopoietic factors might be needed to potentiate the cells for the 
myeloid lineage development before PU.1 or collaborate with PU.1. Most of the 
studies involving initiation of gene expression by enforced PU.1 expression 
utilize the hematopoietic progenitors or other hematopoietic cells (Dakic et al., 
2007; DeKoter et al., 1998; Ito et al., 2009; Kitamura et al., 2012; Laiosa et al., 
2006; Nerlov and Graf, 1998).  
Therefore, for further investigation on the initiation of C1q gene 
transcription, more pluripotent cell types are needed. The best choice would be 
the embryonic stem cells that are more pluripotent than HEK293 cells. Stable 
transfection of the myeloid-specific PU.1 and other possible myeloid-specific 





4.4 The evolution of the C1q gene cluster 
At genomic level, the human C1q subunit genes are highly clustered in 
tandem on a stretch of 25-Kb fragment on human chromosome 1 in the order of 
C1qA-C1qC-C1qB (Sellar et al., 1991). This conserved genomic organization 
was also observed from the mouse C1q genes on mouse chromosome 4 (Petry et 
al., 1996) and the zebrafish C1q genes on zebrafish chromosome 21 (Hu et al., 
2010).  
Several other gene cluster loci on different chromosomes were characterized 
and evolutionary conserved among mammals and zebrafish, including those in the 
innate immune system (Aggad et al., 2010; Dumoutier et al., 2000; Igawa et al., 
2006; Lutfalla et al., 2003). Moreover, among these evolutionarily conserved 
gene clusters, a number of genes within the same cluster were reported to be 
associated with certain diseases (Igawa et al., 2006; Kotenko, 2002; Vilcek, 2003). 
Furthermore, with regards to the transcription regulation, the evolutionary 
conservations and changes in cis-regulatory regions has been shown to be 
important for conservation of critical cell functions and evolutionary changes, in 
addition to those in the protein coding regions (Wray, 2007; Wray et al., 2003). 
Thus the study of the transcriptional regulation of the C1q gene cluster could 
contribute to the understanding of the evolution of gene clusters.  
In this study, chimpanzee, mouse, dog, cattle, chicken and zebrafish were 
chosen as representatives of non-human primates, rodents, carnivores, herbivores, 
birds and fish, respectively, as the C1q gene cluster is conserved in these species 
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(Figure 1.3B). The putative C1q gene promoter regions of these species were 
cloned into pGL3 luciferase vectors and the promoter activities were examined 
via dual-luciferase assay.  
In the transfected RAW246.7 cells, the C1q gene promoters of selected 
mammalian species exhibited various levels of basal activities and different 
modes of response to IFNγ (Figure 3.26). Among these promoters examined, the 
C1q gene promoters of chimpanzee and mouse showed similar basal and IFNγ-
stimulated activities as their human counterparts (Figure 3.26A and 3.26B). 
However, for dog, only the C1qB gene promoter exhibited the same activity 
pattern as its human counterpart, while its C1qA and C1qC promoters showed no 
response to IFNγ stimulation (Figure 3.26C). On the contrary, the activity patterns 
the C1qA and C1qC gene promoters of cattle were similar to that of human 
(Figure 3.26D), but the C1qB gene promoter was inhibited by IFNγ (Figure 
3.26D), although the 53bp IFNγ-responsive element was shown to be conserved 
(Figure 3.13). The basal activities of chicken C1qB and C1qC gene promoters 
were quite low and no response to IFNγ was observed (Figure 3.27A). However, 
relatively high basal activity of the chicken C1qA gene promoter was observed 
and was inhibited by IFNγ. For zebrafish, all the three C1q gene promoters 
exhibited negligible levels of basal activity and did not respond to IFNγ in 
RAW264.7 cells (Figure 3.27B).  
The low basal promoter activities and the inconsistent responses to IFNγ 
observed in promoters from other species might be due to the use of the mouse 
macrophage RAW264.7 cells. This is the major limitation of this study, as 
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evolutionary changes took place in both cis- and trans- elements in the 
transcription regulation system (Wray et al., 2003). The incompatibility of the cis-
acting elements in the promoters of other species to the mouse trans-acting 
system might account for the low basal activity of the chicken and zebrafish C1q 
gene promoters and the different modes of responses to IFNγ observed in this 
study. Although the human and chimpanzee C1q gene promoters exhibited 
equivalent activities as the mouse promoters in the murine macrophage 
RAW264.7 cells, the species-specific differences in the trans-acting elements 
may still cause deviations from their real promoter activity. 
In order to verify whether the incompatibility of the promoters from other 
species to the mouse transcription system due to evolutionary changes is able to 
account for the previous results, the zebrafish PAC-2 cells were used to study the 
zebrafish C1q gene promoters. In these cells, all the three zebrafish C1q gene 
promoters exhibited much higher levels of basal activity with the over-expression 
of ectopic zPU.1, and the promoter activities were further enhanced with over-
expression of ectopic zIRF8 (Figure 3.28). These results suggest that the 
incompatibility of the C1q gene promoters from other species in the mouse 
transcription system could account for the low basal promoter activities and the 
different modes of responses to IFNγ observed in the previous results.  
Notably, only zIFNγ2 is able to affect the zebrafish C1q gene promoter 
activity (Figure 3.29, 3.30 and 3.31), although two zebrafish IFNγ genes were 
previously reported (Igawa et al., 2006), and both were shown to induce the same 
set of genes and are functionally equivalent to mammalian IFNγ (Sieger et al., 
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2009). Regarding the effects of zIFNγ2 to the promoters, the zebrafish C1qB gene 
promoter activity was enhanced (Figure 3.20), while the zebrafish C1qC gene 
promoter was inhibited by zIFNγ2 (Figure 3.31). However, the zebrafish C1qA 
promoter activity was surprisingly enhanced by zIFNγ2, and the enhancement 
was even much stronger than the C1qB promoter (Figure 3.29 and 3.30). These 
results suggest that there are evolutionary changes in the mode of regulation on 
the IFNγ-induced C1q gene expression, with the genomic organization as a gene 
cluster remaining conserved.  
These results suggest that the three independent C1q genes is likely to drift 
apart during evolution resulting in three distinct C1q-like molecule identities and 
the highly conserved genomic organization of the three C1q genes as a gene 
cluster, which enable the coordination of the synchronized expression of the three 
genes, must have offered key physiological advantages that are not compensated 
by C1q-like molecules assembled from a single type of C1q subunit. 
 The evolution of the regulation on the IFNγ-induced C1qA expression is 
likely branched somewhere before mammals, or even before reptiles. Before the 
branching, the C1qA gene promoter was independent in both basal and IFNγ-
induced activity, while after the branching the C1qA gene promoter became semi-
independent and controlled by the superseding C1qB core promoter. However, the 
genomic organization of the three C1q genes as a gene cluster is conserved 
throughout the evolution to coordinate the synchronized expression of the three 
genes, although there are evolutionary changes in the regulation of the IFNγ-
induced C1qA gene expression. 
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4.5 The C1q transgenic mouse model for in vivo study on the 
regulation of C1q gene expression 
The previous results of this project all support the second hypothesis that 
the synchronized expression of the three C1q subunit genes is achieved through a 
core cis-acting element in the form of a gene cluster. However, the investigations 
were all conducted in the in vitro or ex vivo system. In order to further validate the 
hypothesis in vivo, a transgenic mouse model was proposed to investigate the 
natural expression regulation patterns in vivo. In this transgenic mouse model, 
fluorescent reporter genes would be expressed under the control of C1q gene 
promoters. This would enable the assessment of the regulatory effects through 
monitoring the expression of the reporter genes.  
A transgenic BAC construct with the egfp gene under the control of the 
mouse C1qA gene promoter was constructed via homologous recombination and 
used in the mouse ES cell-mediated generation of transgenic mice. The successful 
male chimeric mice were screened for the transgene cassette and its integration 
with the C1qA gene locus, and were shown to be positive for the screening. The 
five male chimeric mice have mated with normal C57BL/6 mice to give rise to the 
F1 generation mice. However, most of the F1 generation mice were black in color, 
which means they do not contain the genomic materials from the transgenic 129 
ES cells. Moreover, the single brown offspring mouse, whose father is the male 
chimeric mouse in cage BR5, was also shown to be negative for the transgene 
cassette. But more brown litters were born with the male chimeric mice in BR5 as 
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their father. They will be screened when they were ready for the tail-snapping to 
isolate their genomic DNA.  
Follow-up studies of the transgenic mouse model would introduce 
mutations to the C1qB gene core promoter to study its influence in the expression 
of the reporter gene under the control of the C1qA gene promoter. This C1qB 
promoter mutated transgenic mice could be used to validate the in vitro data on 
the superseding effects of the C1qB gene promoter over the C1qA gene promoter 
in vivo.  
Bearing in mind that the acquired C1q deficiency is much more frequently 
observed in SLE patients than the rare hereditary C1q deficiency (Edelbauer et al., 
2011; Schejbel et al., 2011; Wu et al., 2011) and the defects in the regulation of 
C1q expression at the transcriptional level could also contribute to the C1q 
deficiency in SLE patients (Figure 1.2), elucidating the regulation patterns of C1q 
expression in vivo would provide greater insights into the pathogenesis of SLE 
than the study of C1q-knockout mice, especially into the acquired C1q deficiency 







4.6 Future work 
Characterization of the putative PU.1 site in the C1qC gene promoter 
Based on the ChIP data that PU.1 is constitutively bound to the C1qC gene 
promoter, regardless of IFNγ-treatment (Figure 2.21), we could hypothesize that 
PU.1 most probably functions as a bridging TF molecule that participates in the 
interaction of the C1qB core promoter and the C1qC promoter.  
This could be tested via the use of the pGL3-C1qC-Luc-B273 plasmid, as 
the addition of the 3' end B273 promoter rendered the 5' end C1qC promoter to 
exhibit much higher basal activity and respond positively to IFNγ stimulation 
(Figure 3.8).  This is an in vitro system that mimics the real situation of the C1q 
gene cluster in the chromosomal context.  
Therefore the mutations at the putative PU.1 element predicted on the C1qC 
gene promoter would disrupt the influence of the 3' B273 promoter on the 5' 
C1qC gene promoter, if the above hypothesis is true that PU.1 functions as a 
bridging TF molecule that participates in the interaction of the C1qB core 
promoter and the C1qC promoter.  
However, this experiment could only validate the involvement of PU.1 and 
the putative PU.1 site on the C1qC gene promoter, as we could not exclude other 
possible cis-acting elements and TFs from participating the interaction between 




Validating the findings using genomic DNA samples from SLE patients  
As mentioned earlier, single nucleotide polymorphisms (SNPs) were found 
at the 5' vicinity of the three C1q subunit genes on human chromosome 1, through 
searching the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP). 
Unlike the SNPs in the protein coding sequence, which were well studied 
(Schejbel et al., 2011), SNPs in the non-coding regions have not been studied and 
have the potential to contribute to the dysregulation of C1q expression at the 
transcription level.  
However, none of the SNPs documented in the NCBI dbSNP database 
located in the putative IFNγ-responsive element site on the C1qB gene promoter. 
Since the SNPs documented in NCBI dbSNP database are from multiple sources 
and mainly non-SLE patients. This suggests that this IFNγ-responsive element 
region is well-conserved in normal individuals and its integrity is important for 
the normal regulation of C1q expression.  
Therefore, based on the proposed SLE pathogenesis model in this project 
(Figure 1.2), possible SNPs in the IFNγ-responsive element region could cause 
the inability of the patients to transiently up-regulate C1q expression levels, which 
leads to the accumulations of apoptotic cells and immune complexes, and 
eventually leads to the production of autoantibodies and lupus nephritis. Although 
the genetic deficiency of C1q due to SNPs in coding regions is relatively rare and 
only accounts for a very small proportion of SLE patients, the SNPs at the 
regulatory regions are not well studied and may account for quite a substantial 
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proportion of SLE patient population. Through the screening for the SNPs in the 
IFNγ-responsive element region from the SLE patient samples, proper treatment 
could be given more specifically before the worsening of the disease conditions. 
Moreover, through the screening on DNA samples from the relatives of positive 
SLE patients, we could possibly inform them to take precautions even before the 
onset of the disease. 
 However, SLE is a complicated autoimmune disease and its pathogenesis 
involves multiple genetic defects and environmental factors. Although the 
dysregulation of C1q might not participate in the pathogenesis of the majority of 
the SLE patients, a small portion of the SLE patients and their relatives may still 
benefit from the screening.  
Ectopic expression of myeloid-specific TFs in embryonic stem cells 
The transcription of the C1q genes were not initiated in the HEK293 cells 
with ectopic expression of myeloid-specific PU.1 and IRF8. One of the proposed 
reason is the low pluripotency of HEK293 cells and its potential to be 
reprogrammed is limited, as they were isolated from fetus kidney, which is mostly 
composed of differentiated cells (Graham et al., 1977).  
Other early hematopoietic factors might be needed to potentiate the cells for 
the myeloid lineage development before PU.1 or collaborate with PU.1. Most of 
the studies involving initiation of gene expression by enforced PU.1 expression 
utilize the hematopoietic progenitors or other hematopoietic cells (Dakic et al., 
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2007; DeKoter et al., 1998; Ito et al., 2009; Kitamura et al., 2012; Laiosa et al., 
2006; Nerlov and Graf, 1998).  
Therefore, for further investigation on the initiation of C1q gene 
transcription, more pluripotent cell types are needed. The best choice would be 
the embryonic stem cells that are more pluripotent than HEK293 cells. Stable 
transfection of the myeloid-specific PU.1 and other possible myeloid-specific 
factor could possibly induce the transcription initiation of endogenous C1q genes.  
The future use of the transgenic mouse model 
The rationale of the transgenic mouse model is to investigate the natural 
C1q expression regulation patterns in vivo. Follow-up studies of the transgenic 
mouse model would introduce mutations to the C1qB gene core promoter to study 
its influence in the expression of the reporter gene under the control of the C1qA 
gene promoter. This C1qB promoter mutated BAC transgenic mice could be used 
to validate the in vitro data on the superseding effects of the C1qB gene promoter 








Chapter 5 - Conclusion 
C1q is a complement protein present in the serum and plays an important 
role in modulating the host immune system (Lu et al., 2008; Nayak et al., 2010). 
The genetic deficiency of C1q, which impairs the production of functional C1q, 
has profound impact on the immune system, as it almost certainly cause the 
autoimmune disease, systemic lupus erythematosus (SLE) (Carneiro-Sampaio et 
al., 2008; Schejbel et al., 2011). Although the genetic C1q deficiency is relatively 
rare, acquired C1q deficiency is more frequently observed in SLE patients, which 
would contribute to SLE pathogenesis (Edelbauer et al., 2011; Wu et al., 2011).   
C1q is assembled from three subunits, each being coded by an independent 
gene. The three genes are located as a cluster (C1qA-C1qC-C1qB) and are 
specifically expressed in macrophages and dendritic cells. We observed that the 
three C1q genes were expressed in a synchronized manner at both basal and 
IFNγ-induced levels in human monocyte-derived DCs and macrophages.  
To understand the underlying mechanism, the three gene promoters were 
cloned. In isolation, the C1qA and C1qC gene promoters were suppressed, rather 
than enhanced, by IFNγ. This departs from the expected IFNγ enhancement in 
C1q gene expression. When the C1qB gene promoter was cloned at the 3’ 
direction of the C1qA and C1qC gene promoters across the reporter gene, it 
restored their responses to IFNγ. This was attributed to a 53-bp element in the 




The IFNγ-induced C1qB gene promoter activity was abrogated when PU.1, 
IRF8 and STAT1 expression was knocked down using shRNA. PU.1 and IRF8, 
but not STAT1, were shown to bind to the 53-bp element. However, shRNA 
knockdown of STAT1 inhibits IFNγ-induced IRF8 expression and subsequently 
inhibits the IFNγ induction of the C1qB gene promoter.  
The C1q gene cluster is conserved across different animal species and 
studies of these C1q gene promoters also revealed responses to IFNγ, but the 
modes of response vary. Evolutionary changes were revealed between the 
regulation patterns of C1q expression in the mammalian species and those in the 
zebrafish, but the genomic organization of the three C1q genes as a gene cluster is 
still well conserved to coordinate the expression of the three genes. 
 To understand the C1q gene promoters in vivo, a C1q transgenic mouse 
model was generated by expressing GFP under the C1qA gene promoter. This 
would helps in elucidating the regulation patterns of C1q expression in vivo and 
thus provides greater insights into the pathogenesis of SLE than the study of C1q-
knockout mice, especially into the acquired C1q deficiency in SLE patients. 
Collectively, our results reveal a novel transcriptional mechanism by which 
the expression of the three C1q genes is synchronized, offer an excellent model 
for dissecting SLE pathogenesis due to acquired C1q deficiency and provide a 
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